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Leukocyte recruitment following cerebral ischemia reperfusion (I/R) has been shown to 
amplify inflammatory processes and enhance brain injury. Potent anti-inflammatory and 
neuro-protective properties have been attributed to the melanocortin receptor system, 
thus targeting this system may provide a novel therapeutic strategy for the treatment of 
stroke. Melanocortin receptor (MC) subtypes MC1, MC3 and MC4 have previously been 
shown to mediate MC anti-inflammatory actions, however their relative importance is 
poorly understood and may differ with the pathophysiological environment. 
In this study the bilateral common carotid artery occlusion (BCCAo) mouse model of 
global stroke was used with intravital microscopy to investigate the potential of 
melanocortin targeted compounds in modulating cerebral I/R induced leukocyte 
recruitment. While under basal conditions the cerebral microcirculation provides a poor 
substrate for leukocyte recruitment, BCCAo induced significant leukocyte recruitment by 
40 min of reperfusion, with leukocyte rolling increasing from 21.5 cells/mm2/min to 191.0 
cells/mm2/min and adhesion from 42.1 cells/mm2/min to 282.3 cells/mm2/min. 
Extending reperfusion to 2 h resulted in further increases in adhesion to 1500% of sham 
levels. Treatment with the non-selective melanocortin agonist, α-MSH, significantly 
reduced I/R induced leukocyte recruitment (Rolling by 80% at 40 min and 68% at 2 h 
and adhesion by 68% at 40 min and 82% at 2 h). The relative contributions of the 
melanocortin receptor subtypes were investigated in this model using MC selective 
compounds and receptor mutant mice. The MC1 selective BMS-470,539 provided most 
potent inhibition of leukocyte recruitment at 40 min with the MC1 mutant e/e mice also 
showing enhanced leukocyte rolling and circulating TNF-α, while MC3-/- mice showed no 
inflammatory phenotype. However by 2 h the inhibitory effects of BMS-470,539 subsided 
and e/e mice no longer showed abnormalities in leukocyte recruitment. On the other 
hand MC3 targeted compounds were highly effective at this later time point. These 
investigations reveal an important role for MC1 immediately following BCCAo with a later 
shift toward MC3 mediated processes by 2 h. Due to no observed changes in receptor 
mRNA and that by 2 h α-MSH treatment was found to reduce NF-κβ related gene 
expression but not at 40min. It is likely the apparent shift in receptor importance is due to 
the activation of distinct signalling pathways rather than change in receptor expression. 
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1.1. The global burden of Stroke  
1.1.1. Aetiology 
Stroke is a neurological disorder caused by the cessation or reduction of the blood 
supply to the brain, resulting in significant neuronal damage and rapid loss of function. 
Stroke may result from an ischemic (>80 % of incidence) or haemorrhagic (~13 % of 
incidence) event, affecting the brain in either a focal or global manner [1]. Focal ischemic 
stroke (~68 % of cases) results from the obstruction of either a pre-cerebral or intrinsic 
artery or arteriole; this may be caused by an embolus, a thrombus or an atherosclerotic 
plaque [1]. Whilst global stroke accounts for ~12 % of ischemic strokes and arises when 
blood flow to the entire brain is interrupted most often due to cardiac arrest or trauma [2].  
1.1.2. Epidemiology and socio-economic impact 
Stroke is the third most common cause of death, behind cardiac disorders and all 
cancers combined [3], killing around 53,000 people in the UK each year [4] and 5.5 
million worldwide [5]. Depending on age, co-morbidity, type, and severity of stroke 
between 20 % and 50 % die within the first month following stroke [6]. Where stroke is 
not fatal, only 10 % of survivors are reported to recover completely, making stroke the 
most common cause of long-term physical disability in the world [4]. Deficits experienced 
by survivors include paralysis, impairments in memory; cognition; co-ordination and 
language. The great need for palliative and rehabilitative care imposes a huge socio-
economic burden, with the total economic cost of stroke in the UK being estimated at £7 
billion per year [7]. 
With stroke treatment consuming 2-4 % of global medical costs [1] the development of 
more effective and cost efficient therapies is essential.  
1.0.      Introduction 
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1.1.3. Risk factors 
Important risk factors for cardiovascular disease and stroke are; smoking, hypertension, 
diabetes and obesity. Levels of obesity have more than doubled in England over the last 
20 years [8] and almost 40 % of men and over 30 % of women in the UK are now 
reported to have high blood pressure [4]. While stroke mortality has been falling in recent 
years, largely accredited to the rising prescription of prophylactic antihypertensive (9 fold 
since 1990) and lipid lowering drugs such as statins (63 fold increase since 1990) [4], 
many of the key risk factors for stroke continue to rise. Increasingly inactive lifestyles 
and an aging population mean that stroke may continue to place a major burden on 
society. Indeed by 2020 it is predicted that stroke and heart disease will be the leading 
cause of death and disability worldwide [5]. 
1.2. The pathophysiology of stroke 
To define the pathophysiology of stroke as a reduced blood supply, leading to cellular 
death and damage due to energy failure, would only be to scratch the surface. Diverse 
and complex mechanisms underlie the pathology of stroke, with destructive events 
extending far beyond the initial ischemic damage. At the onset of stroke disturbance of 
blood flow leads to energy failure and necrotic cell death in the ischemic core [9, 10]. In 
hypoperfused tissues surrounding the core, excitotoxic events and oxidative stress lead 
to delayed necrotic and apoptotic cell death [10]. Upon reperfusion, damage may be 
compounded by enhanced oxidative stress and a cascade of damaging inflammatory 
processes [9, 11, 12]. 
1.2.1. Ischemic damage 
The brain is particularly sensitive to ischemic injury due to its constant high energy 
demands; utilizing 20 % of total body oxygen consumption, and 25 % of total body 
glucose [13]. Neurons are more susceptible to ischemic damage than glial or vascular 
cells and rapidly become dysfunctional or die [11]. Within 20 seconds of global disruption 
of blood flow, electroencephalography (EEG) readings disappear in the mammalian 
brain [14, 15] and during each minute of a large vessel ischemic stroke, it is estimated 
that 1.9 million neurons, 14 billion synapses, and 12 km of myelinated fibres are 
destroyed [16]. 
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In the ischemic core (blood flow reduced to less than 12 ml/100 g/min [17]) loss of high 
energy phosphate compounds leads to rapid energy failure. With cells unable to 
maintain active transport, tightly controlled ionic gradients are disrupted [18, 19]. As a 
result there is a huge intra-cellular influx of Na+ and Ca2+, leading to cell swelling, loss of 
membrane integrity and necrotic cell death [11]. 
1.2.2. The concept of the penumbra and stroke progression 
The ischemic insult may often be contained and/or short lived however it leads to 
derangements in cellular functioning that cannot be corrected via normal homeostatic 
mechanisms [19] 
Surrounding the infarct core exists a region of hypoperfused tissue (blood flow 
approximately 12 - 22 ml/100 g/min [17]) termed the ‘penumbra’ which although 
functionally compromised is not yet irreversibly damaged,  potentially remaining viable 
for 16 to 48 h [18]. In this territory the level of ischemia is insufficient to cause immediate 
cell death but collateral flow maintains neurons at a viable yet critically stressed state 
[19]. As neurons and glial cells depolarize in the ischemic core, voltage gated Ca2+ 
channels open and glutamate is released into the extracellular space [11, 19, 20]. As a 
consequence, N-Methyl-D-aspartate (NMDA) receptors and metabotropic glutamate 
receptors are over activated in the penumbra, leading to increased intra-cellular Ca2+ 
overload and mitochondrial dysfunction [11, 20]. Indeed, it is worth noting that those 
areas of the brain that are acutely sensitive to ischemic damage such as the 
hippocampus and neocortex are particularly enriched with excitatory NMDA and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors [19, 21]. These 
excitotoxic events also lead to the activation of Ca2+ dependent enzymes including; 
phospholipases, endonucleases and proteases [19, 20]. Activated phospholipases 
degrade the cell membrane producing free fatty acids including arachidonic acid (AA) 
[19, 20] thus triggering the production of AA metabolites such as leukotrienes, 
thromboxane and prostaglandins, which promote platelet aggregation and elicit a 
cascade of inflammatory events. 
The pathological events that occur in the penumbra therefore not only cause necrotic 
cell death and apoptosis but also generate stress signals, chemokines and damage 
associated molecular pattern (DAMPs) such as high-mobility group protein B1 (HMGB1), 
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heat shock protein 60 (HSP60) and β-amyloid (Aβ), thus provoking post-ischemic 
inflammatory responses [12]. 
1.2.3. Reperfusion injury 
In the absence of reperfusion, neuronal damage in the penumbra may become 
permanent and indistinguishable from the ischemic core. However where stroke is not 
immediately fatal, pharmacological treatments, surgical intervention or endogenous 
mechanisms may restore blood flow to the infracted region. Despite the clear benefit of 
reperfusion of blood to the ischemic tissue, this can paradoxically serve to exacerbate 
injury, initiating a cascade of adverse reactions [9, 22]. Indeed in a number of animal 
models reperfusion may produce infarct sizes larger than those observed when 
occlusion is permanent [22]. Diverse mechanisms underlie the neuronal damage 
experienced in the penumbra at reperfusion, including oxidative stress, reactive oxygen 
species (ROS) production, and with the restoration of blood flow circulating immune cells 
are recruited to the damaged tissue, initiating a destructive inflammatory cascade. Due 
to its potentially salvageable nature, the penumbra provides a promising target to reduce 
neuronal damage and improve functional outcome whilst extending the window of 
opportunity for therapeutic intervention [23].  
1.3 The role of inflammation in stroke 
Playing a central role in I/R injury and the pathology of stroke is an aberrant 
inflammatory response. The neuro-inflammatory response in stroke comprises of a 
complex cascade of events; characterised by cytokine release, increased expression of 
cell adhesion molecules, leukocyte recruitment and disruption of the blood-brain barrier 
(BBB) [24, 25].  
A disproportionate inflammatory response can be particularly detrimental in the brain as 
it lacks robust antioxidant defences [9]. Free radicals and reactive oxygen species 
(ROS), released by infiltrating inflammatory cells, may be particularly damaging to at risk 
neurons in the penumbra. Oxidative stress increases BBB permeability and reduces 
bioavailability of nitric oxide (NO), a potent inhibitor of leukocyte adhesion and platelet 
aggregation [26]. The accumulation of immune cells in the cerebral microcirculation may 
also lead to occlusion of the vessel and further increase the potential for ischemic tissue 
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damage in the “no-reflow” phenomenon [27]. Additionally oedema may oppose arterial 
influx and potentially bring about further ischemia [28]. Inflammation is thus increasingly 
being seen as a major contributing factor in the pathogenesis of a number of conditions 
affecting the brain including; multiple sclerosis, meningitis, acute brain trauma, 
Alzheimer’s disease, Parkinson’s and stroke [29]. A detailed understanding of the events 
underscoring inflammation, from activation of resident cells to recruitment of circulating 
immune cells, amplification and eventual resolution (Figure 1.1), is therefore necessary 
for the development of therapeutics counteracting inflammatory reactions following 
stroke. 
Figure 1.1 Inflammation following stroke Ischemia reperfusion injury drives neuronal 
damage, but also sets in motion a damaging cascade of inflammatory events. Damage 
associated molecular patterns (DAMPS) and stress signals activate brain resident immune 
cells, which in turn release cytokines and reactive oxygen species (ROS) activating 
perivascular cells and the endothelium. Leukocyte endothelial interactions may then allow for 
recruitment of blood born leukocytes which invade the brain parenchyma and release a variety 
of cytotoxic substances further amplifying neuronal damage. (P. Holloway, unpublished) 
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1.3.1. Resident immune cells 
1.3.1.1 Microglia 
Microglia are the resident immunocompetent and phagocytic cells of the brain and act as 
the primary immune defence in the CNS. In their ramified “resting” forms microglia 
extend branching processes surveying the microenvironment. Sensitive to pathological 
environmental changes in the brain microglia may be activated within minutes of an 
ischemic insult [30]. Activated microglia may functionally transform into phagocytes and 
release a variety of cytotoxic substances such as ROS, proteases and prostanoids whilst 
also secreting pro-inflammatory cytokines such as Tumour Necrosis Factor-alpha (TNF-
α), interleukin (IL)-1β, and IL-6 [9, 30, 31]. However microglia may also provide 
neuroprotection through the production of anti-inflammatory, cytoprotective and 
neurotrophic molecules such as IL-10, Transforming growth factor beta (TGF-β), insulin- 
like growth factor I (IGF-1) and brain-derived neurotrophic factor [9, 30]. Microglia may 
also play a protective role by way of removing extracellular excitotoxins and via 
phagocytosis of infiltrating neutrophils [32]. 
1.3.1.2 Astrocytes 
These specialised glial cells provide a crucial interplay of neurogenic and vascular 
elements. So intimate are these functional connections provided by astrocytes that the 
brain parenchyma and the blood vessels feeding it are no longer considered wholly 
separate entities. In 2000, the neurovascular unit (NVU) was proposed as a 
physiological unit [33], an important concept when discussing the pathology of stroke. 
Astrocyte processes interact with neurons to maintain the synaptic extracellular chemical 
environment. Astrocyte endfeet also contact endothelial cells (ECs) inducing BBB 
properties and maintaining BBB integrity whilst also regulating blood flow in response to 
neuronal energy demand through their release of vaso-active compounds such as 
prostaglandins (PGE), NO and AA metabolites [34]. Additionally these cells may store 
and utilise glycogen which can briefly maintain neuronal activity during hypoglycemia 
and may thus buffer ischemic neuronal damage.  
Astrocytes may play both pro and anti-inflammatory roles following stroke [11, 34]. In 
response to stressors such as ROS, hypoxia and glucose deprivation or inflammatory 
mediators such as TNF-α and IL1-β, astrocytes may release a variety of pro-
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inflammatory compounds, including IL-1β, IL-6, interferon(IFN)-α, and –β, TNF-α; and C-
C motif Chemokine ligand 5 (CCL-5) [34, 35]. Astrocytes are also a major source of the 
potent monocyte chemoattractant (MCP-1) and neutrophil chemoattractant IL-8. 
In addition to their pro-inflammatory actions astrocytes may also provide anti-
inflammatory protection via IL-10, whilst also releasing neuro protective factors and 
promoting neuronal survival and thus should be considered important modulators of 
neuroinflammation [35]. 
A hallmark of CNS injury is the formation of a scar tissue by reactive astrogliosis, 7–10 
days following ischemia, astrocytes form scar tissue at the borders of the infarct which 
persist for life of the patient [34] this scar acts as a neuroprotective barrier to 
inflammatory cells and infectious agents however this barrier may also prevent neuronal 
regrowth and recovery [34]. 
1.3.1.3 Perivascular macrophages 
Perivascular macrophages, located between the basement membrane and glia limitans, 
are continuously replenished by circulating monocytes [11]. While macrophages can 
exist in a spectrum of different activation states they are typically divided into two 
phenotypically distinct populations, M1 and M2.  M1 macrophages have a pro-
inflammatory phenotype releasing cytokines (IL-1β, IL-12, IL-23 and TNF-α), 
chemokines and ROS [11, 36] driving the infiltration of blood born inflammatory cells. 
The other class of macrophages, M2, however possess anti-inflammatory actions and 
release IL-10, TGF-β and IL-1 receptor (IL-1R) antagonists promoting the resolution of 
inflammation [36].  
1.3.1.4 Mast cells 
Mast cells are perivascular cells which may rapidly respond to stimuli by releasing 
cytokines such as TNF-α, histamine, anticoagulants and proteases such as tryptase, 
Matrix metalloprotease (MMP)2 and MMP9 [11, 37]. Following experimental stroke in 
rats these cells have been shown to regulate BBB permeability, oedema formation and 
the intensity of localised neutrophil infiltration [37]. 
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1.3.2. Blood borne immune cells  
Blood born immune cells are recruited to the site of brain injury occurs in response to 
DAMPs and chemokines released from activated mircoglia and perivascular cells and 
damaged parenchymal cells. Infiltrating cells release additional chemotactic signals and 
inflammatory mediators and secrete toxic substances thus releasing more DAMPs and 
serving to amplify the inflammatory cascade. 
1.3.2.1 Monocytes 
Monocytes are a heterogeneous population with at least two main subtypes being 
described and classified by their cell surface markers. 'Classical' monocytes produce the 
anti-inflammatory cytokine IL-10 in response to an inflammatory challenge, whereas pro-
inflammatory ‘non-classical’ monocytes release TNF-α and following stroke are recruited 
to the site of injury [11]. Upon infiltration into the brain parenchyma these cells 
functionally transform giving rise to macrophages with a ramified morphology 
indistinguishable from resident reactive microglia. While on the other hand activated 
microglia may assume an amoeboid phagocytic phenotype similar to infiltrating 
monocytes [32]. Due to lack of discriminating cellular markers and their functional 
similarities, distinguishing blood born monocytes from microglia has provided a 
considerable technical challenge and has confounded a complete understanding of their 
contribution in post-stroke inflammation. However experiments utilising chimeric mice 
with GFP bone marrow have shown that while the vast majority of macrophage-like cells 
in the brain following stroke are resident (GFP-negative) microglial cells, circulating cells 
are first detected on the cerebral venules at 4 to 6 h and reach peak numbers in the 
brain at Day 7 [38, 39].  
1.3.2.2 Neutrophils 
Neutrophils are the most abundant phagocytic leukocytes in the body [40]. These cells 
harbour cytoplasmic granules and secretory vesicles containing a variety of cytotoxic 
substances allowing for a rapid and indiscriminate response to pathogens. Rapidly 
reacting to molecular cues, neutrophils are the earliest leukocyte subtype recruited to the 
site of tissue damage [12, 41]. Activated neutrophils utilize NADPH oxidase to generate 
oxygen free radicals and hydrogen peroxide, which are released during respiratory burst, 
a highly destructive event aimed at the removal of pathogens. Myeloperoxidase (MPO) 
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is also released from azurophilic granules which catalyses the production of cytotoxic 
hypochlorous acid (HOCl) from hydrogen peroxide (H2O2). Additionally MPO may oxidize 
tyrosine to tyrosyl radical which in turn catalyses the oxidative cross-linking of proteins 
[42]. In addition to the damaging respiratory burst neutrophils also release proteases 
MMP8, MMP9, elastase and cathepsins causing significant cellular damage, loss of 
membrane integrity and disruption of the BBB [11]. Proteins released from neutrophil 
granules may further contribute to the inflammatory milieu by prompting the adhesion 
and emigration of inflammatory monocytes [43]. A number of studies have shown 
inhibition of this neutrophil recruitment to reduce infarct size following stroke [44]. 
1.4. The leukocyte recruitment cascade 
The recruitment of leukocytes to the injured or infected tissue is a central element to the 
inflammatory response and in numerous studies has been demonstrated to act as a rate 
limiting step [45]. Therefore targeting this process may provide a key point of 
intervention in the inflammatory cascade and understanding the mechanisms governing 
leukocyte recruitment is vital in developing effective therapies. This recruitment process 
is termed ‘the leukocyte adhesion cascade’ and comprises a succession of adhesion 
and activation events, which culminate in the extravasation of leukocytes from the 
circulation to the site of tissue damage (Figure 1.2). 
In the absence of disease the unique characteristics of the cerebral microcirculation and 
the presence of the BBB confer a vascular phenotype largely impermeable to blood born 
macromolecules. This coupled with the extremely low basal expression of adhesion 
molecules in comparison to other vascular beds [46], make the cerebral 
microvasculature a poor substrate for leukocyte adhesion and extravasation.  However a 
profound increase in the expression of a number of adhesion molecules in the early 
stages of cerebral inflammation result in the capture of circulating immune cells and their 
eventual breach of the BBB into the brain parenchyma. These adhesion molecules and 
their roles in the leukocyte adhesion cascade are summarised in table 1.1. 
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Table 1.1. Adhesion molecules and their role in leukocyte recruitment 
Family Molecule Expression pattern Counter 
receptor 
Role 
Selectins 
L-Selectin 
(CD62L) 
Leukocytes (constitutively 
expressed) 
SLex, P- and E-
selectin 
Capture and rolling, 
Leukocyte 
secondary 
tethering 
P-Selectin 
(CD62P) 
platelets and ECs (Up-
regulated on activation) 
PSGL-1, 
L-selectin 
Capture/rolling 
E-selectin  
(CD62E) 
ECs (transcriptionally up-
regulated on activation) 
PSGL-1, L-
selectin, 
β2 integrins 
Rolling/ slow rolling 
Mucin-like 
glycans 
PSGL-1  
(CD162) 
Leukocytes, and activated 
EC 
All selectins Capture and 
Rolling 
ESL-1 neutrophils and myeloid 
cells 
E-selectin Rolling  
Integrins 
VLA-4  
(α4; CD49d/β1; 
CD29) 
Lymphocytes, monocytes VCAM-1 Rolling, firm 
adhesion and 
transmigration 
Mac-1 
(αM CD11b/β2; 
CD18) 
Neutrophils, Granulocytes, 
NK cells, monocytes, MΦ 
and certain T cells 
(Constitutive, increased on 
activation) 
ICAM-1 Firm adhesion and 
transmigration 
LFA-1 
(αL; CD11a/β2; 
CD18) 
All leukocytes (constitutive, 
activatable) 
ICAM-1 and 
ICAM-2 
Rolling, arrest and 
firm adhesion 
IgSF 
ICAM-1  
(CD54) 
EC, leukocytes, fibroblasts, 
epithelial cells (low 
constitutive, up-regulated 
by cytokines) 
LFA-1, Mac-1 Firm adhesion and 
transmigration 
ICAM-2  
(CD102) 
EC, platelets (constitutive) LFA-1 Firm adhesion 
VCAM-1  
 (CD106) 
EC (low constitutive, up-
regulated by cytokines) 
VLA-4 Firm adhesion and 
transmigration 
PECAM-1  
(CD31) 
EC, platelets, Leukocytes PECAM-1 Adhesion and 
transmigration 
JAM-A (CD321) EC (constitutive) LFA-1 Transmigration 
JAM-B (CD322) EC (constitutive) VLA-4,  JAM-C Transmigration 
JAM-C (CD323) EC (constitutive) JAM-B Transmigration 
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Figure 1.2. The sequential steps of the leukocyte adhesion cascade.  Factors released from activated or damaged resident cells 
cause endothelial cell activation and selectin expression. A) Capture and rolling of the leukocytes from the blood stream is mediated by 
endothelial selectins binding to their leukocyte mucin-like ligands. B) Subsequent Slow rolling involves the synergistic actions of E selectin 
to mucin binding and Integrin binding to their IgSF ligands. C) Arrest occurs upon chemokine mediated transformation of integrins to their 
high affinity conformation. Integrin bond strengthening and signalling mediate the recruitment of additional adhesion proteins. Mac1 – 
ICAM1 interactions then drive D) Crawling across the luminal surface toward preferred sites of transmigration often at sites of matrix 
protein low expression regions. (E) The Extravasation or diapedesis of the leukocyte may then occur either through a trans-cellular or 
para-cellular route. (F) Once in the brain parenchymal leukocytes release a variety of cytotoxic and pro-inflammatory substances 
contributing to neuronal damage and amplifying the local inflammatory response. (P. Holloway, unpublished) 
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1.4.1 Selectin-glycan interactions: Capture and rolling 
The initial capture and rolling of leukocytes is mediated by the interactions of the 
selectins with their ligands. The selectins belong to the calcium-dependent, type I trans-
membrane glycoprotein family of adhesion molecules which comprises of P-selectin, L-
selectin, and E-selectin, named with relation to the cell type on which they were 
originally identified (Platelet, Leukocyte and Endothelium). P and E-selectin are 
expressed by the inflamed endothelial cells with P-selectin also being expressed by 
activated platelets, whereas L-selectin is constitutively expressed by most leukocytes 
[47]. All three selectins have a similar basic structure containing: a short cytoplasmic tail, 
single trans-membrane domain, a variable number of consensus repeats (CRs), an 
epidermal growth factor–like domain and an extracellular N-terminal lectin-like ligand 
binding domain [47, 48]. The CRs provide a length to the selectins necessary to extend 
beyond the negatively charged glycocalyx of the endothelium and permit leukocyte-
endothelial cell interactions [48]. Variations between the lectin-like domains of the 
selectins confer selectivity for their mucin-like glycoprotein ligands such as P-selectin 
glycoprotein ligand-1 (PSGL-1), CD34, CD44 and E-selectin ligand-1 (ESL-1) [47]. 
Although a number of these mucin-like ligands are constitutively expressed on the 
leukocyte cell surface, selectin binding is glycosylation dependant and all known selectin 
ligands require enzymatic modification by a sialyltransferase and fucosyltransferase VII 
[47]. For selectins to be able to bind a ligand the minimal motif of a sialyl-Lewis X 
tetrasaccharide (SLex) is required. Further modifications such as sulphation are required 
to optimize binding to specific selectin isotopes [48, 49]. Selectin-glycan interactions are 
able to mediate capture and rolling of leukocytes under the conditions of blood flow due 
to the transient nature of these bonds, displaying high on- and off-rates. The shear 
stress exerted by blood flow is in fact essential to selectin binding and under static 
conditions the importance of selectins in leukocyte recruitment is greatly reduced, as 
capture and rolling may be bypassed [50]. 
P-selectin is the earliest adhesion molecule to be up-regulated on the luminal-endothelial 
surface in response to pro-inflammatory signals or noxious stimuli.  Released from 
Weibel–Palade bodies (WPB) in endothelial cells and α-granules in platelets, the up-
regulation of P-selectin is rapid and occurs independently of transcription [46, 49].  In 
rats, up regulation of P-selectin has been observed as early as 15 min following 
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ischemic insult [46]. This increase in P-selectin expression mediates the initial capture or 
“tethering” and rolling of leukocytes. 
Subsequent to capture the transient formation of selectin–glycan bonds at the leading 
edge of the leukocyte and the breaking of these bonds at the trailing end allows for the 
rolling of the leukocyte along the endothelium. E-selectin is synthesized de novo in 
response to mediators such as IL-1β, TNF-α and LPS and expression has been 
observed on the endothelial cell luminal surface within 2 h of ischemic stroke in rats [51]. 
Despite this delayed expression of E-selectin its presence on the endothelium temporally 
overlaps that of P-selectin acting synergistically to decelerate rolling leukocytes.  In 
addition L-selectin, via interactions with PSGL-1, may mediate leukocyte–leukocyte 
interactions facilitating secondary leukocyte capture. This allows leukocytes that do not 
express PSGL-1 variants appropriate for E-selectin or P-selectin binding, to reach sites 
of inflammation [47]. 
1.4.2 Integrins and IgSF: Slow rolling and arrest 
In conjunction with selectin-mucin like glycan interactions, integrins binding to their 
immunoglobulin superfamily (IgSF) ligands enable the slow rolling and adhesion of 
leukocytes in the cerebral microvasculature within the first few hours of CNS injury [52]. 
The integrins are a large family of membrane spanning glycoprotein adhesion molecules 
expressed predominantly by leukocytes. Integrins are hetero-dimmers consisting of one 
α-subunit non-covalently bound to a β-subunit The integrin subfamilies found to be most 
relevant to leukocyte recruitment are the β1-integrin and β2-integrins [47, 53]. The 
immunological importance of the β2-integrins is illustrated by the phenotype of patients 
with leukocyte adhesion deficiency type 1 (LAD-1). These patients lack a functional β2-
integrin gene and consequently display impaired wound healing and severe infectious 
complications [48]. 
Members of the IgSF expressed on the endothelial surface serve as ligands for the 
leukocyte integrins. In the cerebral microcirculation these include; intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and platelet 
endothelial cell adhesion molecule-1 (PECAM-1).  
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The process of leukocyte arrest from rolling is also mediated by integrin-IgSF 
interactions and is rapidly initiated in response to selectin mediated signalling and 
chemokine activation [47, 48, 53].  Chemokines produced by endothelial cells, platelets 
and perivascular cells may be secreted to the luminal surface and bound to endothelial 
extracellular matrix components such as heparin sulphate and glycosaminoglycans, 
protecting them from proteolytic cleavage and also serving to localise the chemotactic 
signal [47]. Detection of these chemokines by leukocytes triggers intracellular signalling 
and a conformational change in the integrin cytoplasmic domain [54]. This change 
propagates to the extracellular domain inducing a transformation from a bent low-affinity 
form to the extended intermediate and high-affinity conformations [55]. These integrin 
activation events enable leukocyte arrest on the endothelial surface [54]. Integrins on the 
leukocyte surface may exist in a range of these conformational states at any one time, 
thus allowing for a highly dynamic control of integrin affinity and leukocyte arrest [47, 54]. 
Experiments using genetic knockout mice have provided strong evidence for the critical 
role of the integrins in the inflammatory response of the cerebral microcirculation 
following acute cerebral ischemia. In studies by Connolly et al. [44] knockout mice for the 
integrin ligand ICAM-1 showed a significant decrease in leukocyte extravasation 
following MCAo which translated into a 75 % decrease in infarct volume and a 3.7-fold 
decrease in mortality. Additionally mice null for the integrin β subunit CD18 subjected to 
transient focal cerebral ischemia, displayed a 53 % decrease in infarct volume compared 
to CD18+/+ mice [56]. Furthermore this effect was only observed in the presence of 
reperfusion.   
1.4.3 Crawling and transmigration 
Before crossing the walls of post capillary venules, neutrophils and monocytes have 
been observed to “crawl” along the endothelium seeking out preferred sites for 
diapedesis following chemotactic gradients [47].  
Following successful recruitment to the EC luminal surface, leukocytes must then breach 
and transmigrate across the endothelium. Leukocytes have been reported to migrate 
either in a para-cellular fashion, through reorganisation and utilisation of inter-endothelial 
junction molecules or by a trans-cellular route involving the formation of vesiculo-
vacuolar organelles consisting of ICAM-1-containing caveolae [57] In the 
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microvasculature of the brain, the ability of leukocytes to utilise the para-cellular route is 
limited due to the highly-organized inter-endothelial tight junctions of the BBB. In 
inflammatory pathology of the CNS, and also in the similarly immune privileged retina, 
the up-regulation of leukocyte trafficking has been widely documented as occurring 
preferentially via trans-cellular diapedesis pathways [58-60].  
Subsequent to infiltration of the endothelial cell barrier, migrating immune cells must 
then penetrate the endothelial basement membrane (BM) followed by the glia limitans 
with its distinct basement membrane [61]. Whereas extravasation through the vascular 
endothelial-cell barrier may be rapid (~2–5 min), penetrating the BM takes place over a 
considerably longer period (5-15 min) [47]. While endothelium and endothelial BM 
penetration is understood to be mediated through the actions of the β1-integrins, the 
mechanisms that drive the leukocyte migration across the parenchymal basement 
membrane are not as well characterised.  However MMP–2 and MMP-9 cleavage of 
dystoglycan, a transmembrane protein with the role of anchoring the astrocyte endfeet to 
the parenchymal BM, has been shown to play an important role in this process [62]. 
Furthermore tissue plasminogen activator (tPA) has also recently been suggested to 
possibly play a role in this leukocyte migration through the parenchymal BM [60]. 
Upon migration into the cerebral parenchyma leukocytes may release an array of 
cytotoxic agents including MMPs and a further release of cytokines such as IL-1β [25, 
63-65]. Indeed studies have demonstrated a correlation between increasing levels of the 
cytokine IL-1β and an amplified infarct severity following ischemic stroke [66].  
The detrimental effects of leukocyte recruitment following stroke have been supported by 
several reports demonstrating reduced neurological injury in rat models of stroke, 
through therapeutic targeting of various adhesion molecules [67-69]. Further to this, 
animals with deficiency in adhesion molecules display reduced infarct volume after 
transient focal cerebral ischemia [12] and reduced neuronal damage in experimental 
autoimmune encephalomyelitis [70]. 
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1.4.4. Time course of inflammation and stroke progression 
The temporal progression of the post-ischemic inflammatory response is complex, with 
immune cells differentially and synergistically contributing to the developing brain injury 
[32]. Although the term inflammatory cascade suggests a linear sequence of events, the 
cellular and humoral inflammatory response following stroke in fact consists of a number 
of feedback loops and self-reinforcing processes with temporal overlaps leading to an 
amplification of the response (Figure 1.1), pushing forward a general progression of 
events. Figure 1.3 demonstrates the temporal pattern of chemokine and chemotactic 
signal release along with the relative activation and recruitment of immune cells in the 
brain following stroke [32, 71-77].  
 
 
  
39 
 
Figure 1.3 Time course of the inflammatory response following stroke. within minutes following 
stroke pre-formed TNF-α and IL-1β are released from resident activated cells with a second peak in 
these cytokines being from their release by invading immune cells and resident cell de novo synthesis. In 
response to pro-inflammatory signals endothelial adhesion molecules are up regulated, with P-selectin 
exocytosed from WPBs being the most rapid, with a second peak resulting from the de novo synthesis of 
this adhesion molecule. Microglia, can be activated (dashed lines) within minutes following stroke and 
may functionally transform into macrophages releasing a variety of cytokines and chemokines. While 
astrocyte activation and up regulation is more delayed. Neutrophils are the first blood born immune cells 
to arrive in the brain where they release a number of cytotoxic compounds. The arrival of monocytes is 
more delayed, with those giving rise to an M1 phenotype enhancing inflammatory responses but with the 
arrival of M2 cells making the beginnings of inflammatory resolution. Time points are taken from 
experimental findings in rats due to the dearth of data in human or murine stroke (references given to the 
right of each row). Existing data from both human and mouse studies have however been found to 
correlate well. P Holloway, unpublished.  
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1.4.5. Inflammatory resolution 
Whist pro-inflammatory mediators orchestrate and augment the acute-phase of the 
inflammatory response this also initiates the release of a number of “pro-resolution” 
factors that promote catabasis (the return to homeostasis). Upon the arrival of 
macrophages and monocytes, signals are released that inhibit further leukocyte 
trafficking, promote the normalization of chemokine gradients and the return to a non-
inflammatory environment [78]. Key players in this process include lipoxins, D series 
prostaglandins and resolvins [78]. Additionally alpha-melanocyte stimulating hormone (α-
MSH) has been suggested as acting as an endogenous factor promoting resolution. 
Hijacking such endogenous systems for the resolution inflammation may prove to be 
extremely fruitful in halting a pathological inflammatory reaction whist retaining 
processes for the removal of dead cells and initiation of tissue repair. 
1.5. Animal models of stroke 
Due to the complex pathology of stroke and the elaborate interplay between numerous 
cell types which underlies the inflammatory process the disease cannot yet be 
adequately replicated in vitro. Thus for the investigation of prospective therapeutics, 
animal models must be utilised in combination with in vitro studies. Whilst non-human 
primates may have a brain structure and cerebral vasculature most similar to humans, 
ethical consideration and cost mean that experiments on primates represent only a small 
proportion of animals used in stroke research [79]. Due to the availability of genetically 
manipulated animals, rodents are currently the preferred model organisms [80]. 
However, generating a reproducible rodent model which accurately mimics the human 
condition has proven to be challenging [81].  
1.5.1. Current models  
There are currently less than 10 experimental models of focal stroke [81]. In such 
models ischemia may be produced by either introduction of a filament into the middle 
cerebral artery, Macrosphere embolization or photochemical induction of a common 
carotid artery thrombosis. Out of these middle cerebral artery occlusion (MCAo) is the 
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most reproducible [81]. However focal stroke models produce infarct sizes far larger than 
those observed in non-fatal human stroke with rodent models displaying a peak infarct 
volume occupying 20-40 % of the brain [82] whereas CT scans reveal this to be on 
average only 4.4 % in humans [83]. 
For the production of global ischemic stroke models there are four major arteries which 
may be occluded in combination, with the minimum being occlusion of both common 
carotid arteries (BCCAo) [80]. Such methods however require deep anaesthesia and 
invasive surgery, which in itself may affect physiology. Additionally animals vary in their 
susceptibility to ischemic damage, merely amongst rodents there exists significant 
variation in the wiring of major vessels supplying the brain [84], gerbils for instance do 
not possess a Circle of Willis [85]. Other global stroke models include the application of 
a neck tourniquet or the induction of cardiac arrest by administration of cold potassium 
chloride  (KCl) [86, 87]. 
1.5.2. Comparison of human and rodent brain 
The use of studies in mice have enabled a great insight into the pathophysiology of 
human stroke, however between 65 and 75 million years of evolution separate these 
species [88] and as such there can be huge discrepancies in physiology that must be 
understood before meaningful data can be extrapolated. Despite the obvious disparity in 
size there are a number of differences between the human and rodent brain that limit the 
translation of results obtained. Humans have gyrencephalic brains and relatively far 
greater amounts of white matter than found in the lissencephalic rodent brain. Despite 
white matter ischemia often being more severe than grey in humans, due to lower 
collateral flow, studies of white matter damage are to some extent limited in rodent 
models [89]. As such, in comparison to grey matter pathophysiology, the current 
understanding of mechanisms underlying white matter damage and the role of 
oligodendrocytes in I/R remains relatively incomplete [89].  
In addition to macroscopic differences between human and rodent brains, cellular 
elements and their relative abundance also contrast. Throughout evolution the number 
and structural complexity of astrocytes have increased to support more sophisticated 
neuronal circuitry [34]. As such humans not only have larger, more functionally diverse 
astrocytes but the astrocytes to neuron ratio found in the human cortex is higher, 1.5:1 
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compared with that found in rodent cortex, 1:3  [34, 90, 91]. Due to their intimate 
involvement in blood flow regulation, anti-oxidative capabilities and pro-and-anti-
inflammatory potential, the quantitative and qualitative differences in human and rodent 
astrocytes may impact stroke pathophysiology [34]. As such this is one of the many 
aspects that should be taken into consideration when translating stroke therapies to 
humans.   
1.5.3. Comparison of human and rodent innate immune response 
Due to the different pathological pressures placed on humans and mice differences in 
both the components and functioning of each species immune systems have developed. 
Whilst the overall organisation of the immune system is largely similar between mice and 
humans, it should not be taken for granted that anti-inflammatory therapies effective in 
mice will have the same effect in humans. 
Whereas the human immune system is strongly supported by a predominance of 
circulating neutrophils which account for 50-70 % of all leukocytes, neutrophils only 
make up 10-25 % in mice who rely on a larger population of lymphocytes (75–90 %) 
which in humans is between 30 and 50 % [88].  
Not only do the relative populations of cellular elements differ between human and 
murine immune anatomy but also the molecular and chemical features vary. A number 
of immune-related molecules including IL-8 receptor alpha (CXCR1), IL-8, neutrophil-
activating peptide-2 (CXCL7), CCL18, monocyte chemoattractant protein (MCP)-4, and 
eotaxin-2/3 (CCL24/CCL26) have been found to be expressed in humans but not mice 
[88, 92, 93]. On the other hand CCL6, macrophage inflammatory protein-1 gamma 
(CCL9), and MCP-5 are present in mice but not in humans [88, 93]. Also in mice, P-
selectin may be induced by TNF-α and lipopolysaccharide (LPS) via an NF-κβ regulated 
promoter element, however in humans P-selectin is not under the control of NF-κβ and 
expression levels are unaffected by TNF-α and LPS [94]. E-selectin in humans is 
strongly up-regulated in response to TNF-α perhaps suggesting a more prominent role in 
leukocyte recruitment than in mice [88].  
The impact of these differences must therefore be considered when translating findings 
between species and in the identification of drug targets. Indeed subtle differences in the 
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melanocortin receptor system exists between species, the main macrophage MC 
receptor in mice is MC3 where as in humans it is MC1 [95]. Such discrepancies must 
therefore be taken into account when analysing data from murine models. 
1.5.4 Efficiently utilising rodent models 
Considering the above differences in physiology and the various limitations of the 
disease models efficiently using currently available models and appropriate 
interpretation of data is essential for an effective assessment of a candidate therapy. 
One pitfall in current animal research into potential treatments for stroke is the failure to 
address the issue of co-morbidities. Experiments are largely carried out on animals 
which are otherwise healthy where as in the clinic large numbers of patients present with 
a variety of co-morbidities such as diabetes and obesity [4]. Additionally time of 
administration of test compounds should be carefully assessed, as patients are often 
unable to receive treatments until several hours following stroke. Indeed due to the 
hugely variable nature of stroke it is essential to test compounds in the context of varying 
lengths and severity of ischemia and at differing times of reperfusion. 
Whist no singular perfect model exists, a combination of in vitro techniques utilising 
human cells and effective use of different animal models is required for the exploration of 
potential stroke treatments.  
1.6. Therapeutic strategies for the treatment of stroke 
1.6.1. The challenge of developing an effective therapeutic for stroke 
Despite the huge impact of stroke, current therapeutic options remain extremely limited. 
Surgical interventions include endarterectomy and angioplasty of the carotid artery, to 
mechanically clear the occluded vessel. However i.v administration of tissue 
plasminogen activator (t-PA) within 3 h of stroke onset remains the only approved 
pharmacological treatment for acute ischemic stroke in the western world. Recent 
studies have suggested the therapeutic time window of t-PA may be extended to 4.5 or 
even 9 h following stroke onset [96], although this is still under debate. Nevertheless t-
PA therapy is far from adequate, with clinical audits having shown only 2 % of all 
patients to be eligible [97] and 6.4 % of patients developing substantial brain 
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haemorrhage as a complication [98, 99]. t-PA has also been demonstrated to be a 
significant factor in causing excitotoxic injury, promoting NMDA-mediated cell death 
[100] and in activating MMP-9; potentially enhancing BBB disruption, increasing cerebral 
inflammation and further aggravating any hemorrhagic tendencies [101]. 
The paucity of effective treatments has driven research into a plethora of protective 
compounds. Prior to 2006, a total of 1,082 prospective neuroprotective interventions 
have been published on the treatment of stroke [102]. The translation of these hopefuls 
to the clinic has however been extremely disappointing.  
Neuro-restorative therapies and treatments promoting repair and recovery will not be 
reviewed here however for informative reviews on the use of neurogenic factors and 
stem cell therapies in stroke please see Chen & Chopp, 2006 [103] and Smith & Gavins, 
2012 [104]. 
1.6.2. Promoting reperfusion 
A number of novel thrombolytic compounds have been investigated (summarised in 
table 1.2) yet the risk of haemorrhage remains a significant obstacle when entering 
clinical trials. The most promising of these thrombolytics, Desmoteplase, a component of 
vampire bat saliva, has been shown to reduce this risk [105, 106]. Whilst these 
thrombolytics are targeted toward the opening of the occluded vessel and essential 
restoration of blood flow to the ischemic tissue, such singular treatments fail to 
adequately address the multiple pathogenic events that occur subsequent to 
reperfusion. Thus there is a great need for additional therapeutics targeted toward the 
treatment of ischemia I/R injury and a resolution of inflammation in the brain. 
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Therapeutic 
goal Compound Mechanism of action Outcome of clinical trials Ref. 
Prevention 
E-selectin Induction of mucosal tolerance to E-selectin  Phase II study terminated   
Ximelagatran Thrombin inhibitor intended as a preventative
 of stroke to 
replace aspirin or warfarin 
SPORTIF III and V phase III clinical trials showed high levels of 
Hepatotoxicity  [107] 
Perindopril Angiotensin-converting enzyme (ACE) inhibitor Perindopril group had a 28% relative risk reduction. Trials on-going.  
Thrombolysis 
and 
restoration of 
blood flow 
rtPA (alteplase) Thrombolytic serine protease which cleaves plasminogen to plasmin. Trials successful, FDA approved. Currently in use. [108] 
Streptokinase  A serine protease which  cleaves plasminogen to plasmin Phase III clinical trial ended due to increased risk of intra-cerebral haemorrhage [109] 
Desmoteplase Plasminogen activator derived from the vampire bat saliva In 2009, phase III clinical trials began. Outcome awaited.  [105] 
Ancrod (Viprinex) A fibrinogenolytic agent purified from pit viper venom Phase III ESTAT trial showed Increased risk of haemorrhage  
Protection 
from 
Excitotoxicity 
Clomethiazole Positive allosteric modulator at the GABAa receptor Clomethiazole acute stroke study (CLASS) showed no benefit [110] 
Aptiganel 
Cerestat® 
Glutamate antagonist, non-competitive NMDA channel 
blocker Phase III trial halted due to lack of therapeutic impact.  
Protection 
from free-
radical and 
ROS damage 
 
Cerovive (NXY-
059) Nitrone-based free radical trapping agent Promising initial results, but phase II trial showed no improvement. [111] 
Edaravone  Free radical scavenger 
Approved in Japan since 2001 with modest to large improvements in 
functional outcome. However remains under clinical investigation in 
other countries.  Phase II trials showed improved functional outcome 
[96, 
112] 
Anti-
inflammatory 
protection 
Enlimomab Anti-ICAM-1 monoclonal antibody Phase III trials ended due to enhanced neurological disability. [113]  
UK-279, 276 Selective antagonist of CD11b Phase II trials found no overall benefit. [52] 
Minocycline Inhibits apoptosis by attenuation of TNF-alpha. Also 
suggested to inhibit NF-B translocation in microglia. 
2007 pilot study showed improved outcome. However confirmation 
by a larger controlled double-blinded trial still required. [114] 
Acetaminophen 
(Paracetamol) 
Anti-inflammatory and anti-pyretic via inhibition of cyclo-
oxygenase.  
Phase I clinical trials showed no benefit. Treatment also carries risk 
of liver damage due to the high doses used. [115] 
rIL-1RA Interleukin-1 receptor antagonist Phase II trials promising [116] 
LeukArrest IgG1 antibody to human CD18 Phase III trials showed no benefit. [113] 
Table modified from Holloway et al., 2011 with permission from authors  
Table 1.2 A non-exhaustive list of therapeutic strategies and compounds that have entered clinical trials for stroke therapy. 
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1.6.3. Neuroprotection  
With a more detailed understanding of the pathophysiology of stroke has also come an 
appreciation that simply re-introducing blood flow may not be sufficient to halt stroke 
progression, however the damaging events triggered by ischemia might also provide 
opportunities for intervention, which could extend the therapeutic window. 
Neuroprotective strategies aim to rescue ischemic neurons from irreversible damage by 
targeting key components of the biochemical ischemic cascade. 
Some of the most intensively studied neuroprotective candidates are the glutamate 
receptor antagonists [117]. Glutamate, the most abundant excitatory neurotransmitter in 
the CNS, plays a major role in post stroke excitotoxicity [117]. As such blocking NMDA, 
AMPA, KA, and metabotropic glutamate receptors has provided the therapeutic rational 
for a number of compounds however lack of efficacy along with potential psychiatric and 
cardiovascular side effects have limited their translation to the clinic [118, 119]. 
Furthermore such therapies also fail to act upon non-neuronal cell types such as 
astrocytes, microglia or vascular cells of the ischemic brain.  
Failure of glutamate receptor targeted therapies emphasises the notion that NMDA-
AMPA pathways make up only a subset of reactions leading to ionic imbalance. As such 
a number ion channel modulators have also been investigated for the treatment of 
stroke, including calcium (Nimodipine), sodium (Fosphenytoin) and potassium (BMS-
204352) channel blockers. However to date clinical trials of these therapeutics have all 
terminated due to failure to show benefit [117, 119] most likely due to the diversity of 
mechanisms that underlie cellular damage in cerebral I/R injury. 
Another strategy to achieve neuroprotection has been to quench the damaging effects of 
ROS using free radical scavengers.  Such treatments have the benefit of protecting both 
cells of the brain parenchyma and the vasculature. While a number of trials with free 
radical scavengers have resulted in limited success, Edaravone, a low-molecular-weight 
antioxidant, has been approved in Japan for use as a neurovascular protective agent in 
ischemic stroke since 2001 (although in other countries it still remains under clinical 
investigation) [96]. Aside from protection against free radical induced damage 
Edaravone has also been shown to reduce brain oedema and high-mobility group box 1 
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(HMGB1) induced neuronal cell death [96], thus highlighting the importance of targeting 
multiple aspects of stroke pathology to achieve effective neuro-protection. 
1.6.4 Anti-inflammatory treatment  
Inflammatory processes following stroke cause a significant amplification of cellular 
damage, contributing at multiple levels to a highly cytotoxic environment and providing a 
significant source of ROS. As such, inhibiting this damaging inflammatory response has 
provided a promising therapeutic rational to achieve neuro-protection following stroke.  
Anti-inflammatory therapeutic strategies for stroke have received considerable attention 
due to a number of potential benefits; Anti-inflammatory treatments have an extended 
therapeutic window, and could be administered to patients outside the time window for 
thrombolysis. Indeed due to the major role of inflammation in I/R injury, anti-inflammatory 
treatments would provide a fitting complement to current therapies, which promote 
reperfusion. Furthermore, anti-inflammatory strategies have also proven beneficial in 
haemorrhagic stroke, potentially enabling immediate treatment before imaging and 
exclusion of haemorrhagic stroke. 
A major strategy in developing anti-inflammatory treatments has been to block pro-
inflammatory mediators or adhesion molecules. Pharmacological blockade of different 
integrins using monoclonal antibodies has shown neuroprotection in a number of models 
of stroke [52]. Despite these initial promising studies, such treatments have however, 
failed to show efficacy in clinical trials. Failure of the anti-ICAM-1, Enlimomab, in 2001, 
was attributed to patients developing adverse immune responses to the mouse antibody. 
Furthermore integrins are also known to be involved in a number of other cellular 
processes such as proliferation and apoptosis and the full extent of integrin signalling 
function is still to be fully characterized [52, 55]. The most probable limiting factor to such 
therapies however, is that the inflammatory response is a robust system propagated by 
diverse and redundant pathways, and as such cannot be effectively subdued by 
neutralising just a single component. As such, harnessing endogenous mechanisms for 
the resolution of inflammation, which impact upon multiple elements of the inflammatory 
response may prove to be a fruitful strategy. 
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The melanocortin system has been demonstrated to be an endogenous system to 
counteract inflammation allowing a modulation rather than an indiscriminate termination 
of the inflammatory response [120]. 
1.7. The melanocortin receptor system 
The melanocortin peptides have been shown to exert a multitude of effects on numerous 
physiological functions, including regulatory roles in skin pigmentation [121], energy 
metabolism [122], memory [123], thermoregulation [124, 125], nociception [126] and 
inflammation [127, 128]. Thus the melanocortin system is increasingly being recognised 
as a promising target for pharmacological intervention in a wide variety of disorders 
[129].  
The well documented potent anti-inflammatory and neuro-regenerative circuits centred 
on the melanocortins receptors make them a particularly attractive target for the 
development of novel therapeutics for stroke. 
1.7.1. Melanocortin peptide production 
Adrenocorticotrophic hormone (ACTH) and α, β and γ melanocyte-stimulating hormones 
(MSH) are collectively known as the melanocortin peptides [130]. These peptides are 
derived from the post-translational processing of a large pre-cursor molecule known as 
the pro-opiomelanocortin protein (POMC) which is 241 amino acids in humans [131] and 
209 in mouse and rat [132, 133]. POMC comprises of three main domains; the N-
terminal “pro-γ-MSH” containing the sequence corresponding to γ-MSH; the central 
“ACTH domain”, covering both the ACTH and α-MSH regions and the “C-terminal β-
lipotropin”, which provides the β-MSH peptide (Figure 1.4). 
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A number of enzymes including pro-hormone convertases 1 and 2 (PC1 and PC2) and 
carboxypeptidase E mediate the processing of POMC [134, 135]. PC1 may cleave 
POMC to produce pro-ACTH1–39 and β-lipotropin. Further PC1 mediated processing of 
pro-ACTH1–39  may then lead to the formation of ACTH1–39 [136]. PC2 generates γ-MSH, 
ACTH1–17  and β-endorphin [136]. ACTH1–17  may then be cleaved by carboxypeptidase 
E, amidated by Peptidyl-glycine α-amidating monooxygenase (PAM) and acetylated by 
n-acetyltransferase (N-AT) to form α-MSH [130]. This processing of the POMC protein is 
tissue-specific and extremely versatile; enabling the regulation of melanocortin activity 
through altering their ratios and composition in response to hormonal, neuronal and 
environmental stimuli [134, 137]. For example in the corticotrophs of the anterior 
pituitary, PC1 is the predominate enzyme thus POMC processing biases ACTH 
Figure 1.4  The post-translational processing of POMC Pro-opiomelanocortin 
protein is sequentially cleaved pro-hormone convertases and carboxypeptidase E to 
form the melanocortin peptides ACTH, β-MSH and γ-MSH. α-MSH is produced by 
amidation and acetylation of ACTH 1-17. 
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production. On the other hand in the pituitary pars intermedia, PC2 expression accounts 
for α-MSH and β-endorphin generation [120, 138]. Further enzymatic modifications of 
the POMC derived peptides such as phosphorylation, glycosylation and methylation 
have also been found to be of particular importance in their biological activity, regulation 
and binding specificity [139].  
The melanocortin peptides all share an invariant sequence of four amino acids, His-Phe-
Arg-Trp (HFRW), corresponding to the minimum sequence required for receptor binding 
and being a major determinant of their biological activity [120, 130]. This discovery has 
led to the production of a number of potent and selective melanocortin agonists and 
antagonists (summarised in table 1.3). Such selective melanocortin active peptides have 
proved to be extremely useful tools in elucidating the roles of specific melanocortin 
receptor subtypes.  
More recently the C-terminal tripeptide sequence of α-MSH, Lysine-Proline-Valine 
(KPV), has also been shown to exert anti-inflammatory actions, although these effects 
were found to be independent of receptor binding [140]. The sequences of key 
melanocortin compounds and the two distinct pharmacophores are illustrated in table 
1.4. 
 
  
51 
Modified from Holloway et al., with permission from authors
Class Hormone/ Compound 
Agonist (+) 
Antagonist 
(-) 
Relative affinity 
for MC subtype Pre-clinical data refs 
Endogenous 
peptides 
α-MSH + MC1>3>>4>>5 
↓ TNF-α and IL1-β expression 
following cerebral I/R in mice. 
improved recovery in CNS-
lesioned rats 
[134, 
141-
143] 
β-MSH + MC1>3>4>>5 
↓NF-kB activation and ↓iNOS 
activity in LPS induced brain 
inflammation 
[141, 
144] 
γ-MSH + MC1>3>>4=5 ↓ NO production in mouse model of acute brain inflammation  
[141, 
144] 
ACTH + MC1>3>4>5 
↓TNF-α, IL-6 and NO in murine 
microglial cell lines challenged 
with LPS. Currently in phase III 
trials for haemorrhagic shock. 
[120, 
134] 
Agouti 
signalling 
protein (ASP) 
- MC4>1>>5>3 
↑ inflammatory response to picryl 
chloride challenge in mice over 
expressing ASP 
[128, 
145] 
Truncated 
peptides 
α-MSH 6–9 
(HFRW) + 
No reported 
selectivity 
↓ PMN accumulation in crystal-
induced mouse peritonitis. [140] 
MSH 11–13 
(KPV) Does not bind  
↓Activation of NF-κB following 
central injection of LPS. ↓ PMN 
accumulation in crystal-induced 
mouse peritonitis 
[140] 
Synthetic 
peptides 
based on  
His-Phe-
Arg-Trp 
invariant 
sequence 
NDP-α-MSH 
(Melanotan-I, 
Afamelanotide
) 
+ MC1>3>4> 5 
↑ neuroprotection and functional 
recovery in murine and gerbil 
BCCAo and in rat MCAo stroke 
models. 
[134, 
146-
148] 
Melanotan-II + MC4>1>>5>3 ↑ Nerve regeneration following crush lesion in rat.  [134] 
[D-TRP8]-γ-
MSH + MC3>>5>4 
↓Leukocyte recruitment, and 
chemokine generation following IR 
in mouse mesentery. 
[127] 
SHU9119 
- at MC3/4 
+ at MC1/5 
MC4>1>5>3 exacerbates in LPS induced fever [130, 149] 
HS014 - MC4>>5>3>1 
Blocks the anti-inflammatory 
effects of β-MSH in mouse brain 
inflammation 
[144, 
149] 
Small 
molecule  
THIQ + MC4>>1>>3>5 Weakly ↓ LPS-induced nitric oxide overproduction in brain tissue.  [150] 
BMS-470539 + 
MC1>>4>5 
no measurable 
activity at MC2 or MC3 
↓ leukocyte trafficking in the 
mouse mesentery in LPS-induced 
inflammation and I/R injury. 
[151] 
Table 1.3: A non-exhaustive list of melanocortin based compounds; characterisation of 
receptor binding properties and relevant pre-clinical data 
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Table 1.4: The amino acid sequences of key melanocortin peptides: two distinct pharmacophores  
 
Amino acids forming a ring structures are circled 
 Amino acid 
Peptide 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
α-MSH Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val            
ACTH Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr Pro 
[Dtrp8]-y-
MSH 
 Tyr Val Met Gly His Phe Arg D-Trp Asp Arg Phe Gly            
NDP-αMSH 
(Melanotan I) 
Ser Tyr Ser Nle Glu His D-Phe Arg Trp Gly Lys Pro Val            
Melanotan II    Nle Asp His D-Phe Arg Trp Lys               
SHU9119    Nle Asp His D-Nal Arg Trp Lys               
HSO14    Cys Glu His D-Nal Arg Trp Gly Cys Pro Pro Lys Asp          
KPV           Lys Pro Val            
      
Conserved MC binding 
sequence 
. KPV sequence            
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1.7.2. The melanocortin receptors 
Five melanocortin receptors have been identified (MC1–MC5) and subsequently cloned. 
The differing tissue expression profiles and affinities for the melanocortin peptides are 
summarised in table 1.5. The MCs belong to class A subfamily 13 of the rhodopsin-like 
G protein-coupled receptors [120]. These seven trans-membrane receptors are the 
smallest known G protein coupled receptors, possessing a small second extracellular 
loop and short amino and carboxy terminal ends [120]. The MCs share a high sequence 
homology, with MC4 and MC5 showing 60 % identity [130]. With the exception of MC2, 
which is activated exclusively by ACTH, each MC can be activated by any of the 
endogenous melanocortin peptides. All MCs are positively coupled to adenylate cyclase 
via Gs and activate cAMP based signalling pathways. MC activation has also been 
shown to initiate other pathways via increasing intracellular calcium and secondary 
activation of inositol triphosphate, mitogen-activated protein kinase (MAPK) signalling 
has also recently been reported [152]. As with other G-protein-linked receptors the MCs 
also possess recognition sites for protein kinase C and/or protein kinase A [130, 153]. 
1.7.2.1 MC1  
The MC1 was the first melanocortin receptor to be cloned and originally investigated for 
its role in melanogenesis. MC1 has since been demonstrated to be expressed in many 
non-pigmentary cells including neutrophils, monocytes, micro-vascular ECs and 
astrocytes [120]. Anti-inflammatory and immune-regulatory functions for the MC1 have 
since been demonstrated in a number of studies. Both MS05 and MS09 are selective 
MC1 agonists and have been shown to down regulate the expression and secretion of E-
selectin, VCAM and ICAM in human vascular ECs stimulated with TNF [154, 155]. 
Conversely antibody neutralisation of MC1 increases both the basal and LPS-stimulated 
production of TNF-α [156]. Additionally the excessive production of the MC1 MC4 
antagonist agouti protein, as with agouti allele “lethal yellow” mice, incurs an enhanced 
inflammatory response to picryl chloride [128]. 
1.7.2.2 MC2 
MC2 is exclusively activated by ACTH and is hence often referred to as the ACTH 
receptor. MC2 mediates steroidogenesis and is expressed in the zona glomelurosa (the 
site of mineralcorticoid production) and zona fasciculate (the site of glucocorticoid 
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production) of the adrenal cortex [120]. Mutations in this receptor are associated with 
familial glucocorticoid deficiency, resulting in ACTH insensitivity, frequent childhood 
infection and hyperpigmentation, due to increased circulating ACTH acting on cutaneous 
MC1. 
1.7.2.3 MC3 
The MC3 expression occurs in a wide variety of cell types and has been demonstrated in 
the hypothalamic paraventricular nucleus, arcuate nucleus, cortex, thalamus, and 
hippocampus of the brain and also in peripheral tissues, macrophages and ECs [120, 
134]. MC3 stimulation has been demonstrated to activate both cAMP and inositol 
phospholipid-Ca2+ mediated signalling pathways [120]. MC3 activation has been shown 
to be important in modulating feeding, autonomic functions, and inflammation [130]. The 
role of the MC3 in the inflammatory response has been illustrated by use of the MC3 null 
mouse. These mice present with an exacerbated inflammatory reaction in the 
microvasculature, suggesting the existence of a tonic anti-inflammatory signal centred 
on the MC3 [127]. Additional experiments by Leoni et al,. demonstrated that 
pharmacological treatment with the selective MC3 agonist [D-Trp8]-γ-MSH resulted in 
reduced leukocyte recruitment following I/R injury in the WT mouse mesenteric 
microcirculation and these effects were confirmed to be absent in MC3 null mice [127]. 
1.7.2.4 MC4 
The MC4 is the main melanocortin receptor of the brain, and thought to be exclusively 
found in the CNS [120]. In addition to Gs/cAMP signalling a number of recent studies 
have provided evidence that MC4 can couple to all three major classes of G proteins, Gs, 
Gi/o, and Gq, and may activate MAPK signalling [157]. Although the most studied effects 
of this receptor subtype are in its control of food intake, metabolism, and sexual function, 
MC4 (with a potential involvement of MC3) has also been shown to activate centrally 
mediated anti-inflammatory adrenergic and cholinergic pathways via the spinal cord and 
vagus nerve respectively [134, 158]. 
1.7.2.5 MC5 
The MC5 shows a relatively ubiquitous expression pattern and has important roles in 
exocrine gland (particularly sebaceous gland) function [159]. A limited amount of data 
also points towards immunomodulatory roles in B and T lymphocytes [160-162]. 
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Table 1.5 Characterisation of the melanocortin receptor sub types; expression and 
function 
Receptor 
subtype 
Affinity for 
the natural 
ligands 
Signal 
transduction Function Distribution Ref. 
MC1 
α-MSH > β-
MSH ≥ ACTH, 
γ-MSH 
Gs-cAMP-PKA 
and  
Gq –PLC- Ca2+ 
 
Pigmentation 
Anti-
inflammatory 
Anti-pyretic 
Melanocytes, 
ECs, glial cells, 
fibroblasts,  
macrophage/monocytic cells, B 
lymphocytes, neutrophils, 
Natural killer cells, a subset of 
cytotoxic T-cells, 
keratinocytes, 
periaqueductal grey matter 
[120, 
121, 
158, 
163] 
MC2 ACTH Gs-cAMP-PKA Steroidogenesis  
Adrenal cortex, 
Dermis, 
sebaceous glands, endocrine 
glands, ECs 
[164, 
165] 
MC3 
γ-MSH β-
MSH ≥ ACTH, 
α-MSH  
Gs-cAMP-PKA 
and 
Gq –PLC- Ca2+ 
 
Cardiovascular 
Anti-
inflammatory, 
energy 
homeostasis 
Brain(hypothalamic 
paraventricular nucleus, 
arcuate nucleus, cortex, 
thalamus, hippocampus) heart, 
Macrophages, ECs, 
[127, 
141, 
166] 
MC4 
β-MSH ≥ α-
MSH ACTH > 
γ-MSH 
Gs-cAMP-PKA 
Gq –PLC-Ca2+ 
and Gi 
Feeding control, 
energy 
homeostasis, 
sexual arousal, 
anti-pyretic 
regulation of 
nociception 
Brain (hypothalamic 
paraventricular nucleus, 
arcuate nucleus, cortex, 
thalamus, hippocampus)  
[134, 
167-
169] 
MC5 
α-MSH ≥ β-
MSH ≥ ACTH 
> γ-MSH 
Gs-cAMP-PKA 
Jak/STAT 
Control of 
sebaceous 
secretion 
Possible role in 
immune 
regulation 
Exocrine glands 
T and B Lymphocytes, 
 
[159] 
Proposed main signalling pathway is shown in bold  
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1.7.2.6 Receptor knockout mice 
Knockout animals have provided a wealth of information and insight into the workings of 
particular genes. These have also proved useful tools in elucidating the many functions 
of the melanocortins both in health and disease. Table 1.6 summarises the different 
phenotypes of mice bearing melanocortin related gene mutations. 
Table 1.6: Melanocortin receptor knockout and mutant mice and their phenotype 
 
Mouse 
strain 
Background 
strain Mutation Phenotype Ref. 
Recessive 
yellow (e/e) - 
A frameshift mutation in the 
MC gene causes a single 
nucleotide deletion at 
position 549; resulting in 
MC1 being unable to 
functionally couple to 
adenylate cyclase and 
activate cAMP signalling. 
Yellow coat colour. Reduced 
nociception  and increased 
analgesic responsiveness to  
morphine-6-glucuronide. 
Aggravated inflammatory 
response in a model of 
inflammatory bowel disease. 
[127, 
170, 
171] 
MC3 KO C57BL/6J 
The entire MC3 coding 
region was deleted by 
homologous recombination 
with a cassette. 
Increased fat mass, 
hyperleptinaemic and reduced 
lean mass despite being 
hypophagic and retaining normal 
metabolic rates. Male MC3KO 
mice also develop mild 
hyperinsulinaemia. Increased 
leukocyte recruitment in the 
mesenteric microcirculation 
following I/R injury indicates  an 
enhanced inflammatory response.  
[172] 
MC4 KO C57BL/6J 
homologous recombination 
with  a neomycin-resistance 
gene deleted virtually all the 
MC4 coding sequence 
Obese, hyperphagic, significant 
hyperinsulinaemia, altered 
metabolic rate but normal lean 
body mass.  
[167] 
MC3/4 
double KO MC3KO and MC4KO cross 
Significantly more obese than 
MC4 KO 
[173] 
MC5 KO C57BL/6J 
A 650 bp ApaI/MscI fragment 
of the single coding exon of 
the MC5 gene was deleted 
by homologous 
recombination. 
Impaired sebaceous lipid 
production, defective cutaneous 
water repulsion and 
thermoregulation.  
[159, 
174] 
POMC-null 
mutation 
129SvEv × 
C57BL/6 
Entire third exon replaced by 
a neomycin-resistance 
cassette; depleting all POMC 
derived peptides. 
Yellow coat, obesity, adrenal 
insufficiency and abnormal HPT 
axis.  
[175] 
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1.8. The melanocortin receptor system as a target for the 
treatment of stroke 
1.8.1. The anti-inflammatory potential of the melanocortin receptor system 
The multiple protective physiological effects of the melanocortins make them an 
attractive target for the treatment of stroke. A large number of studies have 
demonstrated efficacy of melanocortin treatments in a variety of models of both acute 
and chronic inflammatory conditions. Indeed ACTH is currently used as a supportive 
therapy for human gouty arthritis [176]. The potent anti-inflammatory actions of the 
melanocortins have however primarily been shown to be independent of steroidogenesis 
and attributed to the activation of MC1 and MC3 with centrally activated anti-inflammatory 
circuits also being attributed to MC4 [120, 134]. 
1.8.1.1 Multiple mechanisms of action 
The anti-inflammatory actions of the melanocortins are mediated by direct effects on 
cells of the immune system but also by an indirect effect, acting on the function of 
resident, non-immune cells [177]. Melanocortin receptor activation provides a 
multifaceted anti-inflammatory response, inhibiting a pro-inflammatory milieu, whilst also 
affecting inflammatory cell proliferation, activity and migration. Indeed such anti-
inflammatory influences are not only exerted through the reduction of pro-inflammatory 
mediators (TNF-α, IL-1β, IL-8, IL-2, INF-γ, iNOS and COX-2) and adhesion molecules 
(ICAM-1, VCAM-1 and E-selectin) but also through the enhanced expression of the anti-
inflammatory, pro-resolving mediators such as IL-10, superoxide dismutase 2 (SOD2) 
and heme oxygenase-1 (HO-1) [142].  
The melanocortins mediate such diverse anti-inflammatory actions through inhibiting the 
translocation of transcription factor Nuclear Factor Kappa-light-chain-enhancer of 
activated B cells (NF-κB) to the nucleus [134, 142]. Ubiquitous and highly evolutionary 
conserved, NF-κB is considered a master regulator of inflammation and is involved in the 
regulation of more than 150 target genes. NF-κB dysregulation has been linked to a 
number of inflammatory diseases, particularly in disorders of the brain [178]. Under 
basal conditions NF-κB is sequestered in the cytoplasm through its interaction with 
inhibitory IκB proteins which mask the nuclear localization signal via their ankyrin repeat 
domains [179]. A number of stimuli, such as inflammatory cytokines or ROS, initiate NF-
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κB signalling. Upon activation the IκB kinase enzyme complex (IKK-α, IKK-β and NF-κB 
essential modulator (NEMO)) phosphorylates IκB on specific serine residues targeting it 
for ubiquitination and subsequent proteasomal degradation [179]. Nuclear localization 
signals on NF-κB are thus exposed, enabling nuclear translocation, binding to DNA κB 
elements, and gene transcription. Melanocortins may inhibit NF-κB by preventing IKK 
activation, either directly by cAMP or via cAMP activation of PKA. It is also possible that 
melanocortin signalling may also interfere with NF-κB signalling by activation of cAMP-
response element binding protein (CREB). For maximal activation, NF-κB must bind co-
activators such as CREB-binding protein (CBP) [179]. CREB activation leads to its 
nuclear localisation where it may compete with NF-κB for the co-activator CBP and thus 
inhibit NF-κB mediated transcription [180]. Melanocortin signalling induces CREB 
activation, this mechanism could therefore provide an additional level of control over NF-
κB (figure 1.5). 
In addition to the cAMP dependant inhibition of NF-κB the melanocortins may also 
initiate other, less well defined, anti-inflammatory pathways (Figure 1.5). Manna and 
colleagues have shown α-MSH stimulation to induce the cleavage of the IL-8 receptors 
CXCR1 and CXCR2 on the neutrophil cell surface, via release of elastase acting in an 
autocrine fashion [181]. While the exact mechanisms underpinning this effect have yet to 
be defined, this process was shown to be mediated via the MC1 and independent of 
cAMP accumulation [181]. 
Some melanocortin peptides have additionally been shown to exert anti-inflammatory 
effects independent of their receptor binding. The α-MSH terminal tri-peptide KPV is able 
to reduce the production of TNF-α, IL-6, and NO induced by a number of 
proinflammatory stimulus [95]. Furthermore KPV has been found to reduce NF-κB 
activation both in vitro [95] and in vivo [182] and reduce PMN recruitment in a model of 
murine crystal-induced peritonitis [140]. However a strong body of evidence 
demonstrates that KPV does not bind to any melanocortin receptor [140, 183-185] and 
that KPV treatment fails to induce cAMP accumulation [140, 185]. Instead, structural 
similarities between KPV and the IL-1β antagonist KPT indicate that KPV may act as an 
IL-1R antagonist. In agreement with this, KPV reduces IL-1β-induced, but not TNF-α 
induced, NF-κB activation [95] and both KPV and α-MSH have been revealed to displace 
surface binding of radio-labelled IL-1β [95, 186]. 
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Figure 1.5. Proposed mechanisms for MC anti-inflammatory activity. A) The classical anti-
inflammatory pathway centred on the melanocortin receptors is the inhibition of NFκ-β 
translocation to the nucleus. Receptor activation increases cAMP levels via Gs and activation of 
adenylate cyclase (AC). cAMP may directly inhibit IKK activity or induce PKA mediated IKK 
inhibition preventing the degradation of I-κB and NFκ-β translocation to the nucleus. cAMP 
accumulation may also activate CREB which has been shown to inhibit NFκ-β activity by 
competing for CBP, thus preventing NF-KB mediated pro-inflammatory gene transcription (a non-
exhaustive list of NFKB genes inhibited by MCs is shown). Less well characterised mechanisms 
for MC activity also exist. B)  KPV has been proposed to work via competitively antagonising IL-1 
receptor thus preventing IL-1 mediated effects such as NFκ-β activation. C) In neutrophils 
activation of MC1 may cause the release of neutrophil elastases from granuels by an 
uncharacterised, cAMP independent pathway. Elastases may then cleave neutrophil cell surface 
IL-8 receptors CXCR1 and CXCR2. (P. Holloway, unpublished) 
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1.8.1.2 An endogenous anti-inflammatory circuit 
Whist melanocortins may have anti-inflammatory actions on leukocytes, leukocytes 
themselves are also a source of melanocortins [158] suggesting that the melanocortins 
may play a role in a self-limiting anti-inflammatory loop. Additionally In vitro, NF-κB 
activation directly stimulates the transcription of POMC the melanocortin precursor [187]. 
The melanocortins may also be considered to promote the effective resolution of 
inflammation, sparing some of the beneficial repair initiating effects of inflammation, 
rather than simply ending the process. An advantage of melanocortins over many other 
anti-inflammatory agents, such as glucocorticoids, is that they do not hamper the anti-
microbial activities of immune cells, indeed they have been shown to enhance them [96]. 
Melanocortin receptor activation has been shown to enhance macrophage phagocytosis, 
not only of zymosan particles but also efferocytosis of apoptotic neutrophils, thus 
promoting resolution. Mice bearing a non-functional MC1 have also showed delayed 
clearance of infection in a bacterial colitis model [171]. These findings may be of 
particular importance in the treatment of immune-compromised patients and patients 
presenting with co-morbidities. Indeed following a marked acute inflammatory response, 
stroke patients often present with delayed immunodepression 1 to 2 days following 
stroke, associated with a higher susceptibility to respiratory and urinary tract infections. 
Modulating rather than terminating the inflammatory response may thus be highly 
beneficial [11]. 
1.8.2. Melanocortins in the brain 
The anti-inflammatory actions of the melanocortin peptides have been proven effective 
in a number of models of brain inflammation. However in addition to this these peptides 
have displayed a number of remarkable behavioural [134], anti-pyretic [188], 
neurotrophic and neuroprotective effects in the brain [189, 190] whilst also modulating 
nociception [191], metabolism [192] and reducing peripheral inflammation [193] through 
centrally mediated pathways.  
1.8.2.1 Modulation of inflammation in the brain 
Treatment with MC agonists has been shown to improve disease severity in a number of 
disorders of the brain where inflammation plays a critical role, including animal models of 
  
61 
stroke [146, 169] and EAE [194]. Polymorphisms in the MC1 gene have also recently 
been related to poor outcomes in multiple sclerosis [195]. Markedly reduced 
concentrations of circulating α-MSH have also been noted to coincide with unfavourable 
outcomes in patients following acute brain injury of both traumatic and vascular origins 
[196]. 
In addition to these actions on local inflammation in the brain, centrally administered 
melanocortin peptides have also been shown to supress inflammation responses in the 
periphery via a vagus nerve-mediated cholinergic anti-inflammatory pathway [147, 193, 
197]. These effects have been shown to be mediated by the melanocortin stimulation of 
vagal cholinergic pathways and the protective actions of acetylcholine via peripheral 
nicotinic acetylcholine receptors. Such mechanisms may be beneficial in the treatment of 
stroke as it has been shown focal brain ischemia can cause significant adverse effects 
not only in the brain but to also contribute to multiple organ damage and dysfunction, in 
particular to the liver [147]. 
1.8.2.2 Antipyretic activity 
The melanocortins have been shown to display potent antipyretic activities, which could 
prove to be an additional beneficial effect in the treatment of stroke. Subsequent to acute 
stroke patients often develop an elevated body temperature, this has been shown to 
exasperate outcomes and correlate with the severity of stroke [198]. Furthermore 
lowering the general body temperature has been seen as a promising neuro-protective 
therapy and is an aim of a number of treatments for stroke such as paracetamol 
treatment and induced therapeutic hypothermia [199-201]. While the exact mechanisms 
underlying the neuro-protective effects of hypothermia are poorly understood, reduced 
temperature, has been proposed to suppress cerebral oxygen consumption, decrease 
intracellular lysosomal enzyme activity, lower free radical formation and inhibition of 
excitatory neurotransmitter release [117, 201].  
In reducing a pyrogen-induced fever, -MSH has been shown to, on a molar basis, 
exhibit a potency 25,000-fold greater than paracetamol when injected into the cerebral 
ventricular [188] while central administration of the MC antagonist SHU9119 to febrile 
rats exacerbated fever. Furthermore MCs are expressed in key hypothalamic 
thermoregulatory centres and during fever, the concentration of -MSH has been shown 
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to naturally increase by 2–3-fold, suggesting an endogenous role in control of fever [188, 
202]. 
1.8.2.3 Nociception 
The melanocortins have also been shown to modulate the perception of pain in a 
functionally antagonistic manner to the endogenous opioidergic system in the brain 
[191]. Such observations have led to the understanding that melanocortins and 
endorphins initiate opposing actions, thus the POMC system is particularly important in 
regulation of homeostasis by the differential production of melanocortin and endorphin 
peptides [134]. Whereas Opioids induce analgesia, inhibit sexual behaviour and have 
amnesic properties, the melanocortins promote sexual arousal, antagonize morphine-
induced analgesia and enhance short term memory [134].  
The administration of melanocortin receptor agonists has been shown to be pro-
nociceptive in a number of studies. Additionally treatment with the MC4 antagonist 
SHU9119 produces analgesic effects in rats, surprisingly in a more potent manner than 
the μ-opioid receptor agonist, morphine [126]. These may have implications in 
highlighting melanocortin agonists as potential analgesic drugs, but also emphasises the 
importance of selective agonists of the MCs in the treatment of cerebral inflammatory 
conditions, to avoid enhancing nociception. 
1.8.2.4 Feeding behaviour and metabolism: Obesity as a stroke risk 
factor  
The first evidence for a role of the melanocortin peptides in the regulation of human 
appetite came in 1998 with description of two children possessing mutations of the 
POMC gene resulting in defects of ACTH and -MSH synthesis [203]. The children 
displayed severe metabolic derangement hyperphagia and obesity. Since then an 
increasing body of evidence demonstrates the importance of the CNS melanocortin 
receptor, MC4, in obesity. Whilst beyond the scope of this thesis, the MC4 effects of both 
on lipid metabolism and feeding behaviour may be of particular interest in the 
development of drugs targeting obesity, a major risk factor of stroke [204]. These 
anorectic effects may also prove to be of some small benefit in controlling weight gain, 
which can occur subsequent to stroke. However, although the feeding and anorectic 
effects of melanocortins have been postulated to occur solely through the actions of 
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MC4, a recent study in rat models of stroke has disappointingly shown no beneficial 
effects of selective stimulation of the MC4 by the agonist RY767 [205]. 
1.8.2.5 Neurotrophic actions 
The neurotrophic properties of the melanocortin peptides are well documented. They 
have been shown to stimulate turnover of acetylcholine in the hippocampus and 
enhance neurotransmission. -MSH is considered a neurotrophic factor both in foetal 
development and in adulthood [190]. Several studies have also shown improved 
functional recovery following CNS and peripheral nerve lesions in rats when treated with 
melanocortins [189]. More recently the immediate early gene Zif268 has been 
associated with these actions. Zif268 is a gene known to be involved in injury repair and 
memory formation and is dependent on synaptic activity [146]. Melanocortins have been 
suggested to initiate neuronal repair mechanisms and promote synaptic plasticity via 
MC4 mediated induction of Zif268 [146]. The melanocortin mediated recruitment of 
astrocytes to the site of injury may also help regulate ionic balances and remove excess 
excitatory amino acids, whilst enhancing the release of astrocytes derived trophic factors 
and promoting neuronal growth and survival [206]. 
Protective roles of the melanocortins in neuro-degeneration have been exemplified by 
improved functional outcome in animal models of stroke and diabetic neuropathy upon 
treatment with melanocortin peptides [134]. In dogs melanocortin treatment has been 
shown to improve the recovery of auditory evoked potentials following brain 
ischemia/reperfusion [207]. Treatment with NDP-α-MSH has also shown to improve the 
recovery of behavioural functions, spatial learning and memory following BCCAo global 
stroke in gerbils [169].  
1.8.3. Melanocortins in ischemia reperfusion 
The protective actions of the melanocortins have been documented in animal models of 
I/R injury in a variety of organs including; heart [208], renal ischemic injury in mice and 
rats [209], intestinal I/R [210] and cerebral I/R in mice [211] gerbils [169] and dogs [207].  
Furthermore, recent investigations have found NDP-α-MSH treatment to induce 
protective phenotypic changes in the heart similar to those achieved in ischemic 
preconditioning [212]. Ischemic preconditioning is an intrinsic protective phenotype 
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induced by repeated brief episodes of ischemia and involves CREB phosphorylation and 
STAT3 activation.  In the rat heart NDP-α-MSH was found to promote a powerfully 
cardio-protective environment via the activation of the IL-6/STAT3 signalling pathway 
whilst also inducing suppressor of cytokine signalling 3 (SOCS3), a powerful cytokine 
antagonist [212]. Ischemic preconditioning has also recently been shown to be beneficial 
in the brain [213]. Attempts to reveal the molecular and cellular mechanisms underlying 
the neuroprotection provided by ischemic preconditioning have identified MAPK 
signalling to play a key role and the up regulation of the anti-apoptotic Bcl-2 protein to 
also be a major determinant [213]. Bcl-2 has been shown to be up regulated in 
astrocytes treated with α-MSH [214] additionally MC4 activation has been shown induce 
MAPK signalling pathways [157], these effects may therefore prove beneficial in stroke. 
The pleiotropic neurovascular protective and anti-inflammatory actions of the 
melanocortins, described above, thus make these receptors a promising therapeutic 
candidate to address the aberrant inflammatory response proceeding stroke. 
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Given the wealth of data demonstrating a pathological role of inflammation following 
cerebral I/R and enhanced leukocyte recruitment to exacerbate neuronal damage, it is 
proposed that inhibiting leukocyte recruitment in the cerebral microcirculation is a valid 
therapeutic strategy to suppress post stroke inflammation and progression of neuronal 
injury. 
Considering that melanocortin treatments have previously been shown to reduce the 
expression of adhesion molecules E-selectin, VCAM and ICAM on endothelial cells in 
vitro and in models of lung inflammation, peritonitis and both mesenteric and cremasteric 
I/R melanocortin compounds reduce in vivo leukocyte accumulation, it is hypothesised 
that melanocortin treatments will be effective in abrogating I/R induced leukocyte 
recruitment in the cerebral microcirculation. Given that melanocortin receptor activation 
has been shown to inhibit nuclear translocation of NF-κβ it is expected that reductions in 
leukocyte recruitment will also coincide with reduced expression of pro-inflammatory 
signalling molecules such as TNF-α whilst also enhancing expression of pro-resolving 
molecules such as IL-10. 
Previous studies have shown MC1 and MC3 to be the melanocortin receptor subtypes 
which initiate anti-inflammatory signalling, with MC4 also activating centrally mediated 
anti-inflammatory signals to the periphery. As such it is likely that either MC1 or MC3 may 
be crucial in mediating any anti-inflammatory actions observed with a possible 
involvement of MC4 should the peripherally administered melanocortin compounds reach 
the brain parenchyma. Due to the low BBB permeability of peptide melanocortin 
compounds it is however proposed that either MC1 or MC3 will be the key mediators of 
any observed inhibitory actions. Given that a wealth of in vivo and in vitro data support 
roles for both MC1 and MC3 it is however possible that both these receptors may play a 
role. Conflicting data on the principle anti-inflammatory receptor in different disease 
models suggest that the role of melanocortin receptors may vary within the different 
physiological micro-environment and/or pathological state. Thus determining which of 
these receptors is most important to anti-inflammatory actions following I/R in the unique 
micro-environment of the cerebral microcirculation would provide a novel contribution to 
the field 
Hypothesis 
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This study utilises the murine BCCAo model of global stroke and intravital microscopy, 
with an aim to assess leukocyte recruitment following cerebral I/R and to ascertain the 
therapeutic value of a number of melanocortin active compounds in modulating this 
neuro-inflammatory response. These investigations will focus on establishing the 
principle anti-inflammatory melanocortin receptor subtype in the context of cerebral I/R 
induced leukocyte recruitment.  
The first aim of this project is thus to establish and characterise the inflammatory 
response following BCCAo. As such leukocyte-endothelial interactions will be quantified 
in wild type (C57BL/6) mice using IVM, in terms of leukocyte rolling, rolling velocity and 
leukocyte adhesion. Circulating levels of pro-inflammatory cytokines and the activation of 
resident microglia will also be established and investigations made at multiple time 
points of reperfusion to investigate the temporal progression of leukocyte recruitment. 
In order to assess the melanocortin receptor system as a potential therapeutic target in 
inhibiting cerebral I/R induced leukocyte recruitment, an initial aim is to establish the 
relative expression of each melanocortin receptor in the brain and blood. Treatments 
using the endogenous non-selective melanocortin receptor agonist α-MSH will then be 
given at different time points in order to determine whether activation of the MRS can 
modulate cerebral leukocyte recruitment and levels of circulating cytokines following I/R. 
The aim of determining the receptor subtype/subtypes responsible for any anti-
inflammatory effects observed will then be achieved through the use of selectively active 
pharmacological compounds (MC1 agonist BMS-470539, MC3 agonist and MC3/4 
antagonist SHU9119). Receptor mutant animals (MC1 mutant e/e mice and MC3-/- mice) 
will also be used with the aim of ascertaining the endogenous importance of these 
receptors to I/R induced leukocyte recruitment and give further insight to the therapeutic 
potential of targeting these receptors. 
Aims 
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A further aim of this project is to establish the mechanism by which the melanocortins 
inhibit leukocyte recruitment, as such NF-κβ related genes will be assessed to find if 
treatments inhibit activation, and the cell type responsible for mediating melanocortin 
effects on leukocyte recruitment determined using a number of in vitro assays. These 
assays will also help to achieve the final aim of this project; to establish whether the 
melanocortin mediated inhibition of leukocyte recruitment observed in mice is also 
effective in human cells. 
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2.1. Materials 
The general materials and reagents used are listed in tables 2.1 and 2.2 
Table 2.1: General materials 
Material Supplier Location 
96-well plates VWR Leicestershire, England 
Falcon tubes (15ml and 50ml) VWR Leicestershire, England 
Microcentrifuge tubes (1.5ml) VWR Leicestershire, England 
Needles (26 G) Becton Dickinson  Oxford, England 
PE10 tubing  Intramedic Oxford, England 
Pipette tips (20 µl, 1-200 µl and 
200-1000 µl) VWR Leicestershire, England 
Serological Pipettes (5ml and 10ml) VWR Leicestershire, England 
Syringes (1 ml and 20ml) Becton Dickinson Oxford, England 
 
 
 
2.0.  Materials and methods 
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Table 2.2: General reagents 
Reagent Supplier Location 
All chemicals (unless otherwise 
stated) 
Sigma Aldrich Pool, England 
α-MSH Abcam-Ascent scientific  Cambridge, England 
β-mercaptomethanol Sigma Aldrich Pool, England 
Bovine Serum Albumin Sigma Aldrich Pool, England 
BMS 470539 Tocris Bristol, England 
[Dtrp8]-y-MSH Sigma Aldrich Pool, England 
Heparin (from porcine intestinal 
mucosa) 
Sigma-Aldrich Pool, England 
KPV Bachem Bubendorf, Switzerland 
Physiological Saline Baxter Healthcare  Thetford, England 
SHU9119 Tocris Bristol, England 
Sodium Pentobarbital (Euthatal) Merial Animal Health Harlow, England 
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2.2. In vivo procedures 
2.2.1. Animals 
All Housing conditions and experimental procedures were in strict accordance with 
Home Office Regulations (Guidance on the Operation of Animals, Scientific Procedures 
Act, 1986) under the project licence 70/6973. Male C57BL/6 mice (20-28g body weight) 
were purchased from Charles River, male Recessive yellow (e/e) and MC3-/- mice (20-
32g body weight) were kindly provided by Professor Mauro Perretti from the William 
Harvey Research Institute, London, England. All animals were maintained on a 12 h 
light/dark cycle with an ambient temperature between 21-23°C with access to standard 
chow pellet diet and water ad libitum. Drug treatments were all administered by 
intraperitoneal (i.p) injection at 10 µg in 100 µl of saline, with exception to BMS 470539 
which was given at 15 µM. Drug dose was chosen with regards to current literature to 
minimise animal usage in does response experiments (see table 4.1 for references). 
Treatments were either given at 30 min before BCCAo or at the start of reperfusion. 
2.2.2. Global stroke model: Bilateral Common Carotid Artery occlusion 
(BCCAo) 
2.2.2.1. BCCAo 
Mice were anaesthetised using an i.p injection of 100 ml/kg sodium pentobarbital. The 
animal was then positioned in a dorsal recumbence under a dissecting microscope with 
its head toward the surgeon and secured in this position using tape. A rectal 
thermometer was inserted and animals were maintained throughout the procedure close 
to 37.5 oC using a heat mat. A skin incision of approximately 1-2 cm2 was then made 
over the ventrolateral neck using surgical scissors. The salivary glands were exteriorised 
and blunt dissection either side of the trachea allowed visualisation of the common 
carotid arteries. The anatomical location of the common carotid arteries are shown in 
Figure 2.1. Sham animals then proceeded to the cranial window step omitting artery 
occlusion. In BCCAo groups both arteries were then occluded using aneurysm clips 
(Fine Science Tools) for five min. Prior to removing the clips a small amount of saline 
was applied to avoid damaging the vessels whist removing the clips. 
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2.2.2.2. Cannulation 
Blunt dissection was used to expose the right jugular vein. A small section of the vessel 
was cleaned of connective tissue using curved forceps and a length of 4-0 braided silk 
suture was passed underneath the vessel. The suture was then cut into two sections 
and one piece moved toward the cranial end of the vessel and tied tightly to occlude 
blood flow. The caudal suture was then tied in a loose knot. Whist the vessel was 
stabilised by lifting the cranial suture a small incision was then made in the vessel 
between the two sutures using a 26 gauge needle, before inserting a cannula, consisting 
of a 27 gauge needle and a length of polyethylene tubing (PE-10) attached to a syringe 
containing saline. Withdrawal of blood into the tubing confirmed successful insertion. 
The cannula was then secured in place by tightening the caudal ligature around the 
cannula. 
Figure 2.1. BCCAo. Diagram showing the location of the trachea, common carotid 
arteries and jugular veins. (P. Holloway, unpublished) 
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2.2.2.3. Cranial window 
Animals were placed in a stereotactic frame in a sphinx position and their heads 
securely positioned using the ear bars. An area of skin on the scalp was removed using 
surgical scissors to expose the parietal bone and then the underlying periosteum was 
removed using forceps. A high-speed micro-drill (1/4 bit, Fine Science Tools) was used 
to thin an area of the skull to one side of the midline approximately 5x5 mm in 
circumference, drilling intermittently and periodically applying cold saline to minimize 
heat induced activation and tissue damage. Once the skull was sufficiently thinned the 
island of bone was carefully removed using forceps. Artificial cerebrospinal fluid (aCSF; 
NaCl 131.9 mM, CaCl2 1.26 mM, CaCl2.2H2O 1.26 mM, KCl 2.95 mM, MgCl2.6H2O 0.64 
mM, MgCl2 0.5 mM, (NH2)2CO 6.69 mM, C6H12O6 3.69 mM) was used to suffuse the 
exposed brain before a 12 mm circular cover slip was carefully positioned over the 
window. 
2.2.2.4. Intravital microscopy 
Five min prior to IVM, 100 µl of rhodamine-6G (0.02 % in saline) was injected via the 
cannulated jugular in order to fluorescently label leukocytes. The cerebral 
microcirculation was visualized using an Olympus BW61WI microscope with water-
immersion objective lens; magnification x 40 (LUMPlan FI/IR, Olympus) and a 12V 100 
W halogen light source through a CY3 filter. Sections of un-branched pial venules 100 
µm in length and 30-70 µm in diameter were selected and a Photometrics® CoolSnap™ 
HQ2 colour camera (Intelligent Imaging Innovations) was used to record 2 min time-
lapse videos using Slidebook 4.2 software (Intelligent Imaging Innovations Inc). 
2.2.2.5. Video analysis 
Videos were analysed manually offline, in terms of leukocyte rolling cell flux, leukocyte 
rolling velocity and adhesion of the leukocytes. Leukocytes travelling along the venular 
wall at a velocity much less than the central line blood flow were defined as rolling cells. 
White blood cell velocity (VWBC) was calculated by advancing the video frame by frame 
and measuring the distance the leukocyte travels along the venular wall within a given 
period of time and expressed as µm/sec. Leukocytes that remained stationary on the 
venular wall for 30 seconds or longer were considered to be adherent. Assuming the 
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vessel as being cylindrical the number of rolling and adherent leukocytes were 
calculated per mm2 of vessel per min using the following equations: 
 
 
2.2.3 Plasma protein leakage 
To assess vessel integrity and BBB compromise plasma protein leakage was measured 
using IVM. Following IVM of leukocyte endothelial interactions the mouse remained 
under the microscope and was injected i.v with 250 mg/Kg of fluoroscein isothiocyanate 
(FITC)- conjugated albumin (5mg/µl saline Sigma-Aldrich). 5 minutes following FITC-
albumin injection a vessel of 30-70µm in diameter was viewed in an area clear of other 
Figure 2.2; The parameters for Intravital video analysis. A) Rolling cell flux; the 
number of cells rolling on the vessel wall past a chosen point. B) Rolling velocity; 
the speed of cell rolling (µm/sec) C) Adherent Cells; number of cells that remain 
stationary on the vessel wall for 30 seconds or longer.  
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vessels and a snapshot taken using the FITC channel (excitation 450-490 nm; emission 
535-620 nm). Albumin leakage was quantified during offline analysis of snapshots using 
ImageJ software (National Institute of Health, USA). Mean fluorescence intensity was 
measured across three selected areas inside the vessel (internal, black squares), 
immediately outside the vessel (external, white squares), and areas with no obvious 
fluorescence (background, dashed white square) (Figure 2.3). Averages were taken of 
the three measurements for each area and albumin leakage determined using the 
following calculation: 
: 
Figure 2.3. Measurement of plasma protein extravasation. Protein 
extravasation was measured by the leakage of FITC conjugated albumin. 
Fluorescent intensity was measured immediately outside the vessel (white 
boxes) and the background (Dashed white boxes) subtracted. This value 
was then divided by the internal fluorescence (black boxes) - background. 
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2.2.4. Neutrophil depletion 
Neutrophil depletion in C57BL/6 mice was achieved by i.p injection (10 ml/kg) of anti-
mouse PMN serum (diluted in sterile saline 1:10, Gentaur, Product Number: AIA31140) 
daily for two days prior to BCCAo surgery. Control animals were injected with IgG 
isotype matched serum (Gentaur, Product Number: AIS403). PMN depletion was 
confirmed 48 h following injection by total white blood cells count using blood withdrawn 
from the tail vein diluted 1:20 in Turk's solution using. WBC differential counts were 
obtained from blood smears stained with Wright-Giemsa (Sigma Aldrich). Both counts 
were compared with samples taken immediately before the first injection of anti-mouse 
PMN serum. In all cases PMNs were found to be depleted by >85 % 
2.2.5. Tissue and serum sample collection 
A number of different in vitro tests were performed on samples collected from 
experimental animals. As such tissue and blood samples were collected in a number 
different ways, according to the experimental requirements: 
2.2.5.1. ELISA, Bead Array and Western blot 
Blood samples were taken by cardiac puncture under terminal anaesthesia (sodium 
pentobarbital, 100 mg/kg) using a heparinised syringe and then centrifuged at 12,000 
RPM at 4 °C for 6  min. The supernatant was collected and snap frozen in liquid nitrogen 
and stored at -80°C. Brains and other tissues were removed, snap frozen and stored at -
80°C. 
2.2.5.2. Immunohistochemistry 
At the conclusion of experiments animals were injected with an i.p. overdose of 200 
mg/ml sodium pentobarbital. Following confirmation of respiratory arrest the thoracic 
cavity was opened and the right atrium cut open before perfusing animals through the 
left ventricle with 20 ml PBS over 5 min. The brain was then collected and immediately 
transferred to a bath of isopentane on dry ice, and left to freeze before transferring to -80 
°C for storage 
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2.2.5.3. qRT-PCR 
Following sham or BCCAo surgery blood and brain samples were taken and immediately 
transferred to RNAprotect Animal Blood Tubes or RNAse Later (Qaigen) respectively 
and stored at 4 °C until use for RNA isolation.  
2.2.6. Quantification of brain oedema 
Brain oedema was determined using the wet/dry method. Briefly, brains were removed 
rapidly and weighed. Samples were then incubated for 48 h at 70 °C until fully 
dehydrated and then re-weighed. The % brain water determined by the following 
calculation was taken as a representative of brain oedema.  
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2.3. In vitro procedures 
2.3.1. Western blotting 
Frozen brain samples were defrosted and homogenized in NP-40 buffer (10 % glycerol, 
1 % nonidet P-40, 2  mM Ethylenediaminetetraacetic acid (EDTA), 137 mM NaCl, 20 
mM Tris HCl, pH 8), 6 µl/mg of tissue, containing EDTA-free protease inhibitor (1 tablet 
per 10 ml; Roche). Samples were then incubated at 4 °C under constant agitation for 1 
h. 1 ml of the homogenized sample was transferred to a 1.5 ml eppendorf and 
centrifuged at 4 oC, 13,000 RPM, for 10 min. The supernatant was then removed to a 
clean aliquot and a Nanodrop ND-1000 spectrophotometer (Labtech international) set to 
read absorbance at 280 nm was used to determine sample protein content. Samples 
were diluted with the sample buffer to a concentration of 2 mg/ml. Loading buffer 
(Invitrogen) containing 4 % β-mercaptomethanol (Sigma Aldrich) was then added to the 
sample 1 part per 3 parts of sample. Samples were then incubated either for 5 min at 70 
oC when probing for receptor proteins or for 3 min at 95 °C for all other proteins. 26 µl of 
each sample corresponding to 20 µg of protein was then loaded into a NuPAGE® Novex 
Bis-Tris Gel (invitrogen). 10 µl of SeeBlue® (Invitrogen) was used as a pre-stained 
protein standard. 
 Electrophoresis and transfer to a nitrocellulose membrane, 0.45 µm pore size 
(invitrogen), was performed according to the manufacturer’s instructions using XCell 
SureLock® Mini-Cell, NuPAGE running buffer, XCell II™ Blot Module Kit and NuPAGE 
transfer buffer (Invitrogen).  
The nitrocellulose membrane was removed from the blot module and successful protein 
transfer checked by washing with Ponceau S (Sigma-Aldrich) for 30 seconds to visualise 
protein bands. The membrane was then washed with water to remove excess Ponceau 
S and then incubated at room temperature with gentle rocking for 30 min in blocking 
buffer (5 % BSA in TBS-T; 50 mM TRIS buffer, 150 mM NaCl, 0.05 % Tween 20 
adjusted to pH 7.4 using HCl). Blocking buffer was then discarded and the membrane 
incubated with the primary antibody diluted in blocking buffer (antibody concentrations 
given in table 2.3). All primary antibody incubations were done overnight at 4 °C with 
gentle rocking. The primary antibody was then poured away and following 3 x 5 min 
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washes in TBS-T was incubated with the corresponding secondary antibody for 1 h at 
room temperature. Following secondary antibody incubation membranes were washed 3 
x 5 min in TBS-T. Excess TBS-T was blotted off the membrane and the membranes 
were then covered with 2 ml of Pierce ECL Western Blotting 
Substrate (Thermoscientific) and left for 30 seconds before excess substrate was 
removed.  The membranes were then positioned in a Hypercassette™ Autoradiography 
Cassette (GE Healthcare), exposed to Fuji X-ray film RX (Fisher Scientific) and the films 
developed in Kodak developer and fixer (Sigma Aldrich). Developed films were then 
scanned and the mean integrated intensity of each band measured using image J 
software.  
Membranes were stripped by 10 min incubation at room temperature in glycine stripping 
buffer (0.2 M glycine, 3.47 mM sodium dodecyl sulphate, 1 % Tween 20, pH 2.2). The 
stripping buffer was then discarded and membranes incubated for a further 10 min in 
fresh buffer. Membranes underwent 2 x 20 min incubations in PBS followed by 2 x 10 
min incubations in TBS-T, all at room temperature. Blots were then re-probed. Blots 
were normalised for loading against Alpha-tubulin expression. 
Table 2.3: Antibodies used for western blot analysis 
Antibody to; Reacts with Raised in Company  Working Conc. 
MC1 receptor  Mouse, Human Rabbit 
Sigma Aldrich 
(M9193-50UL) 1:1000 
MC3 receptor (a) Mouse, Rat Rabbit 
Sigma Aldrich 
(M4937) 1:2000 
MC3 receptor (b) Mouse, Rat, Human Rabbit 
Acris-antibodies 
(AP10124PU-N) 1:500 
Cyclooxygenase 2   Mouse, Rat, Human Rabbit Abcam (ab15191) 1:1000 
α-Tubulin  Mouse, Rat, Human Chicken Sigma Aldrich (SAB3500023) 1:1000 
Rabbit IgG (HRP 
conjugated) Rabbit IgG Goat 
Sigma Aldrich 
(A9169) 1:12000 
Chicken IgG (HRP 
conjugated) Chicken IgG Rabbit 
Sigma Aldrich 
(A9046) 1:12000 
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Figure 2.4. TNF-α ELISA standard curve. Serial dilutions of recombinant 
mouse TNF-α were assayed using the Quantikine® Colorimetric Sandwich 
ELISA kit to create a 7 point standard curve with a range of 700-10.9pg/ml 
and a 0 pg/ml standard. TNF-α content of unknowns were extrapolated from 
their optical density using the standard curve. Minimum detection limit was 
determined as the lowest significant increase on the standard curve and as 
such is 10.9 pg/ml. 
2.3.2. ELISA  
A Quantikine® Colorimetric Sandwich ELISA kit (R&D Systems) were used for the 
analysis TNF-α cytokine expression in mouse serum samples and was performed 
according to the manufactures guidelines. Optical density was read at 450 nm with 
wavelength correction at 540 nm. TNF-α levels were determined using a standard curve 
(Figure 2.4). Readings were also normalised to sample protein content, determined 
using a Bradford assay as previously described [215]. 
2.3.4. Cytometric Bead Array 
Quantitative detection of IL-6, IL-10, MCP-1, IFN-γ, TNF, and IL-12p70 was performed 
on mouse serum samples using a BD Cytometric Bead Array (CBA) Mouse Inflammation 
Kit (BD Biosciences). In this assay soluble analytes are captured by antibodies 
conjugated to beads of known size and fluorescence thus allowing the analytes to be 
detected and quantified using flow cytometry. In brief, flow cytometer settings were 
optimised for the bead assay using cytometer set up beads (BD biosciences). Capture 
beads for each of the 6 cytokines were mixed and then added to 50 µl of each serum 
sample tested. 50 µl of detection reagent was then added and the mixture incubated for 
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2 h, allowing the formation of capture bead+ analyte + detection reagent complexes. The 
detection reagent contains phycoerythrin conjugated antibodies, which produce a 
fluorescent signal proportionate to the amount of bound analyte thus allowing for specific 
quantification by flow cytometary. A standard curve for each cytokine was setup covering 
a defined set of concentrations from 20 to 5,000 pg/mL. Samples were run at a high flow 
rate on a dual laser BD FACSCalibur using BD CellQuest pro software for acquisition. 
The flow cytometer was set to count 2100 events per sample (300 for each cytokine) 
and gated for FSC vs SSC using the negative control bead sample. Results were 
analysed and quantified with reference to the standard curve using FCAP Array software 
(version 3, Soft Flow, Inc.).  
Figure 2.5. Cytometric bead array standard curves. Curves were generated 
using FCAP array software for IL-6, IL-12, INF-γ, IL-10, TNF-α and MCP-1 with a 
range from 20 to 5,000 pg/mL. 
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2.3.5. Immunohistochemistry 
2.3.5.1. Sample preparation 
Before sectioning frozen brain samples were embedded in an aluminium foil mould filled 
with OCT (Sakura) and the OCT allowed to freeze on dry ice. Samples were then 
transferred to a cryostat and mounted using OCT before obtaining 12 μm sections along 
the coronal plane. Sections were transferred to positively charged microscope slides and 
stored at -20 °C.  
2.3.5.2. Staining 
Brain sections used to stain neutrophils were fixed for 30 min in acetone, while sections 
used for IBA-1 staining were first fixed in 4 % paraformaldehyde in PBS for 30 min 
before rinsing with PBS and undergoing endogenous peroxidase removal through a 15 
min incubation in ice cold methanol containing 1 % H2O2. Slides were then rinsed in PBS 
before blocking with PBS + 2 % BSA + 4 % goat serum for 30 min at room temperature. 
Sections were then coated with primary antibody in antibody diluent (PBS + 1 % BSA + 
2 % goat serum) and incubated overnight at 4 °C in a humidified chamber. Rat anti 
mouse Gr-1 (abcam ab2557) was used at 1:50 to stain neutrophils. Rabbit anti IBA-1 
(Wako) was used to stain for activated microglia and was used at 1:200 in antibody 
diluent as determined by previously performed optimisation experiments. Negative 
control slides were incubated with antibody diluent only. Following incubation the primary 
antibody was removed and slides rinsed three times with PBS. Sections used for 
neutrophil staining were incubated in the dark for 45 min with Alexa Fluor® 488 Goat 
Anti-Rat (invitrogen) at 1:1000 before washing in PBS and mounting with vectorsheild + 
DAPI (Vectorlabs). Slides were then sealed with clear nail varnish and viewed under 
DAPI and FITC fluorescent channels. Sections used for microglial staining were 
incubated for 45 min with biotinylated goat anti-rabbit secondary antibody (Vectorlabs) 
used at a concentration of 1:200 in antibody diluent. Avidin Biotin Complex (ABC) 
solution (Vectorstain elite ABC kit, Vectorlabs) was then prepared by mixing 5 µl of 
reagent A and 5 µl of reagent B in 1 ml of ABC buffers as per the manufacturer’s 
instructions. The ABC solution was then allowed to stand for 30 min for A-B complexes 
to form. The secondary antibody was then removed from the sections before washing 
the slides with PBS. 200 µl of ABC solution was applied to each section and incubated 
for 1 h at room temperature in a humidified chamber. The slides were then rinsed with 
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PBS before visualising antibody staining using 3, 3'-diaminobenzidine (Vector ImmPACT 
DAB peroxidase substrate, Vectorlabs) applied for 1.5 min. Reaction of the chromogen 
was stopped by removing developer from slides and placing them into distilled water. 
Following a brief rinse in distilled water, nuclear staining was achieved using Mayer’s 
Haemalum solution (Vectorlabs), 1.5 min incubation followed by 5 min in running tap 
water. A 30 second incubation in 0.1 % NaHCO3 in dH20 was used as a blueing agent to 
help differentiate nuclear and antibody staining. Sections were dehydrated in increasing 
concentrations of ethanol (1 min in 70 %, 1 min in 90 %, 1 min in 100 %, 1 min in 100 %) 
followed by a 4 min incubation in xylenes and coverslip applied with DPX xylene based 
mount (VWR). 
For analysis of staining, DAB positive cells for microglia or FITC fluorescent cells for 
neutrophils were counted in four randomly chosen fields of view at x40 magnification in 
four different brain regions across at least four brain sections from each animal, at least 
50 µm apart, taken between 1 mm and 3 mm posterior to the bregma (Figure 2.6).  
 
 
Figure 2.6. Location of mouse brain slices used for analysis 
of microglial activation Brain slices were taken between 1mm 
and 3mm posterior to the bregma 
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2.3.6. Quantitative RT-PCR 
2.3.6.1 Brain and blood RNA isolation 
Total RNA was isolated from homogenates of whole brain using an RNeasy Mini RNA 
purification kit (Qiagen). Briefly; samples were lysed and homogenised in a denaturing 
guanidine-thiocyanate–containing buffer and, following the addition of ethanol, the 
sample was applied to an RNeasy Mini spin column. Tubes were briefly centrifuged 
allowing total RNA to bind to the silica-based membrane, contaminants were removed 
during a series of wash steps and the RNA eluted in RNase-free water.  
For whole blood RNA isolation, RNeasy® Protect Animal Blood Kit (Qiagen) was used 
following the manufacturer’s instructions. In brief, blood cells were lysed and intracellular 
RNA stabilised through incubation in RNAprotect solution (Qiagen). Samples were then 
homogenized by centrifugation through QIAshredder spin columns before centrifuging in 
RNeasy MinElute columns, where total RNA was bound to the silica membrane. RNA 
was then eluted in RNase-free water. Concentration and purity of RNA was determined 
by measuring the absorbance at 260 nm using a Nanodrop ND-1000 spectrophotometer 
(Labtech international). The ratio between the absorbance at 260 nm and 280 nm was 
used as an estimate of RNA purity and was found to be between 1.9 and 2.1 indicating 
an absence of contaminants. 
2.3.6.2 qRT-PCR 
Quantitative Real-Time PCR (qRT-PCR) was employed to measure the expression of 
MC1-5, TNF- α and IκB-α mRNA in both brain and blood samples from experimental 
C57BL/6 mice. One step qRT-PCR was performed following the manufactures 
instructions using a QuantiFast SYBR green one step RT-PCR kit (Qiagen) with 
QuantiTect primer assays, containing forward and reverse primers for MC1, MC2, MC3, 
MC4 and MC5, TNF-α and IκB-α (Qiagen) as detailed in table 2.4. A panel of reference 
genes, chosen using criteria set out by Radonic et al. [216] and cross referenced with 
Refgenes Genvestigator online database (Nebion) were tested and the coefficient of 
variance calculated for each reference gene. TATAA-box binding protein (TBP) was 
found to be the most suitable, showing no significant variation in expression across all 
samples tested, and was used in all subsequent calculations to adjust for uncontrolled 
variability between samples when determining relative gene expression.  
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Table 2.4: Primers used for qPCR. 
Protein name Gene name Assay name Cat No.  
MC1 receptor  Mc1r Mm_Mc1r_SG QT00305011 
MC2 receptor  Mc2r Mm_Mc2r_2_SG QT01066338 
MC3 receptor Mc3r Mm_Mc3r_1_SG QT00264404 
MC4 receptor Mc4r Mm_Mc4r_1_SG QT00280861 
MC5 receptor Mc5r Mm_Mc5r_1_SG QT01166494 
IκB-α  Nfkbia Mm_Nfkbia_1_SG QT00134421 
TNF-α Tnf Mm_Tnf_1_SG QT00104006 
TBP Tbp Mm_Tbp_1_SG QT00198443 
All primers were obtained from Qiagen. 
 
Reactions containing 50 ng of template RNA were run in triplicate using an MX3000P 
real time cycler (Stratagene) under the following cycler conditions: Reverse transcription 
at 50 °C for 10 min, Activation at 95 °C for 5 min then 40 cycles of: 95 °C for 10 seconds 
and 60 °C for 30 seconds for denaturation and combined annealing/extension. 
Fluorescence data collection was performed during the annealing/extension phase. 
SYBR Green I was detected at 521 nm with excitation at 494 nm. ROX dye, contained in 
the master mix, was used as a passive reference dye to compensate for non-PCR 
related changes in fluorescence and to provide a baseline to which the signal was 
normalised. Dissociation curves were performed at the end of each reaction confirming 
the presence of a single PCR product per reaction (Figure 2.7).  
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Figure 2.7. qPCR amplification plots and dissociation curve. Successful 
amplification of a transcript showed a sigmoidal shaped amplification curve (A) with a 
geometric, linear and plateau phase. Amplification curves were plotted with ROX 
correction and the threshold was set to 0.1. CT values collected from upper part of the 
log-linear phase. B) Dissociation curves showing a single spike confirmed a single PCR 
product. Any amplification not displaying these characteristics was excluded from data 
analysis. 
  
86 
 
2.3.6.3 PCR efficiency 
For relative quantification of gene expression using the ∆∆CT method the amplification 
efficiencies of the target and reference genes must be comparable. Thus the efficiency 
of the PCR reaction for each gene of interest was calculated by performing a standard 
curve using 100 ng, 10 ng, 1 ng and 0.1 ng of template RNA for each primer and run 
using the standard PCR conditions as detailed above. CT values were collected and the 
difference between CT of target and reference genes plotted against the logarithm of 
RNA loaded. A line of best fit was plotted using Microsoft Excel 2010 software and a 
slope of less than 0.1 for each target gene confirmed that the amplification efficiency 
was comparable and thus suitable for analysis using the ∆∆CT method (Figure 2.8). 
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Figure 2.8. Comparing PCR efficiencies of target and reference gene. 
Different concentrations of RNA template were used to create standard curves 
for each primer set used. A) shows representative amplification curves for 100, 
10, 1, 0.1 and 0ng of RNA template. B) shows the standard curves of each 
primer set used. C) To determine whether the chosen reference gene (Tbp) had 
a comparable PCR efficiency to the target genes, the difference between target 
and reference gene CT value was plotted against RNA concentration. All genes 
tested displayed a slope of less than 0.1 suggesting Tbp to be an appropriate 
reference gene for use in ∆∆CT gene expression analysis. 
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2.3.6.4 Data analysis of gene expression 
Triplicate CT values for each sample were averaged and then the mean CT value taken 
for each treatment group. Data analysis was performed using the Comparative CT 
Method (ΔΔCT Method) as previously described [147] by using the following equation: 
 
Where A is the treated group, B is the sham operated control group and 2-∆∆CT = fold 
change. Data represents the mean ± SEM of the fold change in RNA expression 
compared to the sham operated control group. 
2.3.7. Neutrophil isolation from human blood 
Blood collection and leukocyte isolation was performed with ethical approval from the 
NHS Research Ethical Committee, reference number: 2009, 04/Q0401/40. Control 
samples were taken from healthy individuals with no history of recent acute or chronic 
illness from Hammersmith hospital, London for chemotaxis assays or at the William 
Harvey Research Institute, London for flow chamber assays. Blood was collected from 
the anterior cubital fossa with a 21G needle into a syringe containing 1 part of 3.2 % 
sodium citrate to every 9 parts of blood. All samples were collected and processed within 
4 h.  
2.3.7.1. Histopaque method 
For chemotaxis assays neutrophils were isolated using a sodium diatrizoate polysucrose 
density gradient using Histopaque 1119 and histopaque 1077 (Sigma Aldrich). Blood 
samples mixed with equal volumes of RPMI medium (Sigma Aldrich) were then layered 
on top of the histopaque gradient and samples centrifuged at 1800 rpm for 30 min at 
room temperature. The resulting neutrophil rich layer was removed and mixed with equal 
volumes of RPMI. Samples were centrifuged at 1500 rpm for 15 min and the resulting 
supernatant discarded. Contaminating erythrocytes were lysed in 7.5 mL of ice cold 
water before 2.5 mL of 3.6 % saline was added to restore isotonicity. Samples were then 
centrifuged at 1800 rpm for 10 min, the supernatant aspirated and remaining pellet re-
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suspended. Neutrophils contained in the resulting pellet Cells were counted in a 
haemocytometer using a 1 in 10 dilution in turks solution (Sigma Aldrich) and samples 
made to the desired concentration in RPMI for immediate use in the chemotaxis assay.  
2.3.7.2. Dextran method 
For flow chamber assays neutrophils were isolated using dextran sedimentation and 
gradient-centrifugation. Following collection blood samples were centrifuged at 800 rpm 
for 20 min at room temperature. The upper layer containing the platelet rich plasma was 
then removed and discarded before slowly adding 10 ml of PBS over the remaining 
layer. 8 ml of 6 % dextran solution (Sigma Aldrich) was then added before mixing by 
inversion. Cells were allowed to sediment at room temperature for 15 min. The resulting 
top layer was collected added to fresh 50 ml falcon tubes containing 10 ml of Histopaque 
1077 (Sigma Aldrich). Samples were then centrifuged at 1500 rpm for 30 min. The 
resulting supernatant and buffy coat were aspirated off. The remaining pellet was then 
re-suspended and 9 ml of ice cold saline added before adding 1 ml of 10X hanks 
solution (Sigma Aldrich) to restore isotonicity. Samples were pooled and the volume 
made up to 40 ml with PBS before centrifuging at 1000 rpm for 10 min at room 
temperature. The supernatant was then aspirated off and the pellet re-suspended in 4 ml 
of PBS. Cells were then made up to a concentration of 1x107 cells/ml using PBS and 
kept on ice until use 
.  
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2.3.8. Flow chamber assay 
 
Primary human umbilical vein endothelial cells (HUVECs) were isolated at the William 
Harvey Research Institute, London by collagenase digestion. Cells were cultured at 37.5 
°C, 5 % CO2 and 90 % humidity in Endothelial Cell Growth Medium (ECGM) and used at 
passage 2 for all experiments. The day preceding the experiment, HUVECs were 
Figure 2.9. The IBIDI flow chamber system. A) Photograph of the disposable plastic 
IBIDI µ-Slide VI0.4. B) Cross section diagram of one of the six flow chambers in the µ-
Slide VI0.4, showing how isolated blood cells may be perfused over an endothelial 
monolayer grown in the chamber. (P. Holloway, unpublished) 
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detached using 0.05 % Trypsin/0.02 % EDTA solution  (Sigma Aldrich) and seeded in µ-
Slide VI0.4 flow chamber slides (IBIDI) at a concentration of 2.5x106 cells/ml, 100 µl per 
channel. Cells were incubated overnight at 37.5 °C, 5 % CO2 and 90 % humidity. On the 
day of the experiment 100 % confluence of the monolayer was confirmed 
microscopically, non-confluent cultures were not used. ECs were stimulated by spiking 
the media with TNF-α 10 ng/mL (R&D systems) and incubated for 4 h before 
commencing flow. For α-MSH treated ECs, the corresponding wells were treated with 1, 
10 or 100 µg/ml of α-MSH, 2 h prior to flow, all other wells were treated with saline. 
Isolated neutrophils (1x107 cells/ml) were either pre-treated with saline or α-MSH at 
concentrations of 1 or 10 µg/ml for 30 min before flow. The flow chamber slide was 
positioned under a Nikon Eclipse TE3000 inverted microscope fitted with a x20 phase 
contrast objective (Nikon). The IBIDI µ VI 0.4 flow chamber slides were kept at a 
constant temperature during the course of the experiment using an ibidi Heating System 
(IBIDI) set to 37.5 °C. Ten min before flow, neutrophils, contained in 50 ml falcon tubes, 
were transferred to a water bath set at 37.5 °C.  Immediately before flow commenced 
isolated human neutrophils were diluted 1 in 10 from the stock concentration with 
Dulbecco’s PBS supplemented with Ca2+ and Mg2+ containing 0.1 % BSA PBS + Ca2+ + 
Mg2+ (1 M) to give a final concentration of 1x106 cells/ml. Neutrophils were flowed over 
the endothelial monolayer using a programmable 6 syringe pump (Stoelting) to provide a 
shear stress of 1 dyne/cm2. The flow required to expose cells to this shear stress was 
calculated using the below calculation, assuming a laminar flow profile in a µ-Slide VI0.4 
flow slide.  
 
Initial flow was maintained for 8 min, then at least 3 random fields per treatment were 
recorded for 10 sec each. The number of rolling, firmly adherent (cells stationary for 10 
sec or longer) and transmigrated cells (those changing from bright phase to dark phase) 
were quantified during offline analysis using Image-Pro Plus software (Media 
Cybernetics). These parameters were then given as an average number of cells per 10 
second frame at x 20 magnification. 
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2.3.9. Chemotaxis 
 
Figure 2.10. The chemotaxis assay. A) Photograph of the neuroprobeTM 
chemotaxis plate, showing the 96 well plate and detachable membrane cover. B) 
Cross section diagram of individual wells of the neuroprobe chemotaxis plate. A 
chemoattractant is placed in the bottom well before attaching the membrane cover. 
Isolated leukocytes are then pipetted onto the upper surface of the membrane, 
hydrophobic surrounds prevent liquid from spilling into neighbouring wells. The plate 
is then incubated to allow chemotactic migration across the membrane. The 
membrane is then removed and cells that have migrated into the well are stained and 
counted. (P. Holloway, unpublished)  
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Chemotaxis assays were performed using neuroprobe 96 well disposable plates (Neuro 
Probe Inc.) with 3 µm pore size. Neutrophils isolated from human blood using the 
histopaque method as described above, were used at a concentration of 4 x 106 cells/ml, 
previously determined as the optimum concentration for this assay during initial 
calibration experiments performed in our laboratory. Cells were incubated for 10 min at 
37.5 °C, 5 % CO2 either with RPMI alone or α-MSH (0.1, 1.0 or 10 µg/ml) in RMPI. 
FMLP 10-6 M in RPMI + 0.1 % BSA was used as a chemo-attractant and placed in the 
bottom wells (27 µl per well), whilst RPMI + 0.1 % BSA was used as a control. The top 
chamber was filled with 25 µL of neutrophils. Cells were incubated for 1.5 h at 37.5 °C in 
5 % CO2. Following incubation the remaining fluid was removed from the top wells using 
cotton buds. 25 µL of ice cold EDTA .was then applied to the membrane, left for 5 min 
before being removed. Plates were centrifuged at 1500 rpm for 5 min. The number of 
migrated cells in each well was then counted in a haemocytometer using Turks solution. 
2.4. Statistics 
Results are expressed as mean ± one standard error. Data was analysed either by 
ANOVA with Bonferroni test for post hoc analyses or student T-test for comparison of 
only two groups, using Graph pad prism5 computer software. p<0.05 was considered to 
be statistically significant. 
Group sizes for in vivo experiments were determined based on power calculations 
performed using G* power 3 software (Heinrich Heine University of Dusseldorf) using an 
alpha value of 0.05 and effect size of 1.04. Effect size (δ) was obtained from preliminary 
experiments to this project and calculated using the maximum likelihood estimator of 
Cohen's δ. Calculations to determine δ are given in appendix page 196. To obtain 
statistical power of 0.8, thus giving an 80% chance of correctly rejecting the null 
hypothesis, avoiding a type II error, to determine a difference between two groups, a 
minimum of 4 animals was calculated to be required in in vivo BCCAo experiments and 
as such a minimum n of 4 has been used for in vivo experiments, unless specifically 
stated otherwise (section 5.2.3). Power calculations have not been used for in vitro 
experiments for which a minimum n of 3 has been used. 
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3.1. Introduction 
During the course of this project the bilateral common carotid artery occlusion (BCCAo) 
murine model of global stroke has been utilised to investigate the effects of the 
melanocortins on leukocyte endothelial interactions following stroke. 
Inflammation is a major feature in the pathology of a wide variety of diseases and as 
such numerous methods have been used to obtain inflammatory read-outs when 
assessing pathophysiology and potential therapeutics. Leukocyte recruitment has 
frequently been used as a quantitative parameter to assess the cellular inflammatory 
response. Leukocyte recruitment has been investigated through their accumulation and 
the production of local oedema in; the synovial space in arthritic models, peritoneal 
cavity in models of peritonitis and also in inflamed air pouch models [217, 218]. Utilising 
intravital microscopy however enables direct, real-time measurement of leukocyte and 
endothelial cell activation and behaviour localised to a specific micro-environment. 
Leukocyte recruitment is governed by an exquisitely complex web of inflammatory 
signalling events and as such IVM may provide an insight into the inflammatory milieu 
through the measurement of just a few parameters (rolling, velocity, adhesion and in 
some preparations emigration) [219].  
During this chapter IVM has been used along with traditional IHC and cytokine analysis 
to gain an insight into cellular inflammatory events and characterise the acute neuro-
inflammatory response following global cerebral I/R (by BCCAo) to enable the 
subsequent investigation of the melanocortin receptor system (MRS) as a potential 
intervention. 
3.0.   Characterising the 
inflammatory response in the 
BCCAo murine model of Global 
stroke 
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3.2. Results 
3.2.1. BCCAo causes an increase in leukocyte endothelial cell interactions 
in the cerebral microcirculation 
The effects of cerebral I/R injury on leukocyte recruitment in the cerebral 
microvasculature was investigated by inducing 5 minutes of global blood flow occlusion 
by BCCAo before allowing for varying periods of reperfusion and visualising leukocyte 
recruitment in the pial post capillary venules using IVM (Figure 3.1).  
 
 
Figure 3.1 BCCAo increases leukocyte recruitment in the cerebral 
microcirculation. (A) In sham operated animals relatively few leukocytes (marked by blue 
arrows) could be seen interacting with the endothelium of post-capillary venules. (B) 5 min 
of ischemia produced by BCCAo followed by 40 min of reperfusion was sufficient to incur 
a large increase in leukocyte-endothelial interactions. (C) Allowing for 2 h of reperfusion 
showed a further increase in cell adhesion 
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Leukocyte recruitment was quantified in terms of cell rolling, rolling velocity and 
adhesion (Figure 3.2). While sham surgery, omitting vessel occlusion, produced little to 
no leukocyte recruitment (rolling = 21.5 ± 6.9 cells/mm2/min, adherence = 42.1 ± 14.4 
cells/mm2/min) 5 min of BCCAo was found to induce significant increases in both 
leukocyte rolling (191.0 ± 31.49 cells/mm2/min) and adherence (282.3 ± 49.4 
cells/mm2/min) by 40 minutes of reperfusion (earliest time point tested). The average 
velocity of the rolling cells observed also showed a trend toward a reduction following 
BCCAo. Reperfusion time was then extended to 2 h in this model to investigate the 
progression of inflammatory processes. This resulted in a further increase in leukocyte-
endothelium interactions with adhesion significantly increasing to 659.7 ± 115.6 
cells/mm2/min, approximately 1500 % the level of adhesion observed in sham animals. 
While no further statistically significant increase in rolling was observed when 
reperfusion was extended to 2 h, there was an apparent trend toward an increase. 
Velocity of these cells remained low in the BCCAo 2 h reperfusion group but was not 
significantly reduced in comparison to sham operated groups. In sham operated animals 
left for 2 h before IVM imaging, all four IVM parameters of rolling, WBC velocity and 
adhesion remained unchanged when compared to the 40 min sham group ruling out the 
possibility that the enhanced leukocyte recruitment in the BCCAo 2 h group was due to 
extended time following the beginning of surgery.  
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Figure 3.2. Leukocyte recruitment increases with time of reperfusion. Histograms showing leukocyte endothelial 
interactions as assed by IVM following 5 min BCCAo and either 40 min (white bars) or 2h (grey bars) of reperfusion. 
Leukocyte recruitment was quantified in terms of (A) the number of cells rolling along the vessel wall (rolling cell flux) (B) 
the speed at which those cells roll (WBC velocity) and (C) those cells stationary for 30 second or longer (Adhesion). 
Values represent mean +/- SEM. BCCAo 40 min reperfusion groups n = 6. 2h reperfusion groups n = 4. * denotes 
significance to sham P<0.01 ** = P<0.001. # denotes significance to BCCAo 40 min reperfusion group. Results from Sham 
and BCCAo animals shown here have subsequently been used as saline treated (at the start of reperfusion) controls for 
pharmacological investigations in section 4.0. 
  
98 
3.2.2. Experimental depletion of neutrophils in the BCCAo model 
The rhodamine 6G die used to fluorescently label leukocytes during IVM is non-
specifically taken up by all leukocyte populations, thus in order to determine whether the 
cells found interacting with the endothelium in this model were neutrophils (as supported 
by previous investigations), a sub set of mice were experimentally depleted of 
neutrophils before undergoing BCCAo surgery. In these animals, neutrophils were found 
to be depleted by approximately 84 % when compared to levels prior to treatment with 
anti-PMN serum (see appendix figure A1 and Table A1 for white blood cell counts). 
While the serum was supplied as an anti-PMN serum, levels of other PMN (eosinophils 
and basophils) remained at a relatively low level (0.5 -1 % of the total WBC population) 
and was unchanged following anti-PMN treatment. The absolute levels of other blood 
born immune cells also showed no significant changes following the PMN depletion 
treatment regime, thus this protocol can be regarded as specifically depleting 
neutrophils. Control animals were treated with IgG matched control serum and total 
WBC counts and differential WBC counts showed no significant changes compared to 
pre-treatment levels.  
When subjected to BCCAo it was found that the number of cells found recruited to the 
pial venules of neutrophil depleted mice was significantly attenuated compared to IgG 
control treated mice (Figure 3.3). Leukocyte rolling was found to be reduced by 81 % 
and adhesion by 76 %. This is consistent with the majority or all of those cells observed 
interacting with the vessel wall being neutrophils.  
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Figure 3.3. PMN depletion prevents leukocyte recruitment following BCCAo. C57BL/6 mice were treated with 
anti-PMN serum to deplete circulating neutrophils (Black bars) for two days before BCCAo or sham surgery. IgG matched 
serum treated mice were used as a control (checked bars). Following surgery IVM was used to assess the rolling (A) 
velocity (B) and adhesion (C) of leukocytes. Depleting mice of neutrophils was found to significantly inhibit the number of 
observed leukocytes interacting with venules of the cerebral microcirculation. Values represent mean +/- SEM. All IgG 
and anti-PMN treated groups n = 4. + denotes statistical significance to IgG group P<0.01. 
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3.2.3. BBB integrity and brain oedema. 
The BBB confers a restrictive phenotype that is, under normal conditions, impermeable 
to macro molecules such as albumin. However under certain pathological inflammatory 
conditions the BBB can become compromised and allow un-regulated diffusion of 
molecules and plasma protein leakage into the surrounding parenchyma causing brain 
oedema. In order to evaluate the effect of the BCCAo model on BBB integrity and 
permeability FITC conjugated albumin was injected i.v and pial venules analysed for 
leakage of the fluorescent signal outside of the vessel using IVM. Brain oedema was 
also investigated by measuring the brain water content using the wet/dry method. 
Following 5 min of BCCAo at both 40 min and 2 h of reperfusion no significant BBB 
permeability was observed with the entire fluorescent signal being retained within the 
vessels observed (Figure 3.4 A). Furthermore no elevation in brain water content 
(indicative of oedema) was detected, suggesting that at the time points tested there was 
no breakdown of the BBB (Figure 3.4 B).  
Figure 3.4. BBB integrity and brain oedema. A) representative fluorescent IVM images of 
cerebral venules following i.v injection of FITC labelled albumin. Vessels show no significant 
leakage of the dye in sham or BCCAo treated animals at both 40 min and 2h. B) Brain 
oedema was investigated using the wet/dry method following 5 min of BCCAo and 2h of 
reperfusion. No significant increases in brain water content were observed compared to 
sham operated animals.  
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3.2.4. Investigating brain neutrophil infiltrates 
Previous investigations in our lab (H. K. Smith pending publication) have used the 
myeloperoxidase (MPO) assay as an indirect method to quantify brain PMN content. 
These investigations have demonstrated no significant increases in MPO enzyme 
activity in the brain in this BCCAo model indicative of a lack of neutrophil extravasation. 
To confirm this IHC has been employed to directly stain for neutrophils present in the 
brain parenchyma (Figure 3.5). The specificity of the antibody used (Rat anti-mouse Gr-
1, AB2557, Abcam) was confirmed in blood smears where cells with multilobulated 
nuclei were specifically stained, with approximately 10 % of all nucleated cells being 
stained as is consistent with previously reported C57BL/6 blood neutrophil content (5-20 
%). However across 10 sections taken between 1 mm and 3 mm posterior to the bregma 
in all mice tested, no positively stained neutrophils were observed thus supporting the 
previous findings. 
Figure 3.5. Neutrophil IHC in brain sections. 12μm frozen brain sections were stained with 
anti-Gr-1 antibody to stain for neutrophil. No Gr-1 positive cells were observed across 10 
sections for each group tested n=3. A) Representative images of blood smears taken with a 
x10 objective show specific staining of neutrophils using the anti-Gr-1 antibody. Only cells with 
lobed nuclei were stained (x40 magnified inserts). (B,C) Representative x10 images of brain 
slices from (B) sham operated and (C) BCCAo 2h reperfusion c57BL/6 mice. 
2h reperfusion 
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3.2.5. Microglial activation 
To investigate the activation of the main immune competent brain resident cells, the 
microglia, preliminary experiments have used IBA-1 immuno-fluorescent staining in 
frozen brain sections with an IBA-1 positive cell count being performed in 4 different 
brain regions (Figure 3.6). At 40 min following BCCAo no significant changes in number 
or morphology of IBA-1 positive microglia were detected when compared to sham 
operated animals. However by 2 h of reperfusion a small but statistically significant 
increase in IBA-1 staining was observed in the hippocampus. These cells were typically 
found to display a more bushy morphology with shorter, thicker processes than the 
ramified cells found in sham operated animals (micrograph insert figure 3.6), these 
changes are indicative of the early stages of activation. However in the other areas of 
the brain assessed for IBA-1 staining no increases were detected following BCCAo 
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Figure 3.6. Microglial activation following BCCAo. BCCAo was found to induce a 
significant increase in IBA-1 positive cells in the hippocampus following 2 h of reperfusion. A) 
representative x20 micrographs on IBA-1 stained brain sections from sham and BCCAo 2 h 
reperfusion mice. B) Histograms representing mean ± SEM of IBA-1 positive cell counts 
across four different brain regions assessed. Only in the hippocampal region of the brain was 
a statistically significant increase in IBA-1 expression detected. N=3 for all groups. * denotes 
significance to sham P < 0.05. 
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3.2.6. Brain COX-2 expression 
In order to further investigate the inflammatory environment in the brain parenchyma 
following BCCAo levels of the key inflammatory enzyme COX-2 were assessed in the 
brain by western blot analysis of whole brain homogenates (Figure 3.7). While there was 
a slight tend toward increased brain COX-2 by 2 h of reperfusion, this was not 
statistically significant and no conclusions can be drawn from the current results. As 
such further studies will need to be conducted with greater n numbers to reveal whether 
there is indeed any change in COX-2 expression by 2 h reperfusion. 
 
Figure 3.7. Western blot analysis of whole brain COX-2 expression. Whole brain 
homogenates from C57BL/6 mice subjected to sham surgery or BCCAo with 40 min 
(white bars) or 2h (grey bars) of reperfusion were assessed for COX-2 expression by 
western blot analysis. Histogram and representative blots of three separate western 
blot experiments. For each group n=3 
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3.2.7. Cytokine response to BCCAo 
In order to investigate the effects of BCCAo on circulating levels of soluble inflammatory 
signalling molecules, an ELISA for the key inflammatory mediator TNF-α was performed 
along with multi-cytokine analysis using the cytometric bead array (IL-6, IL-10, MCP-1, 
IFN-γ, TNF, and IL-12p70). minutes following 5 min of BCCAo with levels remaining 
below the reliable detectable range of the kit (defined as the first statistically significant 
change on the standard curve). However by 2h of reperfusion TNF-α levels were 
significantly elevated, above the detection limit, with levels rising to 11.3 pg/ml compared 
to the control value of 4.2pg/ml (Figure 3.8). 
 
 
Figure 3.8. Serum TNF-α.concentrations detected by ELISA TNF-α levels in 
serum samples from C57BL/6 mice subjected to sham surgery or BCCAo with 40 
min (white bars) or 2h (grey bars) of reperfusion. N= 3 for all groups. * denotes 
significance to sham P<0.01. Red line indicates reliable detection limit of the kit. 
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Cytometric bead arrays (CBA) showed no detectable level of IL-12p70 or IFN-γ protein 
expression across all samples tested. While low levels of IL-6 were detected in serum 
samples (at the lower detection range of the kit used), these remained unchanged 
following BCCAo. MCP-1 was undetectable in both sham groups but was increased to a 
statistically significant level following BCCAo and 2 h of reperfusion to 49.94 pg/ml, this 
was however still below the limit of detection of the CBA as stated in the manufacturers 
guidelines (52.7 pg/ml). TNF-α levels detected by the CBA supported the results from 
the quantikine ELISA, showing a significant increase following BCCAo 2 h reperfusion to 
17.69 pg/ml. The anti-inflammatory cytokine IL-10 was at levels below the detectable 
range in sham operated and BCCAo 40 min groups nevertheless by 2 h of reperfusion 
there was an induction of IL-10 expression to 34.7 pg/ml which however was not 
statistically significant (P>0.05).  
Figure 3.9. Serum cytokine levels detected by CBA. Levels of IL-6, IL-10, MCP-1, IFN-γ, 
TNF, and IL-12p70 protein were analysed using the CBA in serum samples from C57BL/6 
mice subjected to Sham surgery or BCCAo with reperfusion times of 40 min or 2h. No 
detectable levels of IL-12p70 or IFN-γ were detected across all samples tested. Histograms 
represent mean ±SEM of (A) IL-6 (B) IL-10 (C) MCP (D) TNF-α. Red lines represent the 
reliable limit of detection for each cytokine tested. N=3 for all groups. P<0.01 
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3.2.8. Melanocortin receptor expression 
To allow for an investigation into the MRS as a potential therapeutic target in this murine 
model, expression levels of each of the melanocortin receptors were assessed in both 
the whole brain and blood of C57BL/6 mice. Expression was tested at both 40 min and 2 
h of reperfusion along with BCCAo mice treated with the endogenous melanocortin 
peptide α-MSH at the start of reperfusion, to test for any ligand mediated change in 
receptor expression. Western blot analysis initially confirmed MC1 and MC3 expression 
in brain showing consistent expression levels across all treatments (appendix figure A2). 
However, upon using tissues from MC3-/- mice as negative controls, no difference in 
staining using the MC3 antibody (Sigma Aldrich M4937) was observed between WT and 
MC3-/- tissues. PCR confirmed absence of the MC3 transcript in the MC3-/- mice (appendix 
figure A3). Similar results were obtained when using an alternative MC3 antibody from a 
different supplier (Acris antibodies AP10124PU-N). Thus suggesting both MC3 
antibodies tested display non-specific binding to protein at the same molecular weight as 
predicted for the MC3. In the absence of a specific antibody for the MC3 qRT-PCR was 
used to quantify the expression of all 5 melanocortin receptors at the mRNA level. qRT-
PCR analysis of RNA isolated from blood confirmed the presence of all MC1 MC3 MC4 
and MC5 but failed to detect any MC2 transcript (figure 3.10). No significant changes in 
receptor expression were detected across all treatments for MC1, MC3 and MC5. 
However the MC4 transcript was found to be significantly decreased following α-MSH 
treatment at 40min of reperfusion, showing an approximate 5 fold reduction compared to 
the 40min sham operated group. However MC4 levels did not remain suppressed and α-
MSH treated groups showed no significant difference at 2 h reperfusion to the saline 
treated group. 
qRT-PCR revealed mRNA expression of all 5 melanocortin receptors in C57BL/6 brains 
(Figure 3.11), with CT values suggesting MC4 to be by far the most abundant transcript 
(data not shown). Relative quantification of MC expression showed no significant 
changes in receptor expression in response to all treatments tested, with invariant MC1 
and MC3 expression being consistent with the results from western blot analysis.  
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Figure 3.10. Total blood MC mRNA expression. Total blood RNA was isolated from whole 
blood of C57BL/6 mice subjected to Sham surgery, BCCAo saline treated or BCCAo α-MSH 
treated (10µg i.p at the start of reperfusion) with reperfusion times of 40 min or 2h. qRT-PCR 
used to quantify the mRNA levels of MC1-5. Values represent mean ± SEM of fold change in 
expression compared to 40 min sham operated control. No MC2 mRNA was detected in blood. 
N = 3 for all groups. + denotes statistical significance P<0.01 
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Figure 3.11. Total brain MC mRNA expression Total brain RNA isolated from experimental 
animals was assessed for MC1-5 mRNA using qRT-PCR. Values represent mean ± SEM of 
fold change in expression compared to 40 min sham operated control. N = 3 for all groups. 
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3.3. Discussion 
The aim of these investigations were to validate and characterise the leukocyte 
recruitment response in a murine model of global cerebral I/R injury. Experiments using 
intravital microscopy to visualise leukocyte-endothelial interactions in the pial venules of 
the brain demonstrated that as early as 40 minutes following 5 minutes of global 
ischemia there is a significant increase in leukocyte recruitment (Figure 3.1 and 3.2). 
While rhodamine 6G fluorescent labelling of cells is unable to distinguish between 
leukocyte sub populations, neutrophil depleting experiments demonstrated that, in line 
with previous investigations, at this acute phase of the inflammatory response the 
recruited cells consisted largely or even entirely of neutrophils (Figure 3.3). Extending 
the time of reperfusion time to 2 h resulted in a further enhancement of leukocyte 
recruitment with adhesion of leukocytes reaching approximately 1500 % that of sham 
operated animals however by this time point no extravasated neutrophils were recorded. 
Accompanying the observed progression of leukocyte recruitment was a significant 
increase in total circulating blood levels of the pro-inflammatory cytokine TNF-α along 
with an activation of brain resident microglia. 
3.3.1. The BCCAo model as a tool to investigate I/R induced leukocyte 
recruitment. 
In this study C57BL/6 mice have been used in a BCCA model of global stroke. The 
C57BL/6 strain was selected not only as it is the background strain for many genetically 
modified mice, but also due to its sensitivity to cerebral ischemic injury. C57BL/6 mice 
generally have hypoplastic posterior communicating arteries resulting in an incompletely 
formed circle of Willis and reduced collateral blood flow [220]. Studies by Yang et al. 
revealed that of seven different commonly used mouse strains C57BL/6 mice were the 
most susceptible to cerebral ischemia following BBCAo [221] producing reliable 
neurological and histopathological evidence of ischemic neuronal death [221]. The 
poorly developed posterior communicating artery found in C57BL/6 mice results in an 
approximate 90 % reduction in cerebral blood flow following BCCAo which is highly 
reproducible. BALB/c mice on the other hand have been found to have variable degrees 
of anastomosis resulting highly variable reductions in blood flow (between 70-90 %) 
following BCCAo. 
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The C57BL/6 strain thus allowed the BCCAo model to be used as a simple and 
reproducible model of cerebral ischemia reperfusion injury in which leukocyte 
recruitment could be investigated.  
3.3.2. Length of reperfusion and the time course of the inflammatory 
response 
Contrasting to the microcirculation of peripheral tissues constitutive leukocyte endothelial 
interactions in the pial vessels of the brain is almost entirely absent, however in 
response to phlogistic stimuli cerebral vessels may support a rapid increase in leukocyte 
recruitment [222, 223]. In this model while few leukocyte-endothelial interactions were 
observed in sham animals, significant increases in both rolling and adhesion of 
leukocytes was observed in the pial venules as early as 40 min into reperfusion. 
Neutrophil depletion studies demonstrated this recruitment of leukocytes to be largely, if 
not entirely, consisting of neutrophils. Previous investigations have revealed neutrophils 
to be the earliest leukocytes to respond to ischemic damage, with their levels of 
recruitment correlating with infarct volume [224]. Increases in the levels of circulating 
monocytes have also been reported following cerebral I/R however this is typically 
observed as a delayed response occurring approximately 3 days post-stroke [225]. In 
keeping with the results of the present study, Ishikawa et al. have also demonstrated 
rolling and firm adhesion of leukocytes in cerebral venules at 40 min of reperfusion in 
C57BL/6 mice but in this case following 1 h of BCCAo [27]. The levels of leukocyte 
recruitment reported by Ishikawa et al. are comparable to those found in this study 
despite the large difference in magnitude of ischemic insult (1 h BCCAo compared to 5 
min used in these investigations). This model of 5 min BCCAo was previously developed 
in our lab (H. K. Smith et al., pending publication) to provide a sufficiently robust 
inflammatory response while minimising mortality following ischemia. The relatively short 
time of ischemia required thus suggests post ischemic inflammatory responses to be 
highly sensitive and rapidly triggered. Indeed Ritter et al. have revealed leukocyte 
adhesion to cerebral venules within just 15 min of reperfusion following MCAO (2h of 
ischemia) [76]. However, to my knowledge, the findings of the present investigations still 
represent the earliest time point following initiation of the ischemic insult (45 min) at 
which leukocytes have been observed to adhere to cerebral microvessels. While these 
observations of leukocyte adhesion are seemingly earlier than expected from 
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investigations of integrin expression, recent studies have revealed integrin up regulation 
at an earlier stage that previously predicted. Morrison et al., have recently demonstrated 
that following stroke significant increases in neutrophil CD11b (the protein subunit that 
pairs with CD-18 to form the heterodimeric integrin macrophage-1 antigen (Mac-1)) 
expression was induced within just 15 min of reperfusion [226]. Neutrophil expression of 
CD11b  has been shown to be an indicator of neutrophil activation allowing cells to firmly 
adhere to the endothelium through interactions with ICAM-1 [226]. Indeed Mac-1 
deficient mice have been shown to be protected against cerebral ischemia and CD11b 
antibodies have been investigated as potential treatments for stroke.  
At the acute phase of the inflammatory response that has been investigated in this study 
no parenchymal extravasated neutrophils were observed in IHC analysis of brain 
sections. Previously, investigations in our laboratory (H. K. Smith, pending publication) 
have indirectly quantified PMN accumulation in the brain by measuring the activity of the 
azurophilic granule enzyme myeloperoxidase (MPO). These studies failed to 
demonstrate any significant increase in brain MPO activity indicating a lack of neutrophil 
extravasation. As such in the present investigations direct IHC was used as an 
alternative method to verify that neutrophils are not present in the brain parenchyma by 
2 h of reperfusion. A rat antibody which specifically binds the murine Ly-6G and Ly-6C 
components of the myeloid differentiation antigen Gr-1 to label neutrophils was used to 
stain brain slices. While this antibody was able to specifically label PMN in blood smears 
no staining was observed in all brain slices analysed. However confirmation of antibody 
staining in a positive control of neutrophil infiltration in the brain tissue would be needed 
along with a more thorough search across all brain regions to confirm the absence of 
infiltrates in this model. Previous investigations show the earliest increase in 
parenchymal neutrophil infiltrates to be at 6 h (earliest point tested) [227, 228] however 
most studies focus on infiltration at 24 h post ischemia. Indeed, while neutrophil 
infiltration into other tissues has been observed as early as 30 min [229] the BBB poses 
a considerable obstacle, and migration across the basement membrane alone has been 
documented to take 15 min [47]. Thus a lack of infiltration at this stage is in keeping with 
the findings of others. While these results are by no means conclusive of a lack of 
leukocyte recruitment at this acute phase, the results do support prior MPO 
investigations. 
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3.3.3. BBB integrity 
The BBB allows for the stringent control of blood born molecules entering the brain, by 
regulating the active transport of nutrients and the efflux of toxic molecules, inhibiting 
paracellular diffusion, and regulating the trans-endothelial passage of pathogens and 
circulating leukocytes, thus serving to maintain cerebral homeostasis [230]. The 
breakdown of the BBB following stroke is a complex multi-phasic phenomenon and is 
characterised by an early disruption of tight junctions in response to endothelial calcium 
signalling, oxidative stress and MMP-9 release from resident cells [230, 231]. The 
recruitment of activated leukocytes marks an increase in ROS and MMP along with 
inflammatory cell diapedesis, aggravating vasogenic oedema and increasing the risk of 
haemorrhagic transformation [230]. 
In this model FITC conjugated albumin assessment of cerebral vascular permeability 
and brain water content assessment of oedema, revealed no disruption of blood brain 
barrier by 2 h following 5 min BCCAo. As such this model could not be used, at the time 
points tested, for an assessment of BBB disruption following stroke in subsequent 
investigations of the MRS. Previous studies have shown MCAo and BCCAo in both mice 
and rats to induce significant leakage of cerebral vessels [232-234]. However the 
leakage responses of vessels has been shown to differ with the fluorescent dye used to 
label albumin [235]. Indeed a number of tracers used in previous investigations have 
now been demonstrated to contribute to BBB compromise themselves. The widely used 
evans blue, for example, has been found to inhibit glutamate uptake and may thus 
exacerbate excitotoxicity following cerebral I/R and perturb the physiological 
environment of the NVU [236, 237]. As such this may account for a certain level of 
inherent methodological bias toward greater reported BBB compromise [236]. Extended 
imaging with FITC fluorescent dyes has also been shown to induce phototoxicity. 
microvascular dysfunction and leakage in a number of tissues (although not yet reported 
in the BBB) [235]. In the present study the effects of epiillumination were minimised by 
only subjecting animals to one brief period of fluorescent imaging. More detailed 
investigations, beyond the scope of this thesis could also establish the effect of BCCAo 
on specific BBB junctional molecules such as occludins and ZOs however a recent study 
by Krueger et al. provides convincing evidence that the ultrastructual morphology of tight 
junctions is not entirely representative of BBB failure [236]. Their findings show that 25 h 
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after embolic stroke in rats tight junctions remain regularly maintained despite a massive 
leakage of FITC-albumin in these regions predominantly resulting from dysfunction of 
the endothelium rather than tight junctions [236]. Thus while the lack of any BBB 
disruption found in the current investigations using FITC-albumin, are not likely to be due 
to a lack of assay sensitivity, investigations into endothelial function following ischemia 
may provide useful insights. 
It is likely that increased lengths of ischemia or extending the time of reperfusion would 
result in significant levels of BBB disruption detectable by FITC-albumin in this model. 
The earliest reported observation of BBB disruption in rats is within 60 min of reperfusion 
following BCCAo (30 min of BCCAo, visualised by FITC-dextran) [233] In mice the 
earliest reported BBB disruption following BCCAo is at 48 h in mice (25 min BCCAo, 
visualised with evans blue) [232]. In the current study BBB dysfunction has been 
assessed at a relatively early time point following BCCAo (40 min earliest time point 
tested). At this early phase of the neuro-inflammatory cascade 5 min of BCCAo is not 
sufficient to induce BBB permeability. This lack of any significant BBB disruption found in 
the current investigations is thus in keeping with the relatively short ischemic insult and 
lack of any neutrophil infiltration into the neurophil as observed by preliminary IHC 
investigations (Figure 3.5). It is thus likely that BBB dysfunction in experimental stroke is 
affected not only by the method of measurement but also the duration of ischemia and 
reperfusion and the experimental models used. 
3.3.4. Activation of resident brain microglia 
Microglia represent the resident immune-competent cells of the brain and are highly 
sensitive to pathological changes in the brain [30]. In preliminary studies on microglial 
activation, microglia were stained using IBA-1 which has previously been shown to be 
up-regulated in activated microglia in response to cerebral pathology [238]. By 40 min of 
reperfusion while there was a trend toward an increase in activation (as detected by IBA-
1 staining) this was however not significant, suggesting that even a mild activation in 
resident cells can initiate a cascade of signalling resulting in a significant leukocyte 
recruitment. By 2 h of reperfusion the activation of microglia was however shown to be 
significantly increased specifically in the hippocampus; a region shown to be particularly 
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sensitive to ischemic damage. This correlates with previous findings in a rat model of 
BCCAo in which a hippocampus specific up regulation of IBA-1 was detected [239]. 
Activated microglia may release a variety of cytotoxic substances such as ROS and 
proteases and treatment with the microglial inhibitor tetracycline has been shown to 
protect hippocampal neurones following global ischemia in gerbils [240]. Furthermore a 
number of studies have revealed correlations between microglial activation and CNS 
cytokine levels with infarct severity [30]. The mild and localised activation of microglia 
observed in the present study coincided with an apparent trend toward elevated whole 
brain COX-2 expression, indicative of an enhanced pro-inflammatory environment. COX-
2 is a powerful inducer of inflammation; mediating the synthesis of bioactive prostanoids 
and inducing up-regulation of numerous cytokines including IL-1β and TNF-α [241] [242]. 
This inflammatory mediator is not only produced by inflammatory cells but also by CNS 
neurons and COX-2 inhibitors have previously been shown to provide protection in the 
ischemic hippocampus [242]. While COX-2 up-regulation was not found to be significant 
the results obtained in this study may reflect that analysis was performed on whole brain 
homogenates. Utilising IHC to investigate expression in discrete areas may provide a 
greater insight into the regulation of COX-2 in the brain following BCCAo particularly in 
the vulnerable hippocampal region where the highest microglial activation was observed. 
3.3.5. Cytokine response to BCCAo 
Investigations into circulating cytokine levels following BCCAo using ELISA and CBA 
demonstrate a significant increase in serum TNF-α by 2 h of reperfusion but not at 40 
min. This increase in coincided with the significant increase in leukocyte adherence and 
trend toward an increase in cell rolling in the pial microvasculature at 2 h.  
TNF-α exerts potent pro-inflammatory and pro-coagulant effects, stimulating up 
regulation of leukocyte adhesion molecules, release of IL-1, platelet-activating factor and 
endothelin [243]. TNF-α can contribute to stroke progression at multiple levels through; 
increased ROS via the induction of cyclooxygenase (COX) and NADPH oxidase, 
aggravating vascular permeability and risk of hemorrhagic transformation by activation of 
MMPs, enhancing excitotoxicity and promoting leukocyte infiltration (as reviewed by 
Hallenbeck, 2002 [243] and McCoy & Tansey 2008 [244]) . 
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Synthesised as a monomeric transmembrane protein and inserted into the membrane as 
a homo-trimer. This membrane bound form (tmTNF) may be released by proteolytic 
cleavage to form soluble (sol)TNF thus allowing for a rapid up regulation of circulating 
levels. Both tm and sol forms display biological activity and signal via two receptors 
TNFR1 (CD120a) and TNFR2 (CD120b), with the more ubiquitously expressed TNFR1 
binding solTNF and TNFR2 showing preferential binding to tmTNF [244].  
The early rolling and adherence of cells observed in this study may be in response to the 
cleavage of pre formed TNF-α from the membrane which occurs over 20 min-2 h, as 
opposed to its de novo synthesis. In concordance with the current observations, rodent 
models of stroke have previously shown increased mRNA levels of TNF-α within 1 h of 
ischemia with protein expression being detected within 2−6 h of ischemic onset [245, 
246]. Similarly TNF-α levels have been shown to be elevated in the blood and CSF of 
stroke patients and support a pathological role for TNF-α in stroke [243], [247]. Microglia 
have previously been highlighted as the major acute source of TNF-α following cerebral 
I/R in mice [248] and as such may contribute to the increased levels observed at 2 h in 
this study. However immunoreactivity has also been shown in neurons, astrocytes, 
endothelial cells, macrophages and leukocytes [243] [244] and as such the source of 
increased circulating TNF-α is difficult to determine. 
While TNF-α plays an important role in inducing other inflammatory mediators, with TNF-
α deficient mice showing decreased expression of chemokines and adhesion molecules 
following experimental I/R, TNF-α may also act in an autocrine positive feedback, 
increasing its own secretion [243]. Thus the early levels of TNF-α increase observed in 
the present study may represents the beginnings of a potentiating of TNF signalling and 
induction of other pro-inflammatory molecules. 
In addition to signalling through TNFRs, TNF-α may also exhibit reverse signal 
transduction. Following the cleavage of tmTNF by the sheddase TNF-α converting 
enzyme (TACE; ADAM17) and release of solTNF, the free TNF-α intracellular domain 
may be released and initiate intracellular signalling to stimulate the production of pro-
inflammatory cytokines [244]. Thus the physiological significance of increased serum 
soluble TNF-α as investigated in the present study, may be two fold. However the exact 
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in vivo significance of such TNF-α reverse signalling events are still to be fully 
ascertained.  
While BCCAo was found to induce significant increases in TNF-α, no statistically 
significant increases within the reliable detection range of the kits used were detected in 
all other serum cytokines tested (IL-6, IL-10, IL-12, IFN-ϒ and MCP-1).  
Although MCP-1 levels increased significantly at 2 h following BCCAo, and MCP-1 has 
previously been shown to be increased following experimental stroke aggravating 
ischemic damage [249], the levels reported here remained below reliable detection 
range of the CBA and below a biologically relevant concentration. MCP-1 induces the 
recruitment of monocytes along with other leukocytes sub sets and mRNA and protein 
levels of MCP-1 have previously been shown to peak at around 24 h inducing monocyte 
recruitment by 48 h, thus fitting with the lack of any early detection reported here. Indeed 
many monocyte chemotactic signals require de novo synthesis and are thus released at 
a later time point than neutrophil active factors which are released by rapid 
exteriorisation or proteolytic cleavage [43]. Furthermore neutrophils recruited to the site 
of tissue injury have been shown to induce endothelial secretion of MCP-1 and 
monocyte recruitment through their release of proteinase-3 [43]. It is thus likely that at 
later time points MCP-1 levels will increase in the current model. 
At 2 h reperfusion there was a trend toward an increase in IL-10 levels which was within 
the detection range of the kit but not statistically significant. This cytokine has been 
reported to contribute to anti-inflammatory processes and provide a favourable 
environment for neurogenesis, with low serum levels of IL-10 correlating to poor 
neurological outcome in stroke patients. Able to suppress cytokine receptor activation 
and expression whilst also inhibiting IL-1β and TNF-α, IL-10 is induced at the late stage 
of inflammation and promotes its resolution. As such it is likely that investigations at later 
time points of reperfusion following BCCAo would reveal increased IL-10 expression.  
IL-6 is a pleotropic cytokine with both pro and anti-inflammatory actions having been 
reported. While serum levels of IL-6 have been shown to correlate with infarct volume 
[9], Clark et al., have revealed no difference in neurological outcome or infarct size in 
animals lacking IL-6 following I/R suggesting no direct involvement in pathological 
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events following stroke [250]. Expression tends to follow that of TNF-α in stroke with IL-6 
increases first detected in serum, and then in brain [250], therefore correlating with the 
lack of any increase seen in the present study at 2 h. 
No levels of the pro-inflammatory and immunomodulatory chemoattractant IL-12 or the 
immunostimulatory interferon IFN-γ were detected at the time points tested in this model. 
In line with the present findings, as molecules interfacing the innate and adaptive 
immune system increases in IFN-γ and IL-12 following stroke are later than TNF-α and 
are largely produced by macrophages and B and T-cells. 
While many of the cytokines tested were at low or below detectable levels in serum this 
does not entirely exclude a role in influencing the local inflammatory environment. The 
blood contains a number of proteases which help to contain the spread of local 
inflammatory mediators, Duffy antigen/chemokine receptor (DARC) on eurythrocytes 
may also act to bind and internalize a variety of cytokines and soluble receptors for 
certain cytokines help to sequester their signalling, preventing a fully systemic immune 
response. Thus serum cytokine levels may not always correlate with the magnitude of 
inflammatory events in localised microenvironment at the site of tissue injury. Indeed this 
differential cytokine expression in serum and the local environment has been 
demonstrated in human inflammatory conditions [251]. The benefit of utilising IVM to 
assess leukocyte recruitment in conjunction with analysis of inflammatory mediators, as 
performed in this project, is that localised inflammatory responses can be assessed 
independently of an entirely systemic response. 
3.3.6. Limitations of the model 
3.3.6.1.The pial microcirculation as a model of deeper cortical 
vessels  
In this model, due to limitations in the depth of imaging possible using standard 
fluorescent IVM, leukocyte-endothelial interactions have been investigated in the pial 
vessels of the brain and been taken as representative of events in the deeper cortical 
vessels and the cerebral microvasculature as a whole. A number of differences between 
pial and cortical venules exist, pial venules lack the astrocyte ensheathment 
characteristic of cortical vessels [252] which could conceivably have an effect on 
inflammatory responses. However pial and parenchymal microvessels are understood to 
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share many features, such as ultra-structural features and tight junctions along with 
similar electrical resistance and permeability to tracers [252]. As such these vessels are 
often used as models of deeper inaccessible cortical venules and by enlarge considered 
adequate. Indeed while the exact contribution of leukocytes migrating through pial vs. 
parenchymal vessels to cerebral damage is unknown, pial vessels, lacking a Virchow-
Robin space and glial limitans, may provide an easier route for transmigrating leukocytes 
to navigate, and could conceivably represent the major port of entry in early or mild 
inflammatory events. Nevertheless the possibility cannot be excluded that the 
observations in this study could be unique to pial micro-vessels.  
One further drawback due to the limited depth of imaging possible is the inability to 
directly visualise leukocyte migration into the brain parenchyma. However increased 
leukocyte-endothelial interactions in the pial vessels have been shown to correlate with 
subsequent elevated leukocyte infiltration in the brain parenchyma as a whole. 
Treatments with prospective therapeutics which inhibit leukocyte rolling and adhesion 
have also similarly been shown to reduce leukocyte infiltration into the parenchyma in in 
vivo models [71], whist also reducing the damaging effects of neutrophil emigration [71]. 
Thus, while in the current study at the acute time points tested no parenchymal 
neutrophils have been observed, leukocyte adhesion is a prerequisite for transmigration 
and is indicative of subsequent infiltration. With the advancement of technology and the 
introduction of confocal and multi-photon intravital microscopy it has become possible for 
a greater depth of vision allowing the researcher to explore inflammatory events in the 
deeper cortical vessels. Such investigations have allowed real time visualisation of 
leukocyte migration in the brain. While the use of this minimally invasive technique is still 
in its infancy for the study of leukocyte recruitment, future investigations using this 
technique will undoubtedly provide an insight into the relevance of the pial 
microcirculation in modelling the deeper vessels along with a greater understanding of 
transmigration and leukocyte motility inside the brain parenchyma.  
3.3.6.2. Distinguishing leukocyte subsets 
In this study rhodamine 6G has been used to fluorescently label leukocytes, this dye has 
been previously shown to also label platelets when used at high concentrations however 
the clear difference in size makes these two cell types easily distinguishable. Rhodamine 
however cannot distinguish between leukocyte sub sets (lymphocytes, neutrophils, 
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basophils, or monocytes). While in this study neutrophil depletion has been used to help 
identify these cells, there is also the possibility that fluorescently labelled antibodies 
could be introduced to specifically label and track the recruitment of individual leukocyte 
populations. This approach however carries a number of draw backs. Varying affinity of 
different antibodies means that only a proportion of cells may be visualised, and ex vivo 
separation/staining procedures may activate cells. Furthermore antibodies for specific 
labelling should be selected with care, a number of antibodies used to selectively label 
leukocytes target cell surface molecules that are themselves involved in the adhesion 
process and would therefore affect the very parameters that are being measured. The 
monoclonal antibody, RB6-8C5, that binds Gr-1 (specifically Ly6C and Ly6G), has been 
an important investigational tool to assess neutrophil function [253]. At high doses this 
antibody has been used to experimentally deplete neutrophils, however more recently, 
low doses have frequently been used to endogenously label neutrophils for IVM [225]. 
During studies exploring the impact of submaximal neutrophil depletion Wang et al. 
recently observed that while low doses of RB6-8C5 did not reduce levels of circulating 
neutrophils, the treatment caused an almost complete inhibition of neutrophil migration 
[254]. Subsequent investigations revealed that the antibody inhibited the ability of 
neutrophils to react to chemotactic stimuli, interfering in previously undiscovered 
interactions between Ly6G and the β2 integrins CD11a and CD11b [253, 254]. Thus 
while lacking the ability to differentiate between leukocyte sub populations; the use of 
rhodamine in the present study avoids a host of potential confounding factors.  
3.3.7. Receptor expression 
In order to investigate the MRS as a therapeutic target in this cerebral I/R model, 
expression levels of the melanocortin receptors were first investigated in both the brain 
and blood of C57BL/6 mice, to confirm the presence of the receptors and also to monitor 
the effect of cerebral ischemia and peptide treatment on receptor expression. In these 
investigations MC1 and MC3 expression was initially detected in whole brain 
homogenates which remained consistent across all treatments. Detection of MC3 protein 
in samples from MC3-/- mice (confirmed as such by PCR) however put the specificity of 
this antibody into question. Due to the relatively high homology between melanocortin 
receptors (particularly in the TM1, TM3 and TM7 regions) [255] and similarity in 
molecular weight it may be that these antibodies are cross reacting with other 
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melanocortin receptors present. The reliability of commercially available MC3 antibodies 
has also since been put into question by Kathpalia et al. [256]. During their investigations 
into the natriuretic effect of γ-MSH at Stanford University Kathpalia et al. tested an array 
of commercially available MC3 antibodies (including the Sigma Aldrich antibody used in 
this project). In both western blot analysis and IHC all antibodies tested were unable to 
specifically detect MC3 in mouse brain or kidney showing apparent expression in MC3-/- 
animals [256]. These antibodies and the ones used the present project have previously 
been used in studies characterizing MC3 expression in a number of different tissues and 
disease models. These recent findings could cast doubt on the reliability of the findings 
with regards to MC3 expression in these studies, although the studies were done in 
conjunction with compounds which are reported to show selectivity for the MC3 and also 
looked at the effects of disease progression/exacerbation in MC3-/- mice compared to 
their wild type counterparts. 
During this project the lack of a reliable and specific antibody for the MC3 has thus 
limited the analysis of MC protein expression by western blot analysis or 
immunohistochemistry. However to investigate any transcriptional changes in 
melanocortin receptor expression qRTPCR has been utilised. These studies show no 
significant changes in the blood or brain levels of MC transcript in response to BCCAo at 
either 40 min or 2 h of reperfusion. However upon treatment with the pan receptor 
agonist α-MSH blood levels of MC4 mRNA were found to be significantly reduced by 40 
min of reperfusion.  
While these investigations demonstrate that BCCAo does not induce a transcriptional 
modulation of MCs in either brain or blood, there is still the possibility that MCs are 
regulated post transcriptionally. GPCR expression is highly responsive, and receptor 
phosphorylation may mediate rapid desensitization and internalisation. Receptor 
agonists may induce GPCR internalisation and regulation of membrane localisation 
represents a key point at which ligand responses may be modulated. For instance 
treatment with various melanocortin agonists has been observed to result in 
desensitisation and internalisation of MC4 [257]. Internalisation studies have not however 
yet been performed with other MCs. A number of GPCRs are now also understood to 
require accessory proteins for their function and membrane trafficking. MC2 has 
previously been shown to require the accessory protein, melanocortin 2 receptor 
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accessory protein (MRAP) to allow for membrane localisation and also its signalling 
[258]. Since then a second MRAP (MRAP2) has been discovered, which also facilitates 
membrane localisation but imparts the receptor with an extremely low affinity for its 
agonist [259, 260]. Taken together, these accessory proteins may provide a fine tuning 
of MC2 functioning. No such receptor specific associated proteins have been yet 
discovered for the anti-inflammatory receptors on which the investigations of this thesis 
focus, the MC1 and MC3. However recently co-immunoprecipitations by Chan et al., 
indicate both MRAP and MRAP2 are in fact, able to interact with all five melanocortin 
receptors [261]. While MRAP enhances MC2 function, it has also been found to inhibit 
MC1, MC3, MC4 and MC5 in cAMP response assays and reduce the surface expression 
of MC4 in CHO cells co-expressing MRAP and MCs [261]. MRAP2 on the other hand 
reduces MC3 MC4 and MC5 signalling but has no effect on MC1. Whether or not these 
novel interactions influence receptor functioning and expression in vivo and indeed if 
cerebral ischemia affects MRAP regulation has yet to be determined. However in the 
absence of specific antibodies it is difficult to definitively assess the effect of BCCAo on 
MC regulation and function.  
3.4. Summary 
Using this 5 min BCCAo model with reperfusion, a significant and temporally dependant 
level of leukocyte recruitment has been observed. This recruitment of blood born cells 
coincided with significantly increased levels of circulating TNF-α. While no evidence of 
BBB breakdown or neutrophil infiltration into the brain was observed by 2 h of 
reperfusion, BCCAo was found to induce mild but statistically significant activation of 
resident immune competent glial cells (IBA-1 positive microglia)which was found to be 
localised exclusively to the hippocampus. Investigations into melanocortin receptor 
expression also indicated the presence of multiple melanocortin receptors in both brain 
and blood. As such this model provides multiple parameters (leukocyte rolling and 
adhesion, blood TNF-α levels and microglial activation) at which to assess the MRS as a 
therapeutic intervention in the acute phase neuro-inflammatory response following 
cerebral I/R. 
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3.5. Future Directions  
While this thesis focuses on the acute inflammatory response following BCCAo and the 
early recruitment of leukocytes, to further expand on the data within it would be 
interesting to assess functional outcome following BCCAo. Extending reperfusion to 24 h 
could allow for the investigation of any functional impairment that may arise using 
behavioural tests, histological examination could also be used to evaluate neuronal cell 
death. Indeed evaluations of neuroprotection (beyond the scope of this thesis) could be 
made by assessing differential cell death in the vulnerable CA regions of the 
hippocampus. 
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4.1. Introduction 
Leukocyte recruitment in the CNS is a key process in the pathogenesis of neuro-
inflammatory diseases including Stroke, MS and infection. Furthermore recent studies 
have implemented leukocyte recruitment in other neuropathologies including Parkinson’s 
disease and epilepsy, thus intervening in this neuro-inflammatory process may provide a 
valuable therapeutic opportunity. 
Activation of the melanocortin receptor system has previously been shown to provide 
neuroprotection in a number of models of cerebral ischemia reperfusion injury [169, 207, 
211] and has demonstrated impressive inhibitory actions on leukocyte recruitment in a 
variety of in vivo inflammatory situations [127, 140, 151]. However the relative 
contribution of MC subtypes in mediating these protective effects remains under 
contention and their effects on leukocyte recruitment has not yet been assessed in the 
cerebral microcirculation. 
In this chapter a number of MC agonists and antagonists have been utilised for a 
pharmacological investigation into the effects of melanocortin treatments on leukocyte 
recruitment following cerebral I/R. Furthermore these studies have been used to help 
elucidate the relative importance of MC subtypes in mediating these effects. 
 
4.0.   Investigation into the 
effects of melanocortin agonists 
and antagonists on leukocyte 
endothelial interactions following 
BCCAo. 
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4.2. Results 
4.2.1. Treatment with α-MSH reduces BCCAo induced leukocyte endothelial 
interactions 
To investigate the effects of activating the MRS on leukocyte recruitment a single 10 µg 
i.p dose of α-MSH, an endogenous pan receptor agonist (with exception to MC2, which is 
exclusively activated by ACTH), was given 30 min before initiation of BCCAo. 
Prophylactic treatment with α-MSH was found to provide potent inhibition of BCCAo 
induced leukocyte recruitment (Figure 4.1), reducing both rolling and adhesion of cells 
(Figure 4.2).  
 
 
To investigate whether α-MSH treatment would be effective when given following stroke, 
treatments were brought forward to the start of reperfusion and effects on leukocyte 
recruitment at 40 min and 2 h following BCCAo were compared to treatments 30 min 
prior to BCCAo (Figure 4.2). Treatment with α-MSH at the start of reperfusion provided 
similar levels of protection as pre-treatment, reducing rolling by 80 % (from 191.0 ± 
31.49 cells/mm2/min to 38.25 ± 8.93) and adhesion by 68 % (from 282.3 ± 20.15 
Figure 4.1 α-MSH treatment reduces BCCAo induced leukocyte recruitment 
Representative IVM stills of pial microvessels following sham surgery or BCCAo with 40 
min of reperfusion treated 30 min prior to ischemia with saline or 10μg of α-MSH. 
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cells/mm2/min to 90.35 ± 34.96) (Figure 4.2 B). Both levels of adhesion and rolling 
achieved in BCCAo animals treated either prophylactically or at the start of reperfusion 
were found not to be significantly different from those found in sham operated animals. 
By 2 h of reperfusion however the effects of a single i.p dose of α-MSH 30 min prior to 
ischemia had dissipated, no longer providing significant reductions in rolling or adhesion 
(Figure 4.2 A). Treatments given at the start of reperfusion on the other hand maintained 
a potent inhibitory influence on leukocyte recruitment (Figure 4.2 B). Compared to saline 
treated BCCAo animals at 2 h reperfusion rolling was reduced by approximately 68 % 
(from 243.87 cells/mm2/min to 79.34 cells/mm2/min) and leukocyte adhesion reduced by 
82 % (from 659.70 cells/mm2/min to 121.50 cells/mm2/min). The velocity of rolling cells 
was found to be increased at 2 h with α-MSH treatment compared to saline. This 
increase countered the trend toward a reduction in leukocyte rolling velocity observed 
following BCCAo and the levels were not significantly different to sham operated groups 
(Figure 4.2 B). Future experimental treatments were therefore limited to the more 
effective and clinically relevant time of treatment, at the start of reperfusion. 
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Figure 4.2. The effect of α-MSH treatment on BCCAo induced leukocyte recruitment at different time points . 
Leukocyte endothelial interactions were assed using IVM at either 40 min or 2h following 5 min BCCAo. Treatments of 10 
µg α-MSH were given i.p either (A) prophylactically 30 min before BCCAo or (B) at the start of reperfusion Values represent 
mean +/- SEM. N = 6 for all 40 min groups, n = 5 for 2 h α-MSH group and  n = 4 for all other 2 h treatment groups. 
Statistical analysis was performed across different treatments within the same time of reperfusion. * denotes significance to 
sham P<0.01, ** = P<0.001. + denotes significance to saline treated BCCAo group P<0.01, ++ = P<0.001.  
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4.2.2. The effect of MC selective treatments on leukocyte recruitment  
With the aim of determining the relative contributions of melanocortin receptor sub types 
to the observed reductions in leukocyte recruitment, pharmacologically selective 
compounds were tested in the BCCAo model (Figure 4.3). Selective activation of MC1 by 
a single i.p injection of 15 µM/Kg BMS-470,539 at the start of reperfusion was shown to 
provide a potent inhibition of BCCAo induced leukocyte recruitment at 40 min 
reperfusion. These effects were comparable in magnitude to those achieved with α-MSH 
treatment, with both rolling being reduced by 69 % (from 191.0 cells/mm2/min to 58.1 
cells/mm2/min) and adhesion being suppressed by 80 % (from 282.3 cells/mm2/min to  
58.0 cells/mm2/min) these levels achieved were comparable to those found in sham 
operated animals. However, BMS-470539 treatment becomes less effective by 2 h, with 
neither the reduction in rolling or adhesion being statistically significant when compared 
to the vehicle treated group. Treatment with the MC3 agonist [DTRP8]-γ-MSH was found 
to significantly inhibit adhesion (57 % reduction) but not the number of rolling cells at 40 
min reperfusion. Contrasting the effects mediated by BMS-470539 which appear to 
dissipate by 2 h reperfusion, the effect of [D-TRP8]-γ-MSH on adhesion by 2 h becomes 
more highly significant compared to vehicle treated BCCAo animals (P<0.001), reducing 
BCCAo induced adhesion by approximately 90 %. Additionally a trend toward a 
reduction in the number of rolling cells was observed in [D-TRP8]-γ -MSH treated 
animals at 2 h following BCCAo compared to vehicle treated animals.  
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Figure 4.3. The effect of pharmacologically selective compounds on leukocyte recruitment following BCCAo 
Leukocyte endothelial interactions were assed using IVM in terms of (A) rolling cell flux, (B) WBC velocity and (C) 
adhesion, at either 40 min or 2 h following 5 min BCCAo. Treatments were given i.p at the start of reperfusion using 
either the endogenous pan receptor agonist α-MSH, the MC1 selective BMS-470539 (BMS) or the MC3 agonist [D-TRP8]-
γ-MSH (DTRP). Values represent mean +/- SEM. Statistical analysis was performed across different treatments within 
the same time of reperfusion. BCCAo 40 min reperfusion groups n = 6. α-MSH treated 2 h reperfusion group n = 5 all 
other 2 h reperfusion groups n = 4. * denotes significance to sham P<0.01, ** = P<0.001, + denotes significance to saline 
treated BCCAo group P<0.01, ++ = P<0.001. 
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4.2.3 The effect of α-MSH treatment on NF-κB related genes 
With the aim of investigating whether the observed reductions in leukocyte recruitment 
following α-MSH treatment was due to the ‘classical’ melanocortin NF-κB inhibition 
pathway, the mRNA expression of two NF-κB related genes has been measured using 
qRT-PCR. RNA levels of TNF-α and IκB were investigated in both blood and brain of 
animals undergoing BCCAo surgery with 40 min or 2 h reperfusion and treated with 
saline or α-MSH at the start of reperfusion (Figures 4.4 and 4.5).  
In blood there was a slight trend toward an increase in TNF-α mRNA expression at 2h 
following BCCAo with levels rising 2.4 fold from control levels. This nevertheless was not 
found to be statistically significant, as such further investigations with greater n numbers 
are required to allow for any firm conclusion to be drawn. IκB levels showed a trend 
toward an increase at the earliest time point tested following stroke and by 2 h following 
BCCAo this level showed statistical significance with a 25 fold increase in blood IκB 
transcript from control levels. Following α-MSH treatment this increase in IκB was 
significantly inhibited at 2 h reperfusion but not at 40 min of reperfusion.  
Figure 4.4. Blood mRNA levels of TNF-α and IκB following BCCAo and α-MSH treatment 
Change in blood levels of TNF-α and IκB mRNA transcript as detected by qRT-PCR. Data analysis 
was performed using the ΔΔCT Method and values expressed as fold change from control. N = 3 
for all groups. * denotes significance to sham P<0.01. + shows dignificance to saline treated 
BCCAo group P<0.05 
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While not statistically significant whole brain levels of both TNF-α and I-κB showed 
trends toward an increase following BCCAo. A greater insight into these effects could be 
gained by preforming analysis on a larger study group. 
 
 
4.2.4 The impact of melanocortin agonists on microglial activation and 
circulating cytokines 
In order to gauge the mechanism by which α-MSH treatments reduce leukocyte 
recruitment in this model, IHC has been used in preliminary studies to investigate 
whether treatment suppresses the BCCAo induced microglial activation. Treatment at 
the start of reperfusion with 10 μg α-MSH was however not detected to suppress 
increased microglial activation at 2 h post BCCAo, with no significant differences in IBA-
1 expression in saline or α-MSH treated groups (Figure 4.6). 
Figure 4.5. Brain mRNA levels of TNF-α and IκB following BCCAo and α-MSH treatment 
Change in whole brain levels of TNF-α and IκB mRNA transcript as detected by qRT-PCR. Data 
analysis was performed using the ΔΔCT Method and values expressed as fold change from 
control. N = 3 for all groups. 
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Figure 4.6. Hippocampal microglial activation is not significantly reduced by α-MSH 
treatment Frozen brain sections were stained with IBA-1 to measure microglial activation. A) 
representative X20 micrographs of IBA-1 stained brain slices. B) IBA-1 positive cells were counted 
per field of view in four different brain areas. No significant changes in IBA-1 staining was observed 
between saline and α-MSH treated groups. N=3 for all groups 
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Both ELISA and CBA were utilised to investigate the action of different melanocortin 
agonists on levels of circulating cytokines (Figures 4.7 and 4.8). All melanocortin 
agonists tested were able to prevent the up regulation of TNF-α which occurred 2 h 
following BCCAo, as detected by ELISA. The CBA confirming these findings, however 
with the exception of the BMS-470539 group where the TNF-α reduction detected using 
the CBA was not statistically significant.  
Figure 4.7. ELISA measurements of serum TNF-α following treatment with 
melanocortin agonists Animals undergoing BCCAo were treated with either saline, 
α-MSH, BMS-470539 or [D-TRP8]-γ-MSH at the start of reperfusion and serum levels 
of TNF-α assessed using ELISA. Melanocortin treatments were found to abolish the 
BCCAo induced rise in serum TNF-α as seen in saline groups. N = 3 for all groups. * 
denotes significance to sham (not shown) P<0.01. + shows significance to 2h BCCAo 
saline treated group P<0.01. red line represents the reliable detection limit of the 
ELISA kit used. 
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Across the different melanocortin treatments both IFN-ϒ and IL-12 remained 
undetectable in serum. Both α-MSH and [D-TRP8]-γ-MSH did however induce a 
significant increase in the anti-inflammatory cytokine IL-10 by 2 h of reperfusion. Levels 
of the pro-inflammatory chemokine MCP-1 were also significantly reduced across all 
melanocortin treatments, although these levels were below the reliable detection range 
of the CBA. While IL-6 levels remained unchanged following treatment with BMS-470539 
(BMS), both α-MSH and [D-TRP8]-γ-MSH were found to cause significant increases in 
serum IL-6 levels by 2 h.  
Figure 4.8. CBA detection of serum cytokines: the effect of melanocortin agonist 
treatment following BCCAo  BCCAo groups were treated i.p at the start of reperfusion with 
saline, α-MSH, BMS-470539 (BMS) or [D-TRP8]-γ-MSH. Serum levels of IL-6, IL-10, MCP-1, 
IFN-γ, TNF, and IL-12p70 protein were then tested using CBA at 40 min or 2 h of 
reperfusion. N = 3 for all groups. + denotes significance to saline treated BCCAo group 
P<0.01. Red lines represent the reliable limit of detection for each cytokine tested 
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4.2.5. Utilising the MC3/4 antagonist, SHU9119, to further investigate the 
anti-inflammatory role of MC subtypes 
While BMS-470539 demonstrates almost entirely selective activity for MC1, [DTRP8]-γ-
MSH has been shown to bind and activate other melanocortin receptors [262] (table 
4.1). Furthermore MC1 binding studies and cAMP accumulation assays have not been 
published for [DTRP8]-γ-MSH. Thus, in order to further examine the roles of specific MC 
subtypes on leukocyte recruitment, investigations have been made using co-treatments 
with the MC3/4 antagonist SHU9119. Mice subjected to 5 min BCCAo with 40 min or 2 h 
of reperfusion were treated at the start of reperfusion with α-MSH or [DTRP8]-γ-MSH in 
combination with 10 µg SHU9119 (Figure 4.9). 
Competitive antagonism at MC3 and MC4 using SHU9119 failed to abrogate the anti-
inflammatory influence of α-MSH or [D-TRP8]-γ-MSH on leukocyte recruitment at 40 min 
of reperfusion. On the contrary, co-treatment of [D-TRP8]-γ-MSH with SHU9119 caused 
a more highly significant reduction in leukocyte adhesion than did [D-TRP8]-γ-MSH 
alone. However, by 2 h of reperfusion co-administration of SHU9119 was found to blunt 
the α-MSH induced reductions in rolling and adhesion, and almost completely abolish 
the effects of [D-TRP8]-γ -MSH when compared to singular treatments of either peptide.  
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Figure 4.9. Effects of co-treatment with the MC3/4 antagonist SHU9119 on the actions of melanocortin agonists. 
Leukocyte-endothelial interactions following BCCAo with 40 min or 2 h reperfusion in terms of (A) Rolling cell flux (B) 
WBC velocity and (C) Adhesion. C57BL/6 mice were treated at the start of reperfusion with α-MSH or [DTrp8]-γ-MSH (10 
µg i.p) either alone or in combination with the MC3/4 competitive antagonist SHU9119 (10 µg). α-MSH 40 min co-treatment 
group n = 6 all other co-treatment groups n = 4. Singular treatment 40 min groups n = 6, 2 h groups n =4. Statistical 
analysis was performed comparing different treatments within the same time of reperfusion. + represents statistical 
significance to saline treated BCCAo group P<0.01. ++ = P<0.001.  
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In order to further investigate the lack of any inhibitory effects of SHU9119 when co-
administered with melanocortin agonists at 40 min of reperfusion, treatments of 
SHU9119 were given alone and leukocyte recruitment assessed at both 40 min and 2 h 
following BCCAo (Figure 4.10.). At 40 min of reperfusion antagonism of MC3/4 by a single 
i.p dose of SHU9119 given at the start of reperfusion, was found to significantly reduce 
leukocyte adhesion by 59 % (from 282.3 cells/mm2/min to 116.0 cells/mm2/min) and 
increase WBC velocity by 83 % (from 20.5 cells/mm2/min to 37.7 cells/mm2/min) . These 
effects were however lost when reperfusion was extended to 2 h.  
 
 
 
Figure 4.10. Effect of SHU9119 treatment on IVM parameters Following BCCAo 
animals were either treated i.p with saline or 10μg of SHU9119. Leukocyte recruitment 
parameters were then measured at 40 min or 2 h of reperfusion. N= 6 for 40 min 
reperfusion groups and n = 4 for the 2 h group. Statistical analysis was performed 
between groups of the same time point. + denotes significance to saline treated group 
P<0.01. 
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While the focus of these investigations has been on the MC mediated actions of 
melanocortin treatments and to elucidate involvement of different MCs, MC independent 
actions of α-MSH have previously been reported. These actions are proposed to be 
initiated by the N terminal tripeptide KPV acting perhaps as an IL-1R antagonist. In order 
to determine whether any of the observed effects of the α-MSH treatments given may be 
via receptor independent actions, the influence of KPV treatments on I/R induced 
leukocyte recruitment has been measured (Figure 4.11). By 40 min of reperfusion a 
single i.p dose of KPV (10µg) was able to significantly reduce BCCAo induced leukocyte 
adhesion by 77 % and increase WBC velocity by approximately 3 fold, a trend toward 
reduced leukocyte rolling (55 %) was also observed. However these effects were not 
maintained until 2h of reperfusion, with KPV treatment failing to influence any of the 
parameters measured.  
Figure 4.11. BCCAo induced leukocyte recruitment following KPV treatment. 
C57BL/6 mice were treated i.p with 10 μg of KPV immediately following 5 min of BCCAo. 
Leukocyte recruitment was the assessed in the pial circulation in terms of A) Rolling B) 
Rolling velocity and C) Number of adherent leukocytes. N = 6 for saline 40 min, n = 4 for 
saline 2 h and n = 5 for all KPV treated groups. + denotes significance to saline treated 
groups P<0.05, ++ = P<0.001 
  
139 
4.3. Discussion  
4.3.1. The anti-inflammatory effects of alpha-MSH 
Using BCCAo as a model of cerebral I/R induced inflammation the present investigations 
have demonstrated potent inhibitory actions of exogenously administered α-MSH on 
leukocyte recruitment. With a single i.p injection resulting in an almost complete 
abrogation of BCCAo induced leukocyte recruitment, causing an 80 % reduction in 
rolling and 69 % reduction in number of adherent cells. α-MSH has previously been 
shown to reduce leukocyte recruitment in monosodium urate (MSU) crystal induced 
inflammation [263], LPS challenge and also following I/R injury in the mesentery. 
Consistent with these experimental findings, in humans a negative correlation has been 
observed in the synovial fluid of arthritic patients between α-MSH concentrations and 
neutrophil number. Indeed in light of observations that plasma α-MSH concentrations 
increases in patients following various inflammatory insults including myocardial 
infarction, infectious disease and endotoxin administration [120] and that higher 
melanocortin levels have been shown to correlate with better outcome in stroke [264] 
there is growing evidence that the melanocortins are part of an endogenous system to 
bring about the resolution of inflammation. 
In the current investigations α-MSH was able to significantly reduce leukocyte 
recruitment at 40 min following BCCAo when either administered prophylactically or at 
the start of reperfusion. However while a single dose of α-MSH given at the start of 
reperfusion provided significant inhibition of leukocyte recruitment at 2 h following 
BCCAo, given 30 min before BCCAo the peptide had lost these effect.  
The half-life of iv administered full-length α-MSH has been found to be relatively short 
with reports of measurements from just 7 min when given i.v in rats [265] to 39 min in 
blood [266], with one report measuring 92 min in rabbit plasma [267] . This is most likely 
due to the presence of several serum proteases, with discrepancies between in vivo and 
in vitro half-lives perhaps indicating that extra-vascular or endothelial derived proteases 
may provide a major contribution in the metabolism of α-MSH. As discussed by Wilson 
et al. α-MSH half-life is thus likely to vary in different physiological and pathological 
environments with differing levels of proteases having a large effect on α-MSH longevity 
[265]. Indeed in the context of inflammation increased circulating proteases may further 
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limit the half-life of α-MSH in vivo. The duration of the physiological effects of α-MSH has 
been estimated at 1.5 h for its anti-pyretic activities [95]. While α-MSH is likely to initiate 
downstream signalling events that extend the physiological influence of the peptide 
beyond its longevity, in the presence of a continuing inflammatory process in the current 
model, these effects appeared to subside by 2.5 h following peptide administration. Thus 
it is likely that 2.5 h represents the extent of anti-inflammatory protection provided by a 
single i.p dose of 10 µg α-MSH.  
4.3.2. Central effects of α-MSH and microglial activation  
Microglia rapidly respond to pathogenic environmental changes in the brain and release 
a variety of cytotoxic and pro-inflammatory signals immediately following ischemia. 
However at later time points these cells may promote recovery through the release of 
neurotrophins and transforming growth factor-β1 [18]. Microglia express melanocortin 
receptors (predominantly MC1) and previous reports show α-MSH to reduce brain TNF-α 
(of which microglia are the main source [248]) following i.c.v administration of LPS [268]. 
Furthermore in vitro LPS stimulated microglial cell lines (N9) treated with α-MSH have 
been shown to reduced production of TNF-α, IL-6 and NO [269] and when activated by 
LPS and IFN-ϒ microglia have been shown to produce α-MSH which may act in an 
autocrine fashion [269]. 
The lack of any effect on microglial activation in the present investigations may be 
indicative of α-MSH treatments not reaching the brain parenchyma. α-MSH has 
previously be shown to cross the BBB (albeit to a very limited degree) when 
administered intravenously [270]. A number of previous reports have demonstrated 
peripherally administered α-MSH to affect aspects CNS function [271, 272]. Huang et al. 
have shown i.p injection of α-MSH to suppress LPS mediated fever through actions on 
the brain in rats, the authors suggest the peptide may circumvent the BBB through 
circumventricular organs, which lack a tight BBB [271]. However no investigations were 
made into brain α-MSH concentration. Indeed, investigations into BBB permeability have 
given the most optimistic estimation of brain tissue entry of α-MSH following i.v 
administration to be 1-2 % of the circulating levels [270]. It may be still be that such low 
levels are able to influence brain functions however, given the results obtained herein, 
the single i.p injection administered in these investigations is unlikely to have such far 
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reaching effects. Indeed the lack of any BBB disruption observed in this model would 
further hamper α-MSH transit into the neurophil. Moreover while α-MSH administration 
induced a decrease in MC4 expression in blood (as detected by qRT-PCR) the lack of 
any effects of on MC4 expression in the brain could also be taken to support solely 
peripheral effect of α-MSH in this model. In support of this conclusion and fitting the 
observed reduction in leukocyte recruitment in the present study, investigations by 
Kastenbauer et al. have previously shown systemic administration of α-MSH but not 
intracisternal to reduce the CNS leukocyte infiltration in experimental pneumococcal 
meningitis, suggesting leukocyte recruitment to be inhibited by α-MSH from the blood 
side [273]. In light of the lack of any central effects detected in the current model and the 
poor BBB permeability of α-MSH it is unlikely that the observed actions on leukocyte 
recruitment are mediated via central MC4 anti-inflammatory signalling. 
4.3.3. Pharmacological investigation of MC involvement in modulating 
leukocyte recruitment 
Of the five melanocortin receptors, anti-inflammatory actions have been attributed to 
MC1, MC3 and also to some extent MC4 which mediates centrally activated anti-
inflammatory circuits. Each of these receptors have been shown to be expressed at 
varying levels in the brain, with MC4 being exclusively found in the CNS, while MC1 and 
MC3 have also been shown to be expressed on circulating immune cells and endothelial 
cells (Table 1.5). Numerous studies have provided compelling evidence for a role of both 
MC1 and MC3 in the endogenous control of leukocyte recruitment and as 
pharmacological targets for its modulation. However the exact role of the MC subtypes in 
mediating anti-inflammatory protection remains unclear. 
Having demonstrated potent inhibitory effects of α-MSH treatment in this BCCAo model 
of cerebral I/R induced leukocyte recruitment, selective synthetic melanocortin agonists 
have been investigated in the same model to elucidate the main receptor type mediating 
these effects. Table 4.1 shows the pharmacological properties and doses of each 
melanocortin compound used.  
4.3.3.1. The effect of BMS and DTRP on leukocyte recruitment 
Treatment with the small molecule MC1 selective compound, BMS-470539, provided 
significant inhibition of both leukocyte rolling and adhesion while activation of MC3 using 
  
142 
[D-TRP8]-γ-MSH only reduced levels of leukocyte adhesion suggest a less potent 
inhibitory effect from targeting MC3 (Figure 4.3). However by 2 h following BCCAo 
despite having a more favourable pharmacokinetic profile BMS-470539 had lost its 
inhibitory actions while the action of [D-TRP8]-γ-MSH seemed to have been enhanced. 
Thus suggest a role for MC1 in initiating the anti-adhesive actions on leukocyte 
recruitment in the immediate early stages of reperfusion and that MC3 has a longer 
pharmacodynamic effect in this model and is able to more effectively suppress leukocyte 
recruitment at later time points following the pathological event and/or the time of drug 
administration. 
4.3.3.2. The dual roles of SHU9119 
SHU9119 was used during these investigations as an MC3/4 competitive antagonist for 
use in co-treatment studies to further investigate the role of specific MC subtypes in 
supressing cerebral leukocyte recruitment. Unexpectedly, by 40 min or reperfusion co-
treatment with SHU9119 failed to inhibit not only the α-MSH induced inhibition of 
leukocyte recruitment but also the [D-TRP8]-γ-MSH mediated effects. In fact SHU9119 
was found to enhance these actions, and when administered alone SHU9119 was able 
to reduce leukocyte adhesion at 40 min following BCCAo. However by 2 h SHU9119 had 
lost these effects when administered alone, and in co-treatments was able to inhibit α-
MSH and block [D-TRP8]-γ-MSH effects. Thus supporting a role for MC3/4 in mediating 
later effects on leukocyte adhesion.  
While it was expected that by 40 min SHU9119 would abrogate the effects of α-MSH 
and [D-TRP8]-γ-MSH by inhibiting MC3 anti-inflammatory signalling, and when 
administered alone would enhance the I/R induced inflammatory response by blocking 
endogenous signalling, the observed early actions of SHU9119 may be explained by its 
seldom reported agonist actions at MC1 and MC5 (table 4.1). 
SHU9119 was first synthesised by amino acid substitutions in the super potent MC 
agonist NDP-α-MSH [274] and has since regularly been used in numerous in vitro and in 
vivo studies as an antagonist at MC3 and MC4. In addition to competitively antagonising 
both murine and human MC3 and MC4 with minimal agonist activity, SHU9119 has also 
been found to be a potent antagonist at the frog MC1. However SHU9119 also 
possesses, often overlooked, agonistic activity at human and mouse MC1 and MC5.  
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[274]. Indeed in experiments performed on B16 cell lines co-expressing  MC1, MC3, and 
MC4, SHU9119 treatment resulted in a net increase in cAMP signalling, despite acting as 
an antagonist to MC3 and MC4 [275]. Thus the reduction in leukocyte adhesion observed 
with SHU9119 treatment alone, can be explained by its agonistic actions at the anti-
inflammatory receptor MC1 and perhaps also partly due to agonist like activity at MC3. 
MC5 has not yet been detected on neutrophils, KO mice do not show an inflammatory 
phenotype, and no studies have yet revealed a role for MC5 in supressing innate 
inflammation, however the receptor has been shown to be expressed on T and B 
lymphocytes. As such, given that SHU9119 may also act as an agonist at MC5, a role for 
this receptor should not be entirely ruled out. Indeed a recent paper by Joseph et al., airs 
caution in interpreting data from studies using the MC3 agonist [D-TRP8]-γ-MSH in 
murine cells due to agonistic activity at MC5. [D-TRP8]-γ-MSH was originally developed 
using the endogenous peptide γ2-MSH which shows preferential binding to human (h) 
MC3 and MC4, modification of Trp to the D-isomer was found to cause a 100 fold 
increase in selectivity for MC3 over MC4 and a 250 fold increase in activity at hMC3 
compared to hMC5 [262]. While studies on selectivity at the murine receptors were 
incomplete, [D-TRP8]-γ-MSH has since been widely used as an MC3 selective agonist at 
the murine MC3. Joseph et al., have however recently demonstrated that [D-TRP8]-γ-
MSH is in fact a more potent inducer of cAMP signalling at murine MC5 than it is at MC3 
[262]. Nevertheless the physiological significance of this revelation is still unclear due to 
a limited understanding of MC5 in inflammation.  Taking into account the lack of 
selectivity provided by [D-TRP8]-γ-MSH and that SHU9119 also activates MC5 any 
potential role for MC5 in reducing post BCCAo leukocyte recruitment could only be 
present at the early stages. In co-treatment studies SHU9119 is able to inhibit the [D-
TRP8]-γ-MSH mediated effects at 2 h reperfusion, despite both SHU9119 and [D-TRP8]-
γ-MSH working as agonists at MC5. Furthermore by 40 min of reperfusion while [D-
TRP8]-γ-MSH treatment reduces adhesion and SHU9119 fails to block the effects of [D-
TRP8]-γ-MSH, these peptides have no inhibitory actions on leukocyte rolling, indicating 
an early role for MC1 in inhibiting leukocyte recruitment which perhaps also effects 
processes uniquely involved in leukocyte rolling, while MC3 induces more prominent 
effects by 2 h. 
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Table 4.1; Doses and pharmacological properties of melanocortin compounds 
Binding assays competitive binding for 125I-NDP-α-MSH  
Values show results from assays using human MCs. Data from mouse receptor studies are given in parenthesis.  
N/A = no detectable activity 
- = no data available 
*Moller et al. performed binding studies on cells transfected with the murine MC3, MC4 and MC5, however MC1 studies were performed on a mouse 
melanoma cell line which over expresses MC1, thus the level of receptor expression and conditions may be different compared to the other 
receptors and as such the obtained value should be taken with caution, especially since it does not fit with the human receptor binding data. 
▲ increased calcium observed in MC1 transfected cells but not quantified. 
Compound Dose (i.p) 
Ref. 
for 
dose 
MC binding affinity IC50 
(nM) 
cAMP accumulation EC50 
(nM) 
Ca2+ accumulation 
EC50 (nM) 
Pharmo-
dynamic  
half life 
Pharmo-
kinetic 
halflife  
Refs. 
MC1 MC3 
MC
4 
MC5 MC1 MC3 MC4 MC5 MC1 MC3 MC4 MC5    
α-MSH 10µg [211, 263] 
4.3 
(316*) 
19 
(18) 
19 
(19) 
120 
(96) 
0.45 
(0.70) 
0.73 
(2.10) 
1.6 
(2.6) 
19 
(2.0) 
- 
(4.3) 
- 
(1.3) 
- 
(0.5) 
- 
(1.3) ~2h 7-39 min 
[262, 
265, 
273, 
276-
279] 
BMS-470539 15µM/kg [280] 
120 
(-) 
- 
(-) 
- 
(-) 
- 
(-) 
28 
(11.6) N/A 2600 4400 
- 
(-) 
- 
(-) 
- 
(-) 
- 
(-) ~8 h 1.7 h 
[280, 
281] 
 
[D-TRP8]-γ-
MSH 10µg [127] 
- 
(-) 
6.7 
(-) 
600 
(-) 
340 
(-) 
- 
(120) 
0.33 
(90) 
100 
(5580) 
82 
(48) 
- 
(-) 
- 
(-) 
- 
(-) 
- 
(-) - - 
[262, 
282] 
 
SHU9119 10µg [263] 0.7 (110) 
0.23 
(1.8) 
0.0
6 
(0.1
) 
0.09 
(32) 
0.04 
(0.04) 
2.8 
(-) 
N/A 
(-) 
0.12 
(0.4) 
- 
(-) 
- 
(-) 
- 
(-) 
- 
(-) - - 
[274, 
277, 
278] 
 
KPV 10µg [283] Does not bind any of the melanocortin receptors 
Does not induce cAMP 
signalling ▲ 
- 
(-) 
- 
(-) 
- 
(-) - - 
[284] 
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4.3.3.3 The temporal switch from MC1 to MC3 mediated effects 
Convincing evidence has been provided for the anti-inflammatory actions of both MC1 
and MC3 mediated signalling in a number of different in vivo and in vitro models. 
Both MS05 and MS09 selective MC1 agonists have been shown to down regulate the 
expression and secretion of E-selectin, V-CAM and I-CAM in human vascular endothelial 
cells stimulated with TNF-α [154, 155]. Conversely antibody neutralisation of MC1 
increases both basal levels and LPS-stimulated production of TNF [156]. The anti-
inflammatory action of α-MSH has also been shown to be reduced by MC1 siRNA-
transfection in RAW264.7 macrophages [285]. In vivo, the MC1 agonist BMS-470539 has 
also been shown to reduce cytokine accumulation and leukocyte recruitment in a model 
of lung inflammation [280]. Additionally BMS-470539 has been shown to reduce 
leukocyte recruitment in both mesenteric I/R and PAF activated cremasteric vessels 
[151]. Moreover in both these vascular beds these effects were found to be absent in 
recessive yellow (e/e) MC1 mutant mice [151]. In agouti allele “lethal yellow” mice the 
excessive production of the MC1 MC4 antagonist agouti protein, has also been 
demonstrated to incur an enhanced inflammatory response to picryl chloride [128]. 
On the other hand, treatment with the MC1 selective MS05 failed to reduce MSU 
activation of macrophages and IL1-β release, while γ2-MSH significantly reduced these 
effects and remained potent in macrophages isolated from e/e mice [263]. In vivo, the 
MC3-/- mouse has been shown to display higher levels of leukocyte adhesion and 
emigration in the mesenteric microcirculation following I/R, while the e/e response was 
not significantly different from WT mice [127]. Additionally, in a model of peritonitis, 
treatment with the MC3 agonists γ2-MSH and Melanotan II both reduced PMN 
accumulation, effects which were blocked by antagonism with SHU9119 but not the MC4 
selective antagonist HS024 [263]. Furthermore these anti-inflammatory effects were 
again maintained in e/e mice [263]. 
The above investigations provide a complex picture by which the role of MC1 and MC3 in 
modulating leukocyte recruitment varies not only with pathological stimulus but also with 
the vascular bed. Given that the MC3-/- mouse displayed an inflamed phenotype while 
e/e mice showed none, yet in the exact same mesenteric I/R model that MC1 agonist 
BMS-470539 was effective in reducing inflammation, it may be that these receptors 
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show different endogenous physiological roles but that both may be harnessed 
pharmacologically. While others have demonstrated varying roles for MC1 and MC3 in 
different inflammatory models and differential roles in the physiological and therapeutic 
responses, the present study is the first to report a temporal influence on receptor role. 
Thus adding an additional layer of complexity to the role of the MRS in the inflammatory 
process. 
It might be tempting to conclude that the apparent switch in significance of receptor 
subtype suppressing leukocyte recruitment, is due to receptor up regulation or increased 
receptor internalisation, however as detailed in chapter 3 no change in receptor mRNA 
was detected in blood or brain for both MC1 and MC3. While this does not exclude 
effects on receptor localisation and regulation at the protein level, it should be noted that 
that only a single dose of each drug was given at the start of reperfusion, and it should 
not be assumed that there are still sufficient circulating levels of the drug to activate 
newly up-regulated receptors at later stages of reperfusion. In fact the short half-life of α-
MSH and [D-TRP8]-γ-MSH might suggest otherwise. 
The apparent value of targeting MC1 to reduce early rolling and adhesion and MC3 to 
reduce adhesion at later stages in reperfusion may be a reflection of different signalling 
pathways being initiated by the different receptors and/or drugs. 
4.3.4. The NF-κB pathway in reducing leukocyte recruitment 
Since pharmacological investigations reveal an apparent change in the importance of 
receptor subtype as reperfusion progresses yet qRT-PCR experiments showed no 
change in receptor expression across these time points, an initial investigation has been 
performed into whether these treatments were acting via NF-κB signalling. 
The inhibition of NF-κB regulated transcription is a key element to the broad protective 
actions of the melanocortins, allowing for the inhibition of a plethora of cytokines, 
chemokines and adhesion molecules under its control. These effects are however 
transcriptionally dependant, with previous investigations showing NF-κB DNA binding 
only after 30 min following TNF-α stimulation followed by gene transcription 30 min later 
[286]. As such NF-κB induced transcription is unlikely to mediate the rapid effects on 
leukocyte recruitment observed, at least at 40 minutes, following BCCAo. To investigate 
  
147 
the effects of BCCAo and α-MSH treatments on NF-κB activation, qRT-PCR 
experiments have been performed to determine transcript levels of a key NF-κB 
controlled cytokine TNF-α along with the NF-κB regulator IκB. Bottero et al. have 
previously shown mRNA levels of IκB to correlate extremely well with NF-κB 
translocation as assessed by northern blot and gene reporter assays [286] with levels 
increasing within 30 min of NF-κB DNA binding. As such the real-time PCR 
measurement of IκB mRNA has been proposed as a rapid, sensitive, and powerful 
method to quantify NF-κB transcriptional activity [286]. 
Consistent with the early anti-inflammatory action of melanocortins not having been 
mediated by NF-κB inhibiting actions, both TNF-α and IκB transcript levels were found to 
be unchanged at 40 min following BCCAo in both brain and blood. Thus the production 
of molecules and signalling orchestrating these early leukocyte recruitment events are 
likely to be independent of gene transcription and likewise are the inhibitory actions of 
melanocortin treatments.  
However by 2 h of reperfusion qRT-PCR revealed levels of IκB transcript to be 
significantly elevated in blood (by 25 fold) and TNF-α levels showed a trend toward an 
increase of 2.4 fold which were both supressed by α-MSH treatment (although not 
significantly in the case of TNF-α). While brain levels of both TNF-α and IκB were not 
significantly elevated, there was a strong trend toward an increase. However unlike in 
the blood where α-MSH reduced IκB levels by approximately 60 %, treatment failed to 
induce any change in IκB expression in the brain. This again suggests that in this model 
the peptide did not reach the brain parenchyma but instead exerted its action on blood 
borne or endothelial elements. The IκB inhibition observed in blood reveals that, 2 h 
following administration, α-MSH treatments are able to reduce BCCAo induced genetic 
responses, this effect is likely due to inhibition of NF-κB translocation to the nucleus as 
previously reported by others. Taken in conjunction with the pharmacological 
investigations these later effects inhibiting inflammatory gene transcription may be 
mediated by MC3 signalling or at least it is unlikely that these effects are mediated by 
MC1 or MC4. 
The fact that melanocortin treatments were able to significantly inhibit leukocyte 
recruitment at 40 min after BCCAo despite no detectable change in NF-κB activation 
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may be explained by other anti-inflammatory pathways centred on the melanocortin 
receptors. Indeed the observation of melanocortin anti-inflammatory influences in the 
absence of any transcriptional effect is not unique to the present study.  
In zymosan stimulated primary peritoneal macrophages the α-MSH analogue AP214 
reduced IL-1β and TNF-α release despite having no effect on mRNA levels of these 
cytokines [287]. α-MSH treatment has also been shown to reduce CD14 expression in 
LPS stimulated macrophages by shedding of the receptor from the cell surface and not 
via transcriptional mechanisms [288]. While the exact mechanism underlying these 
effects were not explored, antibody treatments revealed these effects to be mediated via 
MC1, and α-MSH induced release of proteases was proposed as a speculative 
mechanism [288]. 
A seemingly similar mechanism that has been more thoroughly investigated is the α-
MSH induced cleavage of the IL-8 receptors CXCR1 and CXCR2 on the neutrophil cell 
surface [181]. This was found to be mediated by MC1 yet was independent of cAMP 
signalling and having no effect on mRNA levels. Instead this occurred via release of 
neutrophil elastase acting in an autocrine fashion on cell surface chemokine receptors, 
resulting in significant reductions in neutrophil chemotactic ability and oxidative burst 
[181]. As discussed in chapter 1, this demonstrated a novel MC1 anti-inflammatory 
pathway independent of any action on NF-κB activity. Furthermore given that CD14 
shedding has also been observed in response to MC1 activation, this mechanism may 
even extend to proteolytic regulation of other chemokine receptors, thus helping to 
explain some of the reported rapid transcriptionally independent anti-inflammatory 
actions of melanocortin active compounds. 
While the understanding of NF-κB independent MC effects is still in its infancy, these 
mechanisms may fit well with the early MC1 mediated effects on leukocyte rolling 
observed here. While no temporal studies have yet been performed investigating these 
anti-inflammatory mechanisms it is entirely feasible that, due to the lack of transcriptional 
involvement, these pathways are more rapid than the classical inhibition of NF-κB 
nuclear translocation. As such it could be proposed that in the present model activation 
of MC1 results in a rapid reduction in leukocyte recruitment via NF-κB independent 
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pathways while MC3 provides more delayed protection through inhibition of NF-κB 
translocation. 
4.3.5. Receptor independent actions of melanocortins. 
It has been noted that some of the anti-inflammatory actions of α-MSH remain effective 
even with extremely low sub-picomolar concentrations of the agonist. In accordance to 
the experimentally derived binding affinity of α-MSH for the MCs very few, if any, 
receptors would be occupied [95], thus suggesting possible anti-inflammatory pathways 
independent of the melanocortin receptors. These receptor independent events have 
largely been attributed to the C-terminal tripeptide signal of α-MSH, KPV. 
As such, in order to investigate whether the KPV sequence may have an influence over 
leukocyte recruitment in the BCCAo model and thus if the observed actions of α-MSH 
could also be via MC independent pathways, KPV treatments have been tested. 
KPV was found to significantly reduce leukocyte recruitment at 40 minutes following 
cerebral I/R. Thus it appears that the KPV sequence of α-MSH does influence leukocyte 
recruitment and that MC independent mechanisms may be at least partly responsible for 
the anti-inflammatory actions of α-MSH. However by 2 h while still showing a trend 
toward a reduction the significant reduction in leukocyte adhesion observed at 40 
minutes was lost. 
KPV has been previously demonstrated to inhibit the elevation of a number of cytokines 
and reduce NF-κB activation in in vitro and in vivo inflammatory models [182] [95]. 
Furthermore in a murine model of peritonitis KPV also reduced PMN recruitment [140]. 
In the absence of melanocortin receptor binding [140, 183-185] and that KPV treatment 
fails to induce cAMP accumulation [140, 185], the mechanisum by which KPV exerts 
these effects is still incompletely understood. However, structural similarities between 
KPV and the IL-1β antagonist KPT indicate that KPV may act as an IL-1R antagonist. 
Indeed both KPV and α-MSH have been shown to displace surface binding of radio-
labelled IL-1β, and inhibit IL-1 mediated effects [95, 186].  
Synthesised as a precursor molecule which is proteolyticaly cleaved, IL-1β formation 
and release is rapid and independent of de novo synthesis. This pro-inflammatory 
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cytokine plays a key role in the inflammatory pathology of stroke, and is elevated early 
following brain injury [289]. The observed rapid reduction in leukocyte adhesion 
observed in the current model following KPV administration may be a result of KPV 
inhibiting signalling of the rapidly released IL-1β. Indeed IL-1R activation has been 
shown to be required for neutrophil recruitment [290] and an IL-1R antagonist is 
currently undergoing clinical trials to combat post stroke inflammatory reactions [116].  
However in the present investigations the effects of KPV treatment diminish by 2 h post 
BCCAo. It may be that the single does given in this study is not enough to effectively 
antagonise a sufficient number of chemokine receptors as the inflammatory process 
progresses and serum levels of cytokines rise. 
At the time of writing, no data on the exact pharmokinetics of KPV in blood has been 
published or indeed has there been any investigation into the possibility of endogenously 
formed KPV from α-MSH. A number of proteases are present in the circulation, which 
have previously been postulated to be responsible for the limited half-life of α-MSH [95]. 
Different proteases show different specificities for their substrate, elastase cleaves the 
bond after a small non-polar residue such as glycine, which separates the core α-MSH 
sequence from KPV. Since neutrophil elastases are elevated in inflammatory situations 
including stroke it could be possible that endogenous (or even exogenously 
administered) α-MSH is cleaved to give rise to KPV with both α-MSH (1-10) and KPV 
working cooperatively to resolve inflammatory events. Binding studies showing α-MSH to 
displace IL-1β suggest that the KPV sequence may be active even in the full α-MSH(1-13). 
Whether or not KPV signalling occurs in vivo as part of α-MSH or as a cleavage product 
would require further investigation, nevertheless in the present model it would seem  
likely the KPV signalling is in part responsible to the early α-MSH mediated effects. 
The observation that KPV is effective at reducing early leukocyte recruitment in a similar 
fashion to the MC1 targeted BMS-470539 is interesting. In the present model, while α-
MSH may signal via the KPV sequence is a possibility, [D-TRP8]-γ-MSH however does 
not contain this amino acid sequence (Table 1.4) and nor does the molecular structure of 
BMS-470539 mimic it, and as such are unlike to act via the same pathway. The 
similarities between KPV and BMS-470539 in the observed actions on leukocyte 
recruitment and duration of effect, could be a result of both pathways inhibiting cytokine/ 
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chemokine signalling (via blocking IL-1β or via cleavage of receptors) rather than their 
production via NF-κB.  
4.3.6. Melanocortins effect on Cytokine expression 
Investigations into cytokine levels following BCCAo revealed that all melanocortin 
agonists tested reduced the I/R induced rise in TNF-α circulating protein levels by 2 h 
while also reducing MCP-1 (however these levels remained below the accurate 
detectable range of the kit). 
Up-regulated following stroke, TNF-α has also been recognised as a valuable potential 
target in stroke with recent observational studies in humans showing promise for TNF-α 
inhibitor Etanercept [291]. In the present model the non-selective α-MSH proved to be 
the most potent inhibitor of TNF-α and BMS-470539 the least (with only ELISA analysis 
and not CBA detecting a significant decrease). Melanocortin treatments have previously 
been shown to potently inhibit TNF-α via inhibiting NF-κB. As such the reduced TNF-α 
levels found with BMS-470539 at 2 h post stroke would suggest that BMS-470539 also 
activates pathways inhibiting NF-κB as well as rapid actions on leukocyte recruitment.  
As cytokine investigation was performed on seum samples and not whole blood, it may 
be inferred that TNF-α levels being measures are of the soluble form rather than 
membrane bound. As with many molecules governing inflammatory process, there is a 
duality in TNF-α function. While generally considered detrimental in acute inflammatory 
responses, TNF-α may promote repair and tissue remodelling at later time points with 
anti-TNF treatments preventing hippocampal neurogenesis two weeks following cerebral 
ischemia [18, 244]. It has also been suggested that solTNF signalling through TNFR1 
may mediate the damaging inflammatory actions of TNF-α while tmTNF signals through 
TNFR2 could provide protection [18, 244]. While the reduction in solTNF-α found in this 
model is likely to be entirely beneficial, considering α-MSH reduces TNF-α mRNA it 
would also be interesting to investigate the effects on levels of the potentially protective 
tmTNF-α. 
The observed reduction in TNF-α mRNA transcript in the blood following α-MSH 
treatment (although not statistically significant) may account for the decrease in 
circulating TNF-α found with all melanocortin treatments, as occurring by NF-κB 
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inhibition. However in the CBA assay (while not significant) trends toward reduced TNF-
α are observed with α-MSH and BMS-470539 treatment as early as 40 min post BCCAo. 
Thus, inhibition of TNF-α cleavage and release should not be entirely ruled out as an 
explanation for reduced circulating TNF-α, as such future investigations into 
melanocortin regulation of TACE could prove interesting. Especially given that inhibitors 
of this enzyme have proven to be protective in experimental stroke [292].  
In the current investigations, surprisingly, both α-MSH and [D-TRP8]-γ-MSH (but not 
BMS-470539) were found to increase IL-6 levels at both 40 min and 2 h following 
BCCAo. IL-6 is a pleiotrophic cytokine displaying a duality of roles. On the one hand IL-6 
is an endogenous pyrogen with chemotactic activity and increased levels have been 
shown to correlate with poor outcome in stroke patients [18]. Whereas, IL-6 KO mice 
show no protection following experimental stroke [250], under certain conditions IL-6 has 
also been shown to reduce oxidative stress and preserve mitochondrial function [212] 
with up-regulation of IL-6 and its receptor being shown to accelerate nerve regeneration 
following trauma. Furthermore IL-6 can activate the hypothalamic-pituitary-adrenal axis 
and stimulate cortisol production thus stimulating anti-inflammatory signalling  
A number of reports show melanocortin active peptides to reduce IL-6 expression [269, 
287]. However others have reported the contrary with melanocortins inducing IL-6 
expression [293]. This discrepancy seems to be explained by the findings of Lindberg et 
al. in a human microglial cell line that rather than enhancing the inflammatory release of 
IL-6 (in this case in response to Aβ), α-MSH elevates the basal levels [294]. Since in the 
present investigations melanocortin treatments were not given to sham operated animals 
it cannot be concluded that this is the case in the in vivo situation, however that BCCAo 
was not found to induce IL-6 alone, could support the findings of Lindberg. Furthermore 
Lindberg et al. found the increase in IL-6 to be primarily mediated via MC3 thus perhaps 
explaining why IL-6 induction was not observed in BMS-470539 treated animals. 
While in the present model α-MSH is able to increase IL-6, α-MSH has also been 
demonstrated to antagonise IL-6 induced fever. This ability to both induce IL-6 
expression while blocking detrimental IL-6 induced pathways may illustrate the benefit of 
targeting endogenous pathways for the pro-resolving modulation of inflammatory 
processes over an indiscriminate termination of inflammation. Indeed IL-6 up regulation 
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has also been observed in the rat heart following α-MSH administration inducing a 
phenotype similar to ischemic preconditioning. Further investigations will need to be 
made into the exact role of α-MSH mediated increase in IL-6 in the present model, and 
furthermore whether BCCAo induces IL-6 at later stages in the inflammatory cascade. 
Both α-MSH and [D-TRP8]-γ-MSH were found to significantly induce the anti-
inflammatory cytokine IL-10 by 2 h following BCCAo. However BMS-470539 treatment 
did not reveal any up-regulation of IL-10 at the time points tested. It may be that MC1 
prevents early rolling and represses immediate early pro-inflammatory effects while MC3 
may be more prominent in initiating pro-resolving ques. Indeed Vulliémoz et al. have 
found that SHU9119 inhibition of MC3/4 signalling did not affect the pro-inflammatory 
cytokine response, but was found to decrease the pro-resolving IL-10 [295].  
4.4. Summary 
Investigations utilising a number of melanocortin active compounds have revealed 
potent inhibitory actions of the melanocortins on leukocyte recruitment following cerebral 
I/R with corresponding reduction in circulating inflammatory cytokines and up regulation 
of the anti-inflammatory IL-10. However no effect on microglial activation was observed 
and the findings suggest treatments act via peripheral effects and as such are 
independent of MC4. 
In mediating inhibition of leukocyte recruitment MC1 seemingly provided greater 
inhibition at the immediate early stage following BCCAo, being able to initiate signalling 
which reduced leukocyte rolling as well as adhesion. However allowing for progression 
of reperfusion to 2 h revealed these effects to dissipate with MC3 signalling providing 
more effective modulation of leukocyte recruitment. These effects were supported by 
findings from co-treatments with the MC3/4 antagonist MC1/5 agonist SHU9119.  
While analysis of melanocortin receptor mRNA showed no regulatory changes between 
40 min and 2 h of reperfusion, NF-κB genes were only found to be inhibited at 2 h and 
not 40 min. Thus, suggesting NF-κB independent mechanisms centred on MC1 to 
mediate the early suppression of leukocyte recruitment. Differences in cytokine 
regulation between MC1 targeted activation and MC3 targeted/non-specific activation 
also support the hypothesis that MC1 initiates distinct signalling pathways early following 
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reperfusion under the conditions tested. Whereas MC3 activation was found mediated 
more sustained anti-inflammatory protection most likely via inhibition of NF-κB activation. 
4.5. Future Directions 
This work has provided a unique insight into the melanocortin receptors involved in 
modulating leukocyte recruitment in the cerebral microcirculation. In addition to 
understanding the receptor subtype mediating these effects it may also be beneficial to 
gain a greater understanding of the exact signalling mechanisms initiated. Further work 
could also explore the novel finding of a temporal switch in receptor importance, and 
confirm the proposed differences in signalling by assessing NF-κB activation following 
administration of MC1 and MC3 selective drugs in WT and receptor mutant mice. Indeed 
development of agonists not only activating the desired receptor but displaying “directed 
signalling” and activating the desired pathway may provide a fine tuning of melanocortin 
based drugs. In order to fully corroborate these findings it is also important that later time 
points of reperfusion be assessed, along with later treatment times to assess the 
potential for delayed treatment. 
In order to investigate whether melanocortin treatments elicit these anti-inflammatory 
effects via direct actions on leukocytes or through modulating the functioning of 
endothelial cells, perivascular components or neurons, experiments could be performed 
using melanocortin treatments on autologous blood. Blood samples could be taken from 
mice prior to BCCAo surgery and immune cells isolated and fluorescently labelled. 
These cells could then be treated with melanocortin compounds before being re-
introduced into the animal following BCCAo. Treated leukocytes could thus be 
distinguished from untreated and the level of leukocyte recruitment recorded. 
As with all pharmacological investigation, studies can be limited to the selectivity of 
compounds tested and as such future investigations could use newly developed more 
selective compounds such as the MC4 selective agonist recently synthesised by Eliasen 
et al. [296]. However at the time of writing no new selective MC3 compounds have been 
produced. In the present study while the pharmacological studies have provide some 
interesting insights this work has also been backed up by work in receptor mutant 
animals to provide a robust body of evidence.  
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5.1. Introduction 
The production of knockout mice along with the use of strains bearing specific genetic 
abnormalities has provided scientists with a powerful tool to investigate of the role of 
various molecules in the physiological maintenance of homeostasis as well as in disease 
progression. The production of mice lacking specific adhesion molecules has been 
critical in understating the discrete roles of CAMs in the leukocyte recruitment cascade. 
Melanocortin receptor KO mice have also demonstrated critical roles for MC4 in 
metabolism and food intake, MC1 in pigmentation and a role for MC3 in adiposity and 
modulating inflammatory processes. 
While the pharmacological investigations detailed in chapter 4 have revealed a possible 
temporally dependant switch in receptor importance to reducing leukocyte recruitment, 
such studies are limited not only by the pharmacodynamic profile and relative selectivity 
of the compounds used but also in that they fail to give an insight into the endogenous 
functioning of the MRS. Thus results from pharmacological studies have been 
substantiated by utilising a genetic approach to investigating the MRS. In this chapter 
mice bearing a mutation incurring a non-functional MC1 (recessive yellow (e/e) mice) and 
MC3-/- mice have been used to investigate the endogenous role of melanocortin 
receptors in modulating leukocyte recruitment following global cerebral ischemia. The 
phenotypic responses of these animals to pathological challenge has been compared to 
wild type (WT) C57BL/6 mice along with their ability to respond to therapeutically 
administered exogenous α-MSH has also been assessed.  
 
5.0.   Investigations utilising 
receptor mutant mice 
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5.2. Results 
5.2.1. MC1 mutant mice display enhance leukocyte recruitment 40 min 
following BCCAo 
Leukocyte endothelial interactions in the cerebral microcirculation following BCCAo were 
investigated in both MC1 mutant e/e mice and MC3-/- mice at 40 min of reperfusion 
(Figure 5.1). In the absence of a pathological challenge sham operated mice showed no 
significant differences between WT, e/e and MC3-/- strains. However a slight trend toward 
an increase in rolling and adhesion of leukocytes was observed in e/e mice, conducting 
further experiments could provide an insight into whether this is a subtle effect or simply 
due to variation within the group. Following induction of 5 min global ischemia there was 
however a pronounced increase in leukocyte rolling which in e/e mice was over and 
above that found in WT and MC3-/- mice. Whereas in MC3 mice there was a trend toward 
enhanced leukocyte rolling following BCCAo (60 % increase compared to WT mice), in 
e/e mice levels of leukocyte rolling (539.3 cells/mm2/min) were found to be 282.5 % of 
that found in WT. Leukocyte adherence also showed a slight but not significant trend 
toward an increase in the e/e mice (326.3cells/mm2/min) compared to WT (282.3 
cells/mm2/min) while in MC3-/- mice no change in adhesion was observed. This is fitting 
with the results obtained during pharmacological investigations showing MC1 to be 
important in regulating leukocyte recruitment at 40 min following BCCAo and that this 
receptor has a particular influence over leukocyte rolling. A comparison of data from 
pharmacological studies and the results from MC mutant mice is shown in tables 5.1 
Therapeutically administered α-MSH remained active in reducing leukocyte endothelial 
interactions in mice lacking an MC3, suggesting melanocortin receptors other than MC3 
are able to propagate anti-inflammatory responses to α-MSH. In e/e mice α-MSH 
treatment failed to significantly reduce leukocyte rolling. While there was a trend toward 
reduced rolling following α-MSH treatment, leukocyte rolling still remained at a level that 
was greater than that found in BCCAo WT mice treated with saline alone (259.1 
cells/mm2/min compared to 191 cells/mm2/min in WT saline treated). α-MSH treatment in 
e/e mice was nevertheless able to significantly inhibit the number of leukocytes that 
become adherent to the vessel wall (>80 % reduction). While MC3-/- mice showed a trend 
toward increased rolling velocity compared to wild type animals there were no significant 
alterations in WBC rolling velocity found across all treatments and mouse strains tested. 
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A. B. C. 
Figure 5.1. Comparison of leukocyte recruitment in WT, e/e and MC3-/- mice at 40 min after BCCAo. Wild type 
C57BL/6 (white bars), MC1 mutant e/e (lined bars) and MC3-/- (checked bars) mice were subjected to sham or BCCAo 
surgery with 40 min reperfusion and treatment with either saline or 10µg α-MSH at the start of reperfusion. Leukocyte 
recruitment in the cerebral microcirculation was quantified in terms of (A) rolling cell flux (B) WBC rolling velocity and (C) 
Number of adherent cells. WT groups n = 6, e/e and MC3-/- sham group n = 3 all other groups n = 4. Statistical analysis 
was performed between mouse strains, within sham or saline treated groups to determine the phenotypic differences 
between strains, # denotes significance to WT P<0.01. Statistical analysis was also performed between sham, saline and 
α-MSH treatment groups within the same strain. * shows significance to sham group P<0.05 and + shows significance to 
saline treated BCCAo group P<0.05.  
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Tables 5.1. Comparison of IVM parameters from wild type pharmacological studies 
and receptor mutant mice at 40 min reperfusion 
Rolling (cells/mm2/min) 
 
 
 
 
 
 
 
 
 
 
 
 
Velocity (μm/sec) 
 
 
 
 
 
 
 
 
 
 
 
 
Adhesion (cells/mm2/min) 
 
 
 
 
 
 
Strain Sham BCCAo 
  Saline α-MSH BMS DTRP 
Wild Type 21.5 ± 6.9 
191.0 ± 
31.5 
58.1 
±10.4 
58.1 ± 
29.3 
139.1 ±  
38.6 
MC1 
mutant e/e 
85.48 ± 
4.1 
539.3 ± 
153.1 
259.1 
±65.8 - - 
MC3-/- 84.18 ±  56.1 
305.4 ± 
37.14 
72.2 ±  
37.4 - - 
Strain Sham BCCAo 
  Saline α-MSH BMS DTRP 
Wild Type 37.9 ± 6.8 
20.5 ± 
2.7 
66.7 ± 
7.3 
72.1 ± 
9.1 
38.1 ± 
10.7 
MC1 
mutant e/e 
33.3 
±10.1 
28.3 ± 
3.6 
45.3 ± 
5.6 - - 
MC3-/- 66.2 ± 11.2 
53.2 ± 
6.8 
68.33 ± 
24.5 - - 
Strain Sham BCCAo 
  Saline α-MSH BMS DTRP 
Wild Type 42.1 ± 14.4 
282.3 ± 
49.4 
90.35 ± 
34.96 
58.0 ± 
20.7 
121.2 ±  
23.7 
MC1 
mutant e/e 
94.6 ± 
24.0 
326.3 ± 
46.3 
35.5 ± 
10.4 - - 
MC3-/- 28.2 ± 14.3 
251.5 ± 
44.5 
71.1 ± 
39.1 - - 
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5.2.2. Cytokine expression 
The serum protein expression of TNF-α (by ELISA) was measured in both e/e and MC3-/- 
experimental animals and compared to levels found in WT.  
At 40 min following BCCAo serum levels of TNF-α were found to be significantly 
elevated in e/e mice compared to levels in WT and MC3-/- mice. These levels in e/e mice 
at 40 min following BCCAo were found to be greater than those reached in WT following 
2 h of reperfusion. TNF-α levels in MC3-/- mice however were not found to be significantly 
different from WT at the time point tested, also remaining below the detectable range of 
the ELISA kit.  
 
 
Figure 5.2. Comparison of serum TNF-α levels in e/e and MC3-/- mice. Serum samples 
from WT (white bars), e/e (striped bars) and MC3-/- (checked bars) mice subjected to 
BCCAo with 40 min reperfusion were analysed for protein levels of TNF-α by ELISA. N = 
3 for all groups. * denotes significance to sham groups P<0.01, # denotes significance to 
WT P<0.05.  
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5.2.3. Leukocyte recruitment in recessive yellow e/e mice following 2h 
reperfusion. 
With an aim to investigate whether the temporal shift in receptor importance observed 
during pharmacological investigations was also present as a physiological phenomenon, 
recessive yellow e/e mice were also investigated in the 2 h reperfusion model to see if 
the inflammatory phenotype persisted.  
While at 40 min following BCCAo e/e mice displayed significantly higher levels of 
leukocyte rolling than WT, by 2 h of reperfusion no significant differences in the 
leukocyte recruitment response could be observed between e/e mice and WT. Across all 
parameters measured and across all treatment groups no significant differences were 
found between the two strains. There was however a trend toward reduced leukocyte 
adhesion following BCCAo in e/e mice, greater n numbers will be required to determine 
if this is a true effect or an artefact due to the low n numbers used. Indeed due to limited 
availability of the e/e mouse strain and the lack of alternative suppliers it has only been 
possible to obtain an n of 3 for 2 h sham and α-MSH BCCAo groups, whereas power 
calculations (section 2.4) recommend a minimum group size of 4. As such caution 
should be taken in the interpretation of the results from these two groups. However in 
the present investigations it does appear that the lack of any enhanced rolling and 
adhesion at 2 h following BCCAo in e/e mice (n = 4) again mirror the results of the 
pharmacological investigations at 2 h, which also demonstrate the MC1 selective BMS-
470539 loses its anti-inflammatory potency by 2 h of reperfusion. Comparisons of 
pharmacological data and results of investigations in e/e mice at 2 h reperfusion are 
given in tables 5.2.  
Due to limited availability of the MC3-/- strain no studies have been performed at 2 h of 
reperfusion using the MC3-/- mice. 
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Figure 5.3. Leukocyte recruitment in e/e mice following 2h reperfusion Wild type C57BL/6 (white bars) and e/e 
(lined bars) mice were subjected to sham or 5 min BCCAo and treated with saline or 10µg α-MSH at the start of 
reperfusion .leukocyte recruitment was quantified at 2h of reperfusion in terms of (A) rolling cell flux (B) WBC rolling 
velocity and (C) Number of adherent cells. N = 4 for WT sham and saline groups and e/e saline group, n = 5 for WT α-
MSH group and n = 3 for sham and α-MSH e/e groups Statistical analysis was performed between mouse strains, within 
the same treatment group to evaluate phenotypic differences between strains. NS denotes no statistical significance to 
WT group (P>0.05) 
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Tables 5.2. Comparison of IVM parameters from wild type pharmacological studies 
and e/e mice at 2 h reperfusion 
 
 
Rolling (cells/mm2/min) 
Strain Sham BCCAo 
  Saline α-MSH BMS DTRP 
Wild Type 21.9 ± 10.1 
243.9 ± 
74.0 
79.3 ± 
18.5 
80.1 ± 
55.3 
103.7 ± 
29.4 
MC1 
mutant e/e 
0.63 ± 
0.5 
204.7 ± 
138.6 
39.86 ± 
8.8 - - 
 
 
 
Velocity (μm/sec) 
Strain Sham BCCAo 
  Saline α-MSH BMS DTRP 
Wild Type 34.3 ± 8.7 
15.8 ± 
5.7 
55.9 ± 
6.4 
32.2 ± 
4.0 
45.8 ± 
8.0 
MC1 
mutant e/e 
59.3 ± 
16.7 
26.3 ± 
5.8 
36.7 ± 
13.8 - - 
 
 
 
Adhesion (cells/mm2/min) 
Strain Sham BCCAo 
  Saline α-MSH BMS DTRP 
Wild Type 51.9 ± 11.3 
659.7 ± 
115.6 
121.5 ± 
30.5 
238.3 ± 
184.9 
61.75 ± 
10.10 
MC1 
mutant e/e 
166.7 ± 
98.3 
437.2 ± 
106.1 
112.3 ± 
20.4 - - 
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5.2.4. TNF-α levels in e/e mice at 2 h of reperfusion 
TNF-α levels measured in serum of e/e mice following BCCAo and 2 h of reperfusion 
revealed a drop in the enhanced response seen at 40 minutes. This appeared to 
correlate with the observed reduction in leukocyte recruitment parameters, as ELISA 
detection of TNF-α serum levels showed no significant difference between e/e and WT 
animals. However, despite a trend toward an increase, due to the large variability in e/e 
sham animals (as reflected by the large error bars) the elevation in TNF-α levels 
following BCCAo in e/e mice was not statistically significant. α-MSH treatment however 
produced significant reduction in both WT and e/e mice.  
Figure 5.4. TNF-α levels in e/e mice at 2 h reperfusion. Serum samples from WT (white 
bars) and e/e (striped bars) mice subjected to BCCAo with 2 h reperfusion were analysed 
for protein levels of TNF-α by ELISA. N = 3 for all groups * denotes significance to sham 
groups P<0.01, + denotes significance to BCCAo P<0.05.  
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5.3. Discussion 
Investigations in e/e and MC3-/- mice have revealed an enhanced inflammatory response 
in the MC1 mutant e/e mouse at 40 min of reperfusion with elevated leukocyte 
recruitment and serum TNF-α levels. MC3 mice on the other hand showed no 
abnormalities in leukocyte recruitment or TNF-α regulation at this early time point. The 
inflammatory phenotype of the e/e mouse was however not maintained as the post I/R 
inflammatory response progressed with leukocyte recruitment and TNF-α levels being 
unchanged compared to WT at 2 h reperfusion. This work supports an early role for MC1 
in reducing post I/R inflammatory responses. 
5.3.1. Phenotype of melanocortin receptor mutant mice 
In the present model e/e mice displayed enhanced leukocyte rolling and inability to 
regulate leukocyte recruitment at the very onset of the inflammatory response along with 
elevated levels of the pro-inflammatory cytokine TNF-α.  
Leukocyte differential counts have shown no significant differences in circulating PMN or 
monocyte levels in e/e or MC3-/- mice under basal conditions [127, 297]. It is therefore 
unlikely that the observed enhanced leukocyte recruitment in e/e mice is simply due to a 
higher basal number of circulating neutrophils, especially as leukocyte rolling and 
adherence in sham e/e mice were not significantly different from that in WT. 
Inflammatory events have been shown to induce elevated blood levels of immune cells, 
indeed TNF-α alone has been shown to induce neutrophilia [298], it is therefore possible 
that cerebral I/R may induce a greater increase in circulating neutrophils in e/e mice than 
wild type, thus explaining the elevated levels of leukocyte-endothelial interactions. 
However mesenteric I/R has been previously observed to increase the number of 
circulating PMN levels to a similar degree in e/e mice as in WT [297]. Therefore the 
observed exacerbated leukocyte recruitment in e/e mice is likely to be a result of the lack 
of acute MC1 mediated anti-inflammatory signalling. Furthermore the lack of any 
significant phenotype in sham operated e/e mice suggest anti-inflammatory signalling via 
MC1 not to be tonic but that they are reactive to pathological stimuli.  
These findings support the conclusions drawn from pharmacological investigations that 
MC1 is important in enabling rapid anti-inflammatory responses. Furthermore these 
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results demonstrate that endogenous melanocortins may provide this immediate anti-
inflammatory response via MC1, and that MC1 is particularly important in regulating the 
rolling stage of leukocyte recruitment.  
During the pharmacological studies the observation that BMS-470539 and α-MSH 
reduced rolling as well as adhesion was taken as being a more potent anti-inflammatory 
action. However given that in e/e mice only rolling, but not adhesion, was significantly 
enhanced and that α-MSH was still able to reduce adhesion (but not rolling), it may be 
that MC1 plays a critical role in inhibiting the expression of adhesion molecules important 
for leukocyte rolling. Such a mechanism would fit with the early time of the observed 
effect, one that might be assumed to be transcriptionally independent due to the rapidity 
of onset. Selectins, which mediate leukocyte capture and rolling, are rapidly up-regulated 
to the endothelial surface in inflammatory reaction. Indeed exocytosis of weible palade 
bodies (WPB) is induced within minutes of hypoxia, resulting in increased endothelial P-
selectin expression and the release of the neutrophil chemoattractant IL-8 along with 
other inflammatory, pro-thrombotic and vasoactive factors [299]. It is possible that MC1 
signalling inhibits this rapid exocytosis of WPBs. In fact α-MSH has been shown to 
reduce the release of histamine a potent initiator of WPB exocytosis, and that this effect 
is mediated via MC1 [300]. Furthermore TNF-α has been shown to stimulate WPB 
release in a dose-dependent manner. Thus the observed enhanced TNF-α in e/e mice 
may have implications for MC1 mediated effects on WPB exocytosis, P-selectin 
expression and thus leukocyte rolling. While a unique aspect of MC1 signalling appears 
to be on the cleavage of chemokine receptors, no reports have yet shown melanocortins 
to induce the shedding of receptors involved in WPB exocytosis. 
While elevated TNF-α levels observed may play a role in mediating leukocyte 
recruitment, the actions of this cytokine may also enhance the pathological potential of 
invading neutrophils. TNF-α is known to prime neutrophils allowing maximal neutrophil 
degranulation and NADPH oxidase activity following neutrophil activation [298]. 
Neutrophil priming by cytokines may also cause a reduced deformability of cells causing 
a higher retention in capillary beds, and perhaps more likely to cause vessel plugging 
and secondary ischemia [298]. Thus the melanocortin mediated control over TNF-α 
levels may be particularly beneficial in regulating leukocyte recruitment in the brain 
following I/R. 
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5.3.2. Conflicting views on the roles of MC1 and MC3: a difference in timing, 
micro-environment and pathology. 
A number of apparently conflicting reports have been made regarding the role of 
melanocortin receptors in MC1 mutant and MC3 null mice. The MC3-/- mouse has been 
shown to display an enhanced inflammatory phenotype, with increased leukocyte 
recruitment following mesenteric I/R [127]. Since the widely studied endogenous α-MSH 
shows preferential binding to MC1, the discovery of a physiological role for MC3 in 
regulating inflammation, may potentially implicate a role for endogenous MC3 ligand γ-
MSH in suppressing inflammation. However relatively few studies have as yet been 
performed assessing the physiological influence of γ-MSH in controlling inflammation. 
On the other hand in the same mesenteric I/R model the MC1 selective BMS-470539 
provided potent anti-inflammatory amelioration [151] yet the e/e mice showed no 
inflammatory phenotype [127]. This complex scenario, discussed in chapter 4, led some 
to postulate that while both MC1 and MC3 are both expressed in mesentery, MC3 
provides physiological anti-inflammatory protection by endogenous mechanisms (and as 
such also provides a pharmacological target) while MC1 serves no significant 
endogenous anti-inflammatory role in this model but that this receptor could also be 
pharmacologically utilised to reduce inflammation.  
However a number of studies since, while showing important pharmacological roles for 
MC3, have failed to detect an endogenous role in the MC3-/- mouse, with no evident 
exacerbation of inflammatory response observed. Protective effects of AP214 in 
zymosan induced peritonitis were found to be lost in MC3-/- mice but not in e/e mice [287] 
however in this model no physiological role for each receptor was observed, with 
zymosan induced neutrophil recruitment being at comparable levels to WT [287]. Also, in 
a model of lung inflammation MC3 activation by [D-TRP8]-γ-MSH reduced eosinophil and 
lymophocyte accumulation 24 h following a 2 week immunization protocol, with these 
effects being lost in MC3-/- mice. However no inflammatory phenotype was observed in 
either MC3-/- or e/e animals in the absence of pharmacological intervention. These 
studies suggest that the observed inflammatory phenotype of the MC3-/- mouse in 
mesenteric I/R may be a tissue/ pathology specific phenomenon. 
In the present study however no inflammatory phenotype was observed in the MC3-/- 
mouse at the time point tested nevertheless pharmacological results, as discussed in 
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chapter 4, suggest that any MC3-/- phenotype may become obvious with extended 
periods of reperfusion. Indeed that the enhanced inflammatory response detected at 40 
min following I/R in e/e mice subsided by 2 h would suggest that endogenous 
compensatory mechanisms are initiated, of which MC3 could be central. Suggesting the 
importance of endogenous MC3 anti-inflammatory signalling may be unique to I/R as a 
phlogistic stimulus. 
Unlike in mesenteric I/R (35 min I, 90 min R) [127] in the present study an endogenous 
anti-inflammatory role for MC1 was detected, with e/e mice displaying enhanced 
leukocyte rolling and elevated serum TNF-α. This may point toward differential roles for 
melanocortin receptors in a tissue specific and/or temporally dependant manner. Indeed 
while the present study demonstrates an early role for MC1 potentially switching to MC3 
as reperfusion progresses, the I/R protocol used by Leoni et al. is, temporally speaking, 
from the onset of ischemia more in line with the 2 h reperfusion studies performed here. 
As such the observed inflammatory phenotype of the MC3-/- mouse following mesenteric 
I/R and apparently normal e/e mouse fits with the results and predictions made in the 
present study.  
The observation of an endogenous role for MC1 is not however unique to the current 
investigations. e/e mice have been shown to display an exacerbated inflammatory 
phenotype in two distinct models of colitis (dextran sodium sulphate induced and 
bacterial) [171]. In these studies by Maaser et al. the colon of untreated e/e mice 
showed no phenotype under basal conditions, suggesting MC1 is not essential for 
maintenance of homeostasis in the absence of challenge. This is reflected in the present 
findings where e/e mice showed similar levels of leukocyte recruitment in sham operated 
as shown by WT mice, also fitting with the apparent lack of phenotype observed in 
humans bearing MC1 mutations (with exception to hair and skin pigmentation). In DSS 
colitis models however it was found that the resultant inflammatory reactions caused the 
eventual death of all e/e mice while all WT animals survived. In the present study 
however it appears the inflammatory phenotype of e/e mice quickly dissipates as MC3 
mechanisms compensate (looking at even later time points would however be interesting 
in the current model). The apparent differences in magnitude of the MC1 role between 
these two models could be a reflection of the cell types involved. Transplantation of 
MC1+ bone marrow into e/e mice has been shown to provide no improvement in DSS 
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induced colitis and as such reveals a critical role for non-haematopoietic cells, in this 
model most likely epithelial cells. In the present model the most likely effector cells of the 
melanocortins effects are endothelial cells and/or leukocytes (and perhaps also a role for 
perivascular cells). 
In light of the above investigation and the results obtained in this thesis it seems that a 
hypothesis put forward by Montero-Melendez et al. is more in keeping with the present 
I/R model that:  
 “MC1 could be indicated as the physiologic receptor, with an almost ubiquitous 
distribution in a variety of cell types, whereas MC3 could be a “stress receptor” up-
regulated in conditions of tissue injury or inflammation.” [287].  
 Adding to this hypothesis with respect to the results obtained herein: MC1, as the 
physiologic receptor, is able to rapidly respond to stimuli via NF-κB independent 
mechanisms whereas MC3 mediates a delayed but more prolonged effect. 
With the physiological and pharmacological importance of melanocortins varying with 
both vascular bed and pathology, a universal statement on the importance of MC 
subtypes in providing anti-inflammatory protection across different pathologies cannot be 
made, it seems the specific pharmacological target must be determined within the 
specific pathological environment. And while the above statement (with amendments) 
seems accurate in the context of I/R, in light of the current findings that MC importance 
may switch, further investigations into the temporal regulation of melanocortin signalling 
in inflammation will undoubtedly need to be performed. 
5.3.3. Cautionary notes on drawing conclusions solely from studies using 
e/e mice  
As with any study using full KO animals one potential drawback in the use of KO mice is 
that removal of physiologically important genes may lead to compensatory mechanisms. 
In fact Montero-Melendez et al., have previously shown that while in wild type and e/e 
isolated macrophages zymosan challenge induced no change in MC1 MC3 or MC5 
expression, in MC3−/− inflammatory challenge led to marked gene activation for MC1 and 
MC5 [287] perhaps indicating compensatory regulation of other MC in the absence of 
MC3. 
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However in the context of the present findings, with regards to the receptor mutant e/e 
mouse there is an extra consideration that should be noted when drawing conclusions. 
Since the MC1 mutation in the e/e mice merely renders the receptor incapable of 
coupling to adenylate cyclase (the principle MC signalling pathway) as previously 
discussed alterative signalling pathways have been demonstrated to couple to MCs and 
to my knowledge no investigations into Ca2+ or other alternative signalling pathways 
have been performed on MC1 receptors bearing the MC1 e/e mutation. However in 
human cells, while cAMP signalling was reduced, ERK1/ERK2 MAPK remained 
unaffected in melanocytes bearing MC1 defects associated with red hair and fair skin 
[301]. Should the MC1 e/e mutation render the receptor entirely in capable of intra 
cellular signalling it should not be ignored that simply the presence of the receptor may 
still be able to alter physiological responses. One possible explanation for the enhanced 
inflammatory response observed in the e/e mice during these investigations is that MC1 
may be binding endogenous α-MSH (or exogenous in the case of treated mice) and 
acting as a melanocortin sink and suppressing the endogenous anti-inflammatory 
actions. In a similar fashion to how soluble TNF-α receptors may inhibit the inflammatory 
response or how DARC may “mop up” inflammatory cytokines, so non-functional MCs 
could enhance inflammation by binding anti-inflammatory melanocortins. This possibility 
could be ruled out by pharmacologically blocking the MC1 binding site using a 
competitive MC1 selective antagonist co-administered with α-MSH in the e/e mice. 
However while the endogenous agouti signalling peptide shows preferential binding to 
MC1 where it acts as an inverse agonist, to my knowledge at the time of writing no truly 
selective MC1 antagonist is yet commercially available. 
To further complicate the task of elucidating the role of individual melanocortin receptors 
in eliciting an anti-inflammatory response Mandrika.et al. have recently reported that MC 
may stabilize their signalling upon binding α-MSH by forming homo and hetero-dimers 
[285, 302]. In the context of the e/e mouse, MC1 may still retain the ability to form 
heterodimers with MC3 to enhance and transmit an intracellular signal. Indeed the 
existence of such functionally enhancing receptor dimers adds an additional dimension 
to MC signalling and could help to explain the current confusion surrounding which MCs 
mediate specific physiological responses. However, while both MC1 and MC3 have been 
shown to be co-expressed in monocytes and neutrophils, formation of heterodimers has 
yet to be demonstrated in an in vivo setting or in non-transfected cells. 
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While the pharmacological evidence amassed during the course of this project supports 
the role of MC1 observed in the current investigations in e/e mice, the above limitations 
should not be completely over looked. Indeed investigations using e/e mice could in 
future help to determine cAMP independent mechanisms of signalling through MC1 and 
KO mice may also allow for an insight into the roles of hetero-dimerization in 
melanocortin mediated physiological effects. 
5.3.4. Chance behavioural observations and the influence of peripheral 
wounds to cerebral leukocyte recruitment. 
An interesting chance observation made during the course of these investigations was 
that e/e mice appeared to display signs of increased anxiety and aggression when 
compared to WT and MC3-/- mice, despite identical housing conditions. This observation 
has not been quantified and is beyond the scope of the investigations in this thesis 
however, e/e mice often showed signs of fighting and over-grooming. As such some e/e 
mice had to be housed separately. Those animals bearing fight wounds or any injuries 
were excluded from the above results, with those animals that were included in the study 
having been physically examined prior to surgery and found to show no signs of fighting 
or injury. However some animals carrying wounds to the tail and back did undergo 
BCCAo surgery with interesting results (appendix Figure A4). These animals displayed 
highly increased leukocyte rolling and adhesion far beyond any levels previously 
observed during the course of this thesis. It is likely that these effects are not limited to 
the MC1 receptor mutant mice as these effects are maintained (and enhanced) at 2 h 
reperfusion. Instead these observations may relate to the role of co-morbidities in 
enhancing inflammatory responses. Systemic inflammation, such as infection, not only 
increases the risk of stroke but is also associated with poor outcome. Furthermore 
systemic inflammation has been previously shown to aggravate neutrophil infiltration in 
the brain and enhance stroke pathology [303]. McColl et al. have shown that 
administration of IL-1β before initiating experimental stroke caused a threefold increase 
in ischemic damage and that this increase was completely ameliorated by depletion of 
neutrophils [304]. Thus it is likely that in the injured animals observed in this report, their 
previous inflammatory status has served to prime and augment the post BCCAo 
inflammatory responses. Importantly in these injured animals α-MSH treatment still 
appeared to have some effect reducing leukocyte recruitment however investigations 
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into the role of prior inflammation enhancing post stroke inflammation is beyond the 
scope of this thesis. 
5.4. Conclusions 
During this chapter a novel endogenous role for MC1 in mediating early anti-
inflammatory responses has been revealed, with e/e mice displaying enhanced 
leukocyte recruitment and elevated serum TNF-α. On the other hand MC3-/- animals 
showed a comparatively normal phenotype at 40 min post BCCAo. In line with the 
pharmacological studies the importance of MC1 however seemed to diminish as post 
stroke inflammatory processes progressed. While no data has yet been obtained in the 
MC3-/- at 2 h, pharmacological studies would suggest that MC3 mediated signalling 
predominates in this later stage of reperfusion and that MC3 compensatory mechanisms 
may account for the lack of e/e inflammatory phenotype at 2 h. 
5.5. Future Directions 
Regretfully, due to a lack of availability of MC3-/- mice and an absence of alternative 
suppliers of mice bearing the same genetic modification, no studies at the later time of 2 
h reperfusion have yet been conducted in these animals. Data from the e/e mice coupled 
with pharmacological investigations have in these investigations provide a robust body of 
data to support the hypotheis of immediate early anti-inflammatory effects being 
modulated by MC1 with a temporal change in receptor importance occurring as 
reperfusion progresses. However further investigations using the MC3-/- mice would help 
to corroborate these findings and confirm that MC3 mediates transcriptionally dependant 
mechanisms important in supressing the progression of inflammatory events. As such it 
is intended that these experiments be conducted in our lab when the animals become 
available.  
 
While investigations into stress are not within the scope of this thesis the initial chance 
observations of the e/e genotype on their behavioural phenotype with regards to 
stress/aggression may provide an interesting avenue of research. The other initial 
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finding that wounds from fighting enhances leukocyte recruitment in the brain following 
BCCAo also warrants further investigation. Given the known role of systemic 
inflammation on enhancing brain inflammation, investigating the therapeutic potential of 
the melanocortins in the context of co-morbidities would provide an interesting 
progression of the present study. 
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6.1. Introduction 
Due to the complex pathology and multiple pathways and systems underpinning 
neuronal damage in stroke, animal models are undoubtedly required to investigate novel 
therapeutics. However, when assessing prospective therapies it is important to 
understand and explore the differences between the animal and human drug 
target/system. The melanocortin receptor system displays a number of disparities in 
organisation and function between humans and rodents. The most highly expressed 
melanocortin receptor on human macrophages is MC1 where as in mice it is MC3 [95]. 
Furthermore a number of melanocortin agonists and antagonists show different 
potencies and sub-receptor selectivity in MCs from different species (table 4.1). While 
[D-TRP8]-γ-MSH displays a relative selectivity toward MC3 in humans, this compound 
displays differential binding affinities toward murine MCs [262].  Additionally, while 
SHU9119 can act as an agonist at human and mouse MC1 in the frog MC1 the same 
compound acts as a powerful antagonist [274]. 
 In order to assess whether melanocortin based treatments would prove effective at 
reducing leukocyte-endothelial interactions in the context of human cells, experiments 
were performed using two in vitro assays of neutrophil and endothelial cell function using 
human cells. The flow chamber has thus been used as a model of leukocyte recruitment 
to endothelial cells under physiological flow and in addition the chemotaxis assay has 
been used to further investigate the effect of melanocortins on a key process in 
neutrophil trafficking.  
6.0.   Translational potential; 
investigating the effects of 
melanocortin treatments on 
human leukocyte function 
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6.2. Results 
6.2.1. Flow chamber 
In order to model the leukocyte recruitment cascade in vitro using human cells the flow 
chamber assay has been employed. In the flow chamber assay, isolated human 
neutrophils from healthy donors were perfused over HUVEC monolayers activated with 
TNF-α 4 h prior to commencing flow. Neutrophils interacting with the endothelial 
monolayer were quantified in terms of; total number of captured cells, number of cells 
rolling, number of adherent cells (those stationary for 10 sec or longer) and also number 
of cells transmigrating across the endothelial monolayer (those cells turning from bright 
phase to dark phase). While allowing for an assessment of the melanocortins effects on 
the recruitment of human neutrophils, this model also enabled further dissection of the 
melanocortins effects by allowing neutrophils and HUVECs to be treated with α-MSH 
separately.  
Treating HUVEC monolayers for 2 h prior to flow with concentrations of α-MSH up to 100 
µg/ml failed to induce any significant reduction in neutrophil capture, rolling, adherence 
or transmigration following TNF-α stimulation (Figure 6.1). However, there was a slight 
trend toward reductions in adhesion and transmigration. On the other hand treating 
neutrophils with just 10 µg/ml (a comparable dose to that used during the in vivo studies) 
resulted in significant reductions in both neutrophil adherence (68 % reduction) and their 
transmigration (67 % reduction) when compared to cells treated with saline alone. 
Moreover α-MSH treatments also resulted in a trend toward a reduction in neutrophil 
capture (54 % reduction at 10 µg/ml). 
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Figure 6.1. Neutrophil recruitment to TNF-α stimulated HUVEC monolayers. Isolated human neutrophils (1x106 
cells/ml) were perfused over TNF-α stimulated (10 ng/ml, 4 h)  confluent HUVEC monolayers. Either neutrophils or 
HUVEC monolayers were pre-treated with saline containing 0, 1,10 or 100 µg/ml of α-MSH. Leukocyte recruitment was 
quantified in terms of (A) Capture (all cells interacting with the monolayer) (B) the number of rolling cells, (C) number of 
adherent cells (cells stationary for 10 sec or longer) and (D) the number of cells transmigrating across the HUVEC 
monolayer. N = 4 for all groups. + denotes significance to saline treated group P < 0.05. ++ = P < 0.001 
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6.2.2. Chemotaxis assay 
To investigate the influence of different melanocortin treatments on the chemotactic 
functionality of neutrophils the neuroprobeTM chemotaxis assay has been used. 
Neutrophil chemotactic activity was assessed by their ability to cross a pours membrane 
into a lower chamber containing the potent chemo-attractant FMLP.  
While pre-treatments with 1, 10 and 100 µg/ml of α-MSH did not result in a significant 
reduction in cell migration, a trend toward a reduction was observed (Figure 6.2 A). 
Treatment with the MC3 agonist [D-TRP8]-γ-MSH also failed to significantly reduce 
neutrophil migration (P>0.05), however there was a strong trend toward a reduction 
(from 1.6 million cells/ml to 1.1 million cells/ml) which with higher n numbers may prove 
significant (Figure 6.2 B). On the other hand, selective activation of MC1 by treatment 
with 100 µg/ml of the small molecule agonist BMS-470539, caused a highly significant 
reduction in directed neutrophil chemotaxis (from 1.6 million cells/ml to 0.4 million) 
(Figure 6.2 C). This was a reduction of approximately 75 % from the number of cells 
migrating toward FMLP when treated with saline alone and was not significantly different 
from the number of cells found to randomly migrate (bottom well containing medium 
alone). 
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Figure 6.2. Neutrophil chemotaxis to FMLP: the effect of melanocortin 
agonists. Levels of neutrophil chemotaxis found to migrate across a porous 
membrane in the neuroprobeTM chemotaxis plate toward the chemoattractant FMLP 
(10nM). Isolated neutrophils (4 x 106 cells/ml) were pre-treated 10 min prior to 
application to the top well of the chemotaxis plate with varying concentrations of 
either (A) α-MSH (B) BMS-470539 or (C) [D-TRP8]-γ-MSH. Plates were then 
incubated for 1.5h before assessing neutrophil migration. Control and FMLP groups 
n= 5, α-MSH groups n = 5, BMS-470539 and [D-TRP8]-γ-MSH groups n = 3. * 
denotes significance to un-stimulated group P<0.05. **= P<0.001 ++ denotes 
significance to vehicle treated group P< 0.001. 
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6.3. Discussion  
The present in vitro investigations into human cell inflammatory functioning have shown 
α-MSH treatments to suppress neutrophil recruitment to HUVEC monolayers via actions 
on neutrophils and MC1 targeted treatments to significantly reduce neutrophil 
chemotactic activity. 
6.3.1. The flow chamber model 
The flow chamber assay has been used here as an in vitro model of human leukocyte 
recruitment and diapedesis under inflammatory conditions. While this model lacks the 
influence of pathological signalling originating from perivascular, glial and neuronal cells, 
as found in vivo in cerebral I/R, an inflammatory vascular environment has been 
modelled using TNF-α stimulation. Using TNF-α reflects the elevated TNF-α seen in the 
BCCAo mouse model used throughout this thesis. Additionally, since TNF-α acts as a 
key pro-inflammatory signal which is rapidly up regulated in human stroke, TNF-α 
stimulation provides a simplified but relevant inflammatory model to perform initial 
experiments to assess the translational potential of the in vivo findings.  
6.3.1.1. The relative roles of the leukocyte and endothelium: site of 
action 
Flow chamber experiments revealed that pre-treatment of isolated human neutrophils 
but not the HUVEC monolayer provided inhibitory actions on the adhesion and 
transmigration of neutrophils under physiological flow conditions. Both MC1 and MC3 are 
expressed on neutrophils and endothelial cells, however from the current investigations 
it would appear that inhibitory actions of α-MSH are mediated via modulation of 
neutrophil function, since only treatments of neutrophils and not of HUVECs resulted in 
significant reductions in leukocyte recruitment. This fits with the in vivo results which 
suggested melanocortin actions to take place on vascular or circulating cells rather than 
on parenchymal elements.  
While most investigations have previously been performed on the melanocortins effects 
on endothelial adhesion molecules, the present investigations demonstrate endothelial 
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treatments with α-MSH to have limited effects on leukocyte recruitment at the time point 
and does tested.  
Endothelial cells have previously been shown to express MC1 MC2 and MC3 (Table 1.5) 
and α-MSH has been shown to reduce VCAM and E-selectin in an LPS stimulated 
human microvascular cell line. Furthermore MC1 selective compounds have been shown 
to reduce the expression of E-selectin V-CAM and I-CAM in TNF-α stimulated human 
endothelial cells [154, 155]. However in the present model, aside from an 8 min 
exposure to α-MSH when the treated neutrophils were perfused over the endothelial 
cells, α-MSH demonstrated inhibitory actions on leukocyte recruitment in the absence of 
any endothelial cell treatment. Thus, as extremely rapid actions on HUVECs (within 8 
min) are unlikely, the inhibition of leukocyte recruitment appears to be due to α-MSH 
modulation of neutrophil adhesion molecule expression. 
Interestingly α-MSH treatment was able to inhibit leukocyte recruitment when given prior 
to any stimulation of neutrophils, suggesting that α-MSH treatment either prevents 
subsequent activation and/or modifies the constitutive ability of neutrophils to interact 
with the activated endothelium. 
Constitutively expressed on the leukocyte cell surface the adhesion molecule, L-selectin, 
mediates leukocyte recruitment to the endothelial surface with L-Selectin and ICAM-1 
also being able to act synergistically to mediate firm adhesion [305]. One unique 
property of L-selectin is that this adhesion molecule can be rapidly cleaved (within 
minutes) from the cell surface. Endoproteolyticly released L-selectin may then also act 
as a molecular buffer, by binding endothelial ligands and moderating leukocyte-
endothelial interactions [306]. Several non-steroidal anti-inflammatory drugs (NSAIDs) 
have been shown to be able to induce both in vivo and in vitro down regulation of 
neutrophil cell surface L-selectin expression through L-selectin shedding [307]. 
Furthermore, in vivo neutrophil shedding of L-selectin has been shown to inhibit their 
migration into the inflamed peritoneum and conversely inhibition of L-selectin shedding 
increased it [306]. In the TNF-α activated cremaster, inhibiting L-selectin shedding was 
also found to have surprising effects on leukocyte recruitment events subsequent to 
rolling, by increasing leukocyte adhesion and transmigration [305]. 
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While no effects on L-selectin have, as yet, been described following melanocortin 
treatments, in light of melanocortins effects on the shedding of CXCR1, CXCR2 and 
CD14 it is possible that L-selectin shedding may provide an additional mechanism by 
which melanocortin treatments provide anti-inflammatory protection.  
Treatments with α-MSH have however been demonstrated to reduce MSU crystal 
induced CD11b expression on neutrophils. The Mac-1 integrin subunit, CD11b, is up 
regulated early in response to inflammatory stimuli [226] and plays an important role in 
mediating leukocyte adhesion, chemotaxis and migration. In TNF-α activated cremaster 
venules fMLP induced leukocyte recruitment has been shown to be critically dependant 
on Mac-1 expression [308]. It is thus possible that reduced cell surface expression of 
CD11b allows for the inhibition of leukocyte adhesion and migration observed in the 
present model. However further investigation into effects on the topography of neutrophil 
cell surface protein expression (especially with respect to Mac-1, L-selectin, LFA-1 and 
the mucin-like-glycans) will have to be made to understand the exact mechanisms 
underlying the presently observed neutrophil dependant effects. 
6.3.1.2. Limitations of the model 
Neutrophils have been shown to be a major contributing factor to the post stroke 
inflammatory response and neutrophil depletion experiments performed in this project 
point toward neutrophils being the primary cell type recruited in the BCCAo model. As 
such, a simplified in vitro assay has been used to assess the action of melanocortins 
specifically on neutrophil recruitment. However, while investigations into just a single 
isolated population of leukocytes provides a clear picture and high reproducibility, 
allowing for a focused dissection of cellular and molecular mechanisms, this is at the 
expense of relevance. This present assay lacks the in vivo influence of other circulating 
cell types, not only other sub types of leukocytes but also platelets and erythrocytes. 
Leukocyte-leukocyte interactions have been shown to mediate secondary recruitment of 
cells which may lack the necessary adhesion molecules needed to interact directly with 
the endothelium. Therefore where an experiment may show no recruitment of an 
isolated population of leukocytes on the endothelial surface, it may be that in vivo a 
number of these leukocytes are in fact recruited to the endothelial through secondary 
interactions with other leukocytes present in the blood.  
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In addition to other leukocytes, platelets may have significant influence over leukocyte 
recruitment. Indeed platelet P-selectin and not endothelial P-selectin has been 
demonstrated to be critical to neutrophil infiltration in a model of post-ischemic renal 
failure [309]. 
Erythrocytes have also possibly been neglected due to their lack of nucleus and inability 
to divide (and thus be cultured), however considering erythrocytes outnumber PMN in 
normal blood by a thousand fold [310], purely due to their sheer numbers any seemingly 
small role in the inflammatory process could prove highly influential. It is has now been 
established that erythrocytes enhance leukocyte-endothelial interactions by forcing the 
larger leukocytes away from the central flow to the periphery and vessel wall. Recent 
studies have shown erythrocytes to be capable of inducing a number of acute stage pro-
inflammatory effects particularly in response to hypoxia. Under hypoxic conditions 
erythrocytes may generate and release H2O2 which has been shown to diffuse into 
endothelial cells, increase endothelial Ca2+, activation and up regulation of surface P-
selectin [311]. As such erythrocytes have been shown to play a significant role in 
hypoxic lung inflammation.  Furthermore erythrocytes have been shown to express the 
decoy CC and CXC chemokine receptor, DARC. Important for chemokine clearance 
erythrocyte DARC reduced extra cellular levels of CXCL1 and CXCL2/3 and inhibited 
PMN migration into the alveolar space in a murine model of lung inflammation [312]. 
Moreover in the presence of erythrocytes, immunoreactive IL-8 rapidly disappears from 
plasma. Therefore erythrocytes may provide both a pro- and anti-inflammatory influence. 
As such undertaking investigations using whole blood and different mixed populations of 
circulating cells could provide an interesting progression of the present investigations.  
6.3.2. Melanocortin effects on neutrophil chemotaxis 
Neutrophils express numerous chemokine receptors on their cell surface and in 
response to chemotactic stimuli neutrophils undergo activation of the cytoskeletal 
machinery and cell polarisation to produce a leading actin rich lamella and the uropod to 
the rear [313] thus allowing for directed actin dependant motility. Accompanying these 
events are membrane ruffling, lysosomal enzyme release and ROS production [313]. 
The most widely studied chemotactic response is the fMLP activation of neutrophil 
motility. The fMLP receptor is highly expressed on the neutrophil surface (with estimates 
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of 50,000 receptors per cell) [313] and demonstrates a high affinity for its ligand; the 
bacterial fragment and self-stress signal fMLP (originating from degraded bacterial or 
mitochondrial proteins respectively). 
In the present study, just 10nM of fMLP was able to induce significant directed neutrophil 
chemotaxis. While pre-treating with α-MSH and [D-TRP8]-γ-MSH resulted in strong 
trends toward reducing neutrophil chemotaxis, selective activation of MC1 using 100 µg 
of BMS-470539 was able to significantly reduce neutrophil chemotaxis by greater than 
75 %.  
 α-MSH and (CKPV)2 treatments have previously been shown to inhibit neutrophil 
chemotaxis to both IL-8 and fMLP [314, 315]. Furthermore both α-MSH and KPV have 
also been shown to inhibit chemotaxis to a complex mix of inflammatory mediators in 
chemotaxis assays toward supernatants from MSU-stimulated monocytes [316]. These 
responses have been shown to be dependent on elevation of intra-cellular cAMP [314, 
315]. Elevated cAMP is associated with inhibition of a number of neutrophil responses 
such as candidacidal activity, phagocytosis, super oxide production and AA release 
[317]. Treatment with cAMP elevating factors such as forskolin, isoprotereno and PGE1 
have also previously been shown to inhibit neutrophil chemotaxis to fMLP. Thus it is 
likely that the inhibition of chemotaxis observed upon melanocortin treatment is in 
response to MC activation and adenylate cyclase mediated cAMP up regulation. Since 
recent reports have shown MC1 to be the most highly expressed MC on human 
neutrophils [181] it is thus fitting that the MC1 selective BMS-470539 showed significant 
reductions in neutrophil chemotaxis following treatment. Given the current understanding 
of α-MSH effects on neutrophil chemotaxis, it is thus likely that these effects are 
mediated through MC induced elevation in cAMP. 
Paradoxically some inducers of chemotaxis such as fMLP and LTB also elevate cAMP 
levels although only transiently [317] The extent and duration of cAMP accumulation 
may thus  apparently mediate opposing effects on neutrophil function. Indeed an 
emerging body of evidence suggests that the degree of cAMP accumulation may result 
in distinct outcomes [287, 318]. While the melanocortin agonist AP214 elevates cAMP 
and enhances macrophage efferocytosis of apoptotic neutrophils, cAMP elevating 
compounds such as forskolin inhibit efferocytosis [287]. The forskolin cAMP response 
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has however been shown to be 10 times greater than the relatively modest increase 
provided by AP214 [287] and indeed Low levels of cAMP elevation have been shown to 
inhibit efferocytocis [318]. Additionally cAMP levels induced by α-MSH treatment have 
been shown to be similar to that of AP214, thus it may be that not only is the specific 
signalling pathway important to the effect of the melanocortins but also the magnitude 
and duration of that signal. 
While a trend toward a reduction in neutrophil chemotaxis was observed following α-
MSH and [D-TRP8]-γ-MSH treatment with the current n number and under the present 
conditions, drug dose and time point, this remained statistically non-significant. However 
previous reports have demonstrated α-MSH to inhibit neutrophil chemotactic ability. 
Nevertheless in the literature the efficacy of α-MSH to inhibit neutrophil migration to 
FMLP gradients appears to be under contention. While both Catania et al. [314] and 
Capsoni et al. [315] have previously reported α-MSH to reduce neutrophil chemotaxis to 
both IL-8 and FMLP, Manna et al. have however shown that α-MSH reduces IL-8 
induced migration but not fMLP induced migration [181].  The disparity in these findings 
may be due to different treatment regimens, with Catania et al. and Capsoni et al. 
investigating melanocortin effects on neutrophil chemotaxis at an earlier stage and 
toward higher concentrations of FMLP (10-8 M for 90 min) compared to Manna et al. (10-
10 M for 2 h). The fact both Catania and Capsoni used isolated blood neutrophils and 
Manna et al. utilised HL-60 (human monocyte) cell lines induced to differentiate into 
neutrophils in the presence of dimethyl sulfoxide, may also have an effect on neutrophil 
phenotype and cell responses. 
Although no significant effects of α-MSH were observed in the present study, a strong 
trend toward an inhibitory effect was observed. With one of the melanocortin compounds 
tested providing significant inhibition of fMLP chemotaxis, it would seem that both the 
methodology used and results obtained in the present study fit more closely with those 
of Catania and Capsoni. The fact that Manna et al. did not observe any suppression of 
fMLP induced chemotaxis at the later time points than Catania and Capsoni may even 
further reflect a temporal shift in MC receptor function, as has been reported during this 
thesis. 
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To my knowledge, at the time of writing, no studies of the effect of BMS-470539 or [D-
TRP8]-γ-MSH on neutrophil chemotactic ability has yet been published. While at this 
stage these findings are only the result of preliminary experiments and greater n 
numbers may reveal inhibitory roles for both [D-TRP8]-γ-MSH and α-MSH, the observed 
effects of BMS-470539 represent a novel finding, further implicating MC1 as an effector 
of neutrophil functioning. 
6.3.2.1. Relevance of the model 
The fMLP chemotaxis assay is a well-established and reproducible technique to assess 
leukocyte chemotactic function. While fMLP is largely referenced as a bacterial product, 
being ancient endosymbiotic bacteria, mammalian mitochondria also initiate protein 
synthesis with an N-formylmethionine residue, and upon tissue damage degrading 
mitochondria release N-formylmethionine containing breakdown products [319].   
In the context of sterile inflammation, while the study of cytokines that amplify 
inflammatory signals have been extensively studied the molecules responsible for 
initiating inflammatory reactions originating from the damaged tissue (Alarmins and 
DAMPs) are less well characterised [320]. Outside of the cell, mitochondrial elements 
are recognised as “non-self” and may act as a link between tissue injury and 
inflammation. As such mitochondrial proteins likely represent proximal mediators which 
are released from necrotic cells at the site of tissue injury and act as a trigger for local 
and systemic sterile inflammation [320] . 
FMLP mediated neutrophil activation has been shown to be dependent on initiation of 
TNF-α release and TNFR functioning [321], thus demonstrating a link between damage 
recognition and inflammatory signalling suggesting TNF-α may either mediate or amplify 
the fMLP initiated signal.  
While endogenous release of fMLP and other N-formylated peptides has not yet been 
quantified following stroke, mitochondrial dysfunction plays a central role in the ischemic 
cascade. It is thus plausible that these peptides may be highly relevant in post I/R 
inflammation as chemoattractant DAMPs following stroke. Indeed as well as on 
circulating leukocytes fMLP receptors have also been identified on microglia and 
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astrocytes [322] and as such fMLP could be an important component in initiating post 
stroke inflammatory responses  
Hence the present model used represents neutrophil responses to inflammatory initiating 
signals rather than a propagating/amplifying cytokine signal. As such the particular role 
of MC1 found in this study may further fit with the very early role found in the in vivo 
investigations. These initial results on neutrophil chemotaxis demonstrate the MC1 
activation may counteract the very early chemotactic responses of neutrophils to tissue 
damage. Future investigations could also assess the role of particular MCs in modulating 
leukocyte functioning in response to molecules in the amplification phase of 
inflammation, especially considering the apparent temporal switch in MC importance. 
6.4. Conclusions 
In vitro investigations have revealed anti-inflammatory efficacy of melanocortin 
treatments in human cells. The inhibitory actions of α-MSH on leukocyte endothelial 
interactions observed in the flow chamber model are supportive of the results obtained in 
the in vivo stroke model and builds confidence as to the potential to translate 
melanocortin treatments into a human inflammatory disease context. This work has also 
pinpointed these effects to specifically be mediated by melanocortin treatments acting on 
neutrophils rather than the endothelium. Whether the same holds true in the in vivo 
setting and at different time points following activation by different stimulus has however, 
yet to be determined. The chemotaxis assay has been used to further characterise the 
effect of melanocortin treatments on neutrophil functioning. In these pharmacological 
studies an important role for MC1 was revealed in inhibiting neutrophil chemotaxis to 
fMLP. This work thus shows that melanocortin treatments are not only active in 
modulating human cell leukocyte recruitment but can modulate multiple aspects of 
neutrophil functioning in response to different stimulus. 
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6.5. Future Directions 
This work could be furthered to give a greater insight into role of individual MCs, by the 
use of blocking antibodies to the melanocortin receptors. HUVECs and neutrophils could 
again be treated separately with blocking antibodies for different MCs before giving non 
selective melanocortin treatments. Alternatively blocking antibodies could be used to 
study the endogenous production and influence of the melanocortins. However such 
work would rely on the specificity of such antibodies which is currently under some 
conjecture. 
Another, more physiological relevant approach that could be pursued, to further 
investigate the role of MC subtypes in supressing neutrophil recruitment, would be to 
take advantage of natural MC mutations in humans. Loss of function MC1 mutations are 
relatively common in humans, arising in ~80 % of individuals with red hair and fair skin 
[323, 324]. Since MC1 mutations confer these easily observable physical characteristics, 
during blood donor recruitment people with this phenotype could be actively encouraged 
to participate. PCR genotyping for four common MC1 variants; D84E, R151C, R160W 
and D294H, could then be used to further inform results obtained from in vitro assays 
allowing an insight into the role of MC1 in neutrophil function. 
Investigating the role of MC3 and MC4 using this strategy would however be a more 
complex task as these mutations are much rarer and are associated with an obese 
phenotype. In humans, the MC3 missense variants Thr6Lys and Val81Ile have been 
related with reduced in vitro expression of the receptor and diminished functionality [325] 
and is associated with childhood obesity, and elevated body fat percentage in 
comparison to non-carriers [326]. While genetic mutations of MC4 represent the biggest 
monogenic cause of childhood obesity, these are again rare mutation. In a study by 
Farooqi et al. from a group of 500 patients with severe childhood obesity, just 5.8 % 
displayed mutations in MC4 with only 6 individuals being homozygous [327]. Such 
investigations would be further hampered by the difficulties of extrapolating which 
findings are due to direct effects of MC dysfunction on immune functioning from those 
that are secondary to the metabolic dysfunction and the multitude of conditions 
associated with obesity.  
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While the flow chamber model used in the present investigation uses TNF-α (a key pro-
inflammatory cytokine up regulated following stroke) to activate endothelial cells, this 
model could further tailored to more faithfully mimic stroke. Varying levels of glucose and 
oxygen deprivation could be used to activate endothelial cells, as previously performed 
in dermal microvascular endothelial cells by Lee et al.[328]. Furthermore brain 
microvascular cells could be seeded rather than the more readily available HUVECs. 
While the current model used demonstrates a proof of principle, confirming melanocortin 
action on leukocyte recruitment in human cells, this model also provides a useful tool for 
further research into the actions of the melanocortins. 
The current investigations using the chemotaxis assay could also be built upon to 
analyse the chemotactic functioning of neutrophils in response to a number of different 
chemoattractants such as IL-8. Indeed following stroke a number of chemotactic factors 
are released by both resident and infiltrating immune cells, such as; Neutrophil 
Activating Protein 3 (NAP-3, CXCL1) [329], Macrophage Inflammatory Protein-1α (MIP-
1α, CCL3) [330], IL-8 (CXCL8) [331] and fractalkine (CXC3CL1)[332] each of which 
could be investigated in this assay. In the more complex in vivo situation these 
molecules create a pro-inflammatory milieu with multiple signals influencing leukocyte 
functioning. Examining more complex chemotactic solutions could provide an interesting 
insight into how different chemical signals could act to enhance or inhibit the chemotactic 
outcome. In order to model this complex chemical microenvironment experiments could 
be performed substituting the chemo-attractant in the bottom chamber with culture 
medium from cultured neuronal or glial cells that have been deprived of glucose and 
oxygen.  
Another avenue of research could be to introduce a mixed population of leukocytes to 
the top level of the plate. Indeed many chemoatractants display differential chemotactic 
potencies and selectivity for different leukocyte populations, for instance MCP-1 (CCL2) 
attracts monocytes but not neutrophils whereas CXCL1 recruits neutrophils but not 
monocytes. The effect of melanocortin treatments on the composition of leukocyte 
populations recruited could be indicative of therapeutic value. While neutrophil 
recruitment is largely considered a pathological event in stroke and the arrival of 
monocytes leading to an M1 phenotype may enhance inflammatory responses, the 
recruitment of monocytes assuming an M2 phenotype marks the beginnings of 
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inflammatory resolution and is associated with the clearance of apoptotic cells and the 
release of IL-10 and pro-resolution factors. Differential expression of receptors on sub 
sets of monocytes mean that they may respond to different stimuli and be recruited 
differentially. For instance CCR2 is only expressed on inflammatory monocyte thus only 
the pro-inflammatory phenotype will respond to MCP-1. Assessing the effects of 
melanocortins on the composition of leukocyte recruitment could make an interesting 
progression of this project. 
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7.1. Summary of important results 
Throughout this project a murine model of global cerebral I/R has been used to 
investigate the actions of the melanocortins on leukocyte recruitment in the brain. This 
BCCAo model was characterised by a rapid I/R induced recruitment of leukocytes in the 
pial microcirculation, which escalated as the length of reperfusion was extended. 
Neutrophil depleting experiments revealed the recruited cells consisted largely or even 
entirely of neutrophils. Coinciding with the enhanced neutrophil recruitment at 2 h, was 
an increase in circulating TNF-α and an activation of brain resident immune competent 
microglia. 
Melanocortin treatments have been shown to inhibit leukocyte recruitment in a number 
of different models [127, 140, 151], however the effect of these peptides on the 
leukocyte recruitment cascade have until now not been investigated in the unique 
microcirculation found in the brain. During the course of this project the physiological 
roles and pharmacological potential of the MRS has been investigated in an 
inflammatory context relevant to stroke.  
Treatments with the endogenous non-selective melanocortin agonist α-MSH revealed 
potent inhibitory actions on both rolling and adhesion of I/R induced leukocytes. These 
effects appeared to be via actions on vascular or circulating elements as no effect on 
microglial activation was observed, as would have been expected from previous in vitro 
studies [269]. 
Pharmacological investigations identified both MC1 and MC3 to suppress cerebral 
leukocyte recruitment. MC1 was found to be most important at reducing early leukocyte 
recruitment events however by 2 h of reperfusion MC3 mediated anti-inflammatory 
signalling appeared to predominate.  
In addition to inhibitory actions on leukocyte recruitment melanocortin treatments 
reduced the expression of the pro-inflammatory cytokines TNF-α and MCP-1. However, 
7.0.   General discussion 
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indicative of the immuno-modulatory role of the melanocortins, treatments did not result 
in an indiscriminate inhibition of all cytokines but instead both α-MSH and [D-TRP8]-γ-
MSH were found to induce the anti-inflammatory cytokine IL-10 and increase expression 
of the pleiotropic cytokine IL-6. 
The observed switch in MC receptor importance was however unlikely to be due to up 
regulation of the receptor, with qRT-PCR experiments revealing no change in receptor 
transcript. Instead, considering early reductions in leukocyte recruitment were rapid and 
likely to be transcriptionally independent, and that by 2 h there was evidence of classical 
melanocortin signalling and NF-κB inhibition, it is likely that apparent changes in receptor 
importance are due to the activation of different signalling pathways being activated  
Investigations into the physiological role of these receptors in regulating leukocyte 
recruitment, using receptor mutant and KO mice, were found to support the 
pharmacological findings. An enhanced induction of early leukocyte rolling and TNF-α 
expression following I/R in the MC1 mutant e/e mouse suggested an early anti-
inflammatory role for MC1. On the other hand MC3-/- mice displayed no phenotype at this 
early stage. However with an extended period of reperfusion the inflammatory 
phenotype of the e/e mouse had subsided to levels similar to WT suggesting that 
compensatory mechanisms prevail, which according pharmacological studies is likely to 
be MC3 mediated.  
Experiments using an in vitro model of neutrophil recruitment showed that α-MSH 
mediated reduction in leukocyte-endothelial cell interactions was achievable in human 
cells. Furthermore these effects resulted in a significant reduction in neutrophil 
diapedesis, a parameter that could not be measured in the murine model. Despite a 
wealth of evidence on the effects of melanocortin treatments on endothelial adhesion 
molecules, these in vitro investigations revealed neutrophils to be the effector cells of α-
MSH effects on leukocyte recruitment at the time point tested. Further assessment of the 
effects of melanocortin treatments on neutrophil function produced the novel finding that 
MC1 activation enabled the inhibition of neutrophil chemotaxis toward the cellular injury 
chemotactic signal fMLP. 
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This work demonstrates that melanocortin receptor activation can effectively ameliorate 
pathological I/R induced leukocyte recruitment in the unique restrictive environment 
provided by the cerebral microcirculation. While this work highlights important roles for 
MC1 and MC3 in mediating these effects, crucially these studies have also revealed that 
the melanocortin reporter subtype important for providing anti-inflammatory protection 
not only varies with the physiological environment and pathological status (as shown by 
others) but also varies with the temporal progression of pathology. 
7.2. Developing melanocortin drugs for stroke 
While existing preclinical data is overwhelmingly positive, limitations do still exist. One 
potential problem of targeting these receptors is that long term stimulation of the 
receptors has still not been adequately investigated. Initial studies have shown however 
that continual activation of MC4 results in de-sensitisation and an internalization of the 
receptor [333]. and while the present investigations have shown no change in blood 
mRNA levels of MC1 and MC3, studies by Montero-Melendez et al. have shown MC1 
MC3 and MC5 mRNA expression to be reduced in isolated macrophages following 
treatment with high doses of the melanocortin agonist AP-214 compared [287]. 
Slight cardiovascular side effects have also been previously observed with long term 
administration of Melanotan II in obese rats, raising arterial blood pressure and heart 
rate [334] which could limit the use of MC targeted drugs in chronic disorders or for 
prophylactic use. These effects have however been shown to be limited to MC4. In 
obese humans treatment with the highly selective MC4 agonist LY2112688, caused 
increases in blood pressure and heart rate [335]. It may be that such effects are limited 
to obese patients as no studies yet performed in healthy individuals have demonstrated 
elevated blood pressure. Since high blood pressure poses a strong risk factor for stroke, 
cardiovascular side effects could seriously limit the use of MC4 targeted drugs for the 
treatment of stroke.  
On the other hand, very high doses (up to 2 mg/kg daily for 12 weeks) of the non-
selective melanocortin agonist NDP-α-MSH (relative affinity MC1>MC3>MC4>MC5) have 
shown no toxic side effects in both mice and rats. Dosing trials have also been 
performed for NDP-α-MSH in humans. Trialling the peptide for therapeutic tanning, 
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investigators have found 0.08 mg/kg/day for 10 days to produce minimal side effects, 
with short-lived flushing of the face, in approximately 40 % of subjects and nausea in 
less than 10 % [336]. Subsequent dose escalation studies showed up to 0.16 mg/kg/day 
to be well tolerated [336]. The does used in the present study to inhibit cerebral 
leukocyte recruitment equate to approximately 0.4 mg/kg and as such it is feasible that 
these levels could be achieved in man with minimal side effects. Furthermore 
considering the low BBB permeability of melanocortin peptides and the seemingly 
peripheral effects described in the present study, treatments are unlikely to reach MC4 
expressing cells in the CNS and thus minimising cardiovascular side effects. 
The inhibition of NF-κB regulated transcription is a key element to the broad protective 
actions of the melanocortins. Recently the proteasome inhibitor MLN519 has entered 
clinical trials for the treatment of stroke. This drug has a similar action to the 
melanocortins in that it inhibits IkB degradation and has been shown to be greatly 
effective at reducing inflammation and providing neuroprotection up to 10 hours following 
cerebral I/R injury [337]. The outcome of these clinical trials may give an indication of 
feasibility of targeting NF-kB mediated transcription for the treatment of stroke and 
possibly forecast the success of melanocortin targeted therapy.  
Another widely reported mechanism by which the melanocortins can act is via the C 
terminal KPV region. This sequence has been shown to provide potent anti-inflammatory 
actions and the efficacy of this tri-peptide has also been demonstrated in the present 
studies. Due to structural similarities with IL-1β and observations of IL-1R binding 
mounting evidence suggests the terminal α-MSH region acts as an IL-1R antagonist. 
The IL-1R antagonist Anakinra (brand name Kineret) is currently used for the treatment 
of rheumatoid arthritis and in experimental stroke has been shown to reduce neutrophil 
infiltration and decrease infarct size by 50 %, even in co-morbid animals and when 
treatment was delayed until 3 h post stroke [338]. The IL-1R antagonist has even 
undergone phase II clinical trials, showing the drug to be safe and well tolerated in acute 
stroke, with initial evidence also showing improved pathophysiology and clinical outcome 
[116]. 
Thus in addition to highly promising preclinical data, initial clinical toxicological studies 
show melanocortin drugs to be well tolerated and with a number of drugs having similar 
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mechanisms of action showing promise in clinical trials, the existing picture seems highly 
auspicious for the use of melanocortin based drugs to treat post stroke inflammatory 
responses.  
While to my knowledge no clinical trials are underway for drugs which induce cleavage 
of adhesion molecules or inflammatory receptors (an additional mechanism by which the 
melanocortins act), the multitude of mechanisms by which the melanocortins control 
inflammation is likely to provide a potent and broadly acting anti-inflammatory response. 
Due to the robust nature of the host inflammatory response showing functional overlap 
and redundancy in inflammatory signalling, the multifaceted targeting of this response 
provided by the melanocortins, may offer great advantages over therapeutic strategies 
that target a single element of the inflammatory cascade. 
7.3. Conclusions 
Investigations into the importance of melanocortin receptor sub types in modulating post 
I/R leukocyte recruitment in the cerebral microcirculation have revealed potent inhibitory 
actions of MC agonists along with a novel temporal switch in the MC signalling. The 
present work allows one to postulate a new model for MC receptor signalling in 
modulating innate inflammatory responses: 
MC1 provides rapid protection against pathological leukocyte recruitment via 
mechanisms independent of NF-κB regulation, most likely acting via direct effects on 
neutrophils. MC3 activation may also provide potent inhibitory actions on leukocyte 
recruitment however these actions are delayed, inhibiting NF-κB activation and providing 
a more prolonged effect than the immediate MC1 response. 
Figure 7.1 illustrates the key findings and the potential mechanisms put forward in this 
thesis. 
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In light of the novel finding showing a switch in receptor signalling, further investigations 
into the temporal importance of these receptors will need to be performed at later time 
points. With a greater understanding of the roles of these receptors, particularly MC1 and 
MC3, as identified in this study, the development of selective melanocortin ligands 
displaying appropriate pharmacokinetic profiles could thus pave the way for the 
production of powerful new anti-inflammatory drugs for the treatment of stroke. 
Figure 7.1. Proposed anti-inflammatory mechanisms in light of the present 
findings. Melanocortin agonists provide inhibitory actions on leukocyte recruitment 
following cerebral I/R. In vitro experiments suggest these effects are primarily due to 
actions on neutrophils. In vivo experiments revealed MC1 to provide both 
endogenous and pharmacological protection against early leukocyte recruitment and 
TNF-α release. These actions are likely to be independent of transcription and may 
involve autocrine cleavage of cell surface receptors. In vitro studies also showed 
pharmacological activation of MC1 to reduce neutrophils chemotactic ability. MC3 
mediated effects were found to be delayed compared to MC1 actions but provided 
more prolonged inhibition of leukocyte recruitment, inhibiting the transcription of NF-
κB related genes and enhancing the production of anti-inflammatory IL-10. These 
different mechanisums may also take place in different cell types. Proposed MC1 
mechanisms shown in red and MC3 in blue. (P. Holloway, un-published) 
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Given the complexity of MC regulation along with the variable nature of stroke and 
relative difficulty in determining time of onset, an alternative approach which could prove 
fruitful, may be to activate multiple receptors in a non (or perhaps partially) selective 
manner. Indeed given that both MC1 and MC3 have demonstrated to initiate powerful 
anti-inflammatory signalling in the present study it may be that a non-selective approach 
would provide a more robust protection than targeting a single receptor. Indeed the only 
licenced melanocortin based therapy NDP-α-MSH (Afamelanotide, licenced in Italy for 
treatment of Erythropoietic protoporphyria) is a non-selective melanocortin agonist. 
Additionally the non-selective melanocortin agonist AP214 has shown great promise in 
preclinical studies in a number of diseases including lung inflammation, gouty arthritis, 
peritonitis and acute kidney injury [287]. Furthermore in 2011 Action Pharma announced 
positive results from phase IIb trials for AP214 in postoperative acute kidney injury. This 
compound has since attracted attention from global pharmaceutical companies and in 
2012 was purchased by Abbott for $110 million for development to treat kidney injury. 
Given the results of the present investigations, the use of these super-potent non-
selective agonists could provide novel and effective therapeutic interventions to abrogate 
damaging post stroke leukocyte recruitment. 
While the most lucrative strategy for harnessing the MRS to provide anti-inflammatory 
protection in stroke remains unclear, the present study has provided convincing 
evidence that the melanocortin system offers a valuable pharmacological target to inhibit 
post stroke leukocyte recruitment. 
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Effect size (δ) was calculated by the maximum likelihood estimator of Cohen's δ using 
preliminary data in which mice underwent BCCAo and 40 min of reperfusion with either 
saline (control) or dexamethasone (treated) being given i.p 30 min before BCCAo, level 
of adhesion was then measured as a parameter of anti-inflammatory effect. 
Tables A1: Preliminary data used for power calculations 
 
Adhesion 
Group x σ n 
1 (control) 292.54 17.29 3 
2 (treated) 57.47 12.46 3 
 
Calculating effect size using Cohen's δ:  
 
Where σ is defined as :  
 
Solving for σ: 
 
 
Therefore 
 
As such effect size = 1.04 
Power calculations were then performed to determine group size with G* power 3 
software (Heinrich Heine University of Dusseldorf) using a power of 0.8, an alpha value 
of 0.05 and the above effect size. Minimum group sizes to provide sufficient power to 
avoid a type II error was found to be 4. 
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Table A2: WBC counts pre and post PMN depletion 
Cell count Pre-treatment Post-treatment 
IgG Anti-PMN IgG Anti-PMN 
Total WBC (Cells x 103/µl) 10.38 (±0.4) 10.15 (±0.5) 11.1 (±0.5) 9.51 (±0.7) 
PMN (%) 
Neutrophils 18.88 (±1.5) 17.38 (±2.0) 19.38 (±1.6) 1.75 (±0.3) 
Basophils 0.75 (±0.1) 0.63 (±0.2) 0.75 (±0.1) 0.38 (±0.1) 
Eosinophils 1.00 (±0.2) 1.00(±0.2) 1.13 (±0.3) 0.75 (±0.3) 
Lymphocytes (%) 78.00 (±1.8) 79.5 (±2.3) 77.13 (±1.6) 94.13 (±0.4 
Monocytes (%) 1.3 (± 0.2) 1.5 (±0.4) 1.63 (±0.2) 3.00 (±0.5) 
 
Figure A1. PMN depletion in mice. C57BL/6 male mice were treated with either 
anti-mouse PMN serum or IgG matched serum (10ml/kg, i.p.) once daily for two 
consecutive days. Tail vein blood samples, for total white cell count and differential cell 
counts, were collected pre-treatment (before the first i.p injection) and post treatment 
following 2 days of treatment. Anti-PMN treatment reduced total PMN count by ~ 85 %. 
Values are mean ± SEM of 4 mice. ** denotes significant to Anti-PMN pre-treatment 
group P<0.001. 
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Figure A2. Western blot analysis of MC1 and MC3 expression in brain. Histograms and 
representative blots showing MC1 and MC3 expression from whole brain homogenates. C57BL/6 
mice were subjected to sham or BCCAo surgery with 40 min (white bars) or 2 h (grey bars) of 
reperfusion and treated at the start of reperfusion with either saline or α-MSH. No significant 
variation in receptor expression was detected across all treatments. N=3 for all groups 
Figure A3. MC3 antibodies display non-specific binding. (A) PCR analysis 
demonstrates the absence of MC3 RNA transcript in samples from MC3-/- mice. (B) 
Western blot analysis with two separate MC3 antibodies produce bands at the correct 
height in brain homogenates from both wild type and MC3-/- mice suggesting non-
specific binding to other melanocortin receptors or unrelated proteins of a similar 
molecular weight. 
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Figure A4. Enhanced leukocyte recruitment in e/e mice bearing wounds from fighting 
Triangles (with exact values given to the left) represent levels of leukocyte recruitment from 
individual mice that were found to have superficial wounds to the tail and back from fighting. Data 
from these mice was excluded from analysis during this thesis and while no statistical analysis 
could be performed due to n = 1 in each group, leukocyte endothelial interactions in these mice is 
clearly highly elevated when compared to otherwise un-injured animals of the same strain (as 
shown by the white and grey bars). The levels of leukocyte rolling and adhesion detailed here for 
both 40 min and 2 h saline treated BCCAo animals was far greater than levels observed in any 
individual mouse (of any strain or treatment group) across the whole of this project. No notable 
changes in WBC rolling velocity were observed in these mice (data not shown).  
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